Tomoyuki Sasaki1, Shanshan Lian1, Jie Qi1, Peter E Bayliss2, Christopher E Carr3, Jennifer L Johnson4, Sujay Guha1, Patrick Kobler5, Sergio D Catz4, Matthew Gill1, Kailiang Jia5, Daniel J Klionsky6, Shuji Kishi1. 1. Department of Metabolism & Aging, The Scripps Research Institute, Jupiter, Florida, United States of America. 2. Campbell Family Cancer Research Institute, Ontario Cancer Institute, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. 3. Department of Earth, Atmospheric and Planetary Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America. 4. Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, United States of America. 5. Department of Biological Sciences, Florida Atlantic University, Jupiter, Florida, United States of America. 6. Life Sciences Institute, Department of Molecular, Cellular, and Developmental Biology, Department of Biological Chemistry, University of Michigan, Ann Arbor, Michigan, United States of America.
Abstract
Spinster (Spin) in Drosophila or Spinster homolog 1 (Spns1) in vertebrates is a putative lysosomal H+-carbohydrate transporter, which functions at a late stage of autophagy. The Spin/Spns1 defect induces aberrant autolysosome formation that leads to embryonic senescence and accelerated aging symptoms, but little is known about the mechanisms leading to the pathogenesis in vivo. Beclin 1 and p53 are two pivotal tumor suppressors that are critically involved in the autophagic process and its regulation. Using zebrafish as a genetic model, we show that Beclin 1 suppression ameliorates Spns1 loss-mediated senescence as well as autophagic impairment, whereas unexpectedly p53 deficit exacerbates both of these characteristics. We demonstrate that 'basal p53' activity plays a certain protective role(s) against the Spns1 defect-induced senescence via suppressing autophagy, lysosomal biogenesis, and subsequent autolysosomal formation and maturation, and that p53 loss can counteract the effect of Beclin 1 suppression to rescue the Spns1 defect. By contrast, in response to DNA damage, 'activated p53' showed an apparent enhancement of the Spns1-deficient phenotype, by inducing both autophagy and apoptosis. Moreover, we found that a chemical and genetic blockage of lysosomal acidification and biogenesis mediated by the vacuolar-type H+-ATPase, as well as of subsequent autophagosome-lysosome fusion, prevents the appearance of the hallmarks caused by the Spns1 deficiency, irrespective of the basal p53 state. Thus, these results provide evidence that Spns1 operates during autophagy and senescence differentially with Beclin 1 and p53.
Spinster (Spin) in Drosophila or Spinster homolog 1 (Spns1) in vertebrates is a putative lysosomal H+-carbohydrate transporter, which functions at a late stage of autophagy. The Spin/Spns1 defect induces aberrant autolysosome formation that leads to embryonic senescence and accelerated aging symptoms, but little is known about the mechanisms leading to the pathogenesis in vivo. Beclin 1 and p53 are two pivotal tumor suppressors that are critically involved in the autophagic process and its regulation. Using zebrafish as a genetic model, we show that Beclin 1 suppression ameliorates Spns1 loss-mediated senescence as well as autophagic impairment, whereas unexpectedly p53 deficit exacerbates both of these characteristics. We demonstrate that 'basal p53' activity plays a certain protective role(s) against the Spns1 defect-induced senescence via suppressing autophagy, lysosomal biogenesis, and subsequent autolysosomal formation and maturation, and that p53 loss can counteract the effect of Beclin 1 suppression to rescue the Spns1 defect. By contrast, in response to DNA damage, 'activated p53' showed an apparent enhancement of the Spns1-deficient phenotype, by inducing both autophagy and apoptosis. Moreover, we found that a chemical and genetic blockage of lysosomal acidification and biogenesis mediated by the vacuolar-type H+-ATPase, as well as of subsequent autophagosome-lysosome fusion, prevents the appearance of the hallmarks caused by the Spns1 deficiency, irrespective of the basal p53 state. Thus, these results provide evidence that Spns1 operates during autophagy and senescence differentially with Beclin 1 and p53.
Autophagy is an evolutionarily conserved intracellular catabolic process whereby cytoplasmic proteins and organelles are engulfed into autophagosomes and subsequently degraded in autolysosomes, following fusion with lysosomes. Biologically significant roles of autophagy have been illuminated in a variety of physiological and pathophysiological conditions, such as occurs during the adaptation to nutrient starvation, the clearance of damaged proteins and cell organelles, development, cell survival and death, tumor progression and suppression, elimination of pathogens, and aging [1]. It has also been suggested that autophagy can have a beneficial effect on longevity in many lower organisms from yeast to flies, although a clear role in lifespan extension still remains elusive in vertebrates [2]. Furthermore, several interventions that promote longevity, including caloric restriction and chemical treatment with rapamycin, have exploited their impact through autophagy [3].Zebrafish is an ideal organism to study the entire developmental process ex utero and are easily accessible for both experimental and genetic manipulations. Therefore, the zebrafish model system has become a popular platform to explore the mechanisms of human diseases [4]. Recently in our laboratory, we screened mutagenized zebrafish embryos for the altered expression of senescence-associated β-galactosidase (SA-β-gal), which is a versatile senescence biomarker widely used in both cellular senescence and organismal aging studies [5], [6], [7]. SA-β-gal has also been utilized for various detection of embryonic/larval senescence in our studies and those of others [8], [9], [10], [11]. We successfully validated the use of embryonic SA-β-gal production as a valuable screening tool by analyzing over 500 zebrafish mutants [12]. Of our identified mutants, the highest SA-β-gal activity was found to be associated with an insertion in the gene denoted “not really started” (nrs) (currently denoted as zebrafishspinster homolog 1, spns1), which is a homolog of Drosophilaspinster, a gene that regulates aging and lifespan in flies [13]. Zebrafish harboring a homozygous mutation in the spns1 gene revealed embryonic/larval lethality, associated with yolk opaqueness and senescence [12], [14]. Adult zebrafish with a heterozygous deletion of spns1 show accelerated signs of aging, including an increased accumulation of the “aging pigment” lipofuscin in the muscle and liver, and have shortened lifespan [12]. Spinster has been implicated in a lysosomal storage function in flies [13], [15], and Spns1 deficiency leads to impaired autophagic termination and lysosome reformation problems in the mammalian cell culture system [16]. However, it remains unknown how Spns1 physiologically and pathophysiologically has an impact on autophagic homeostasis in conjunction with senescence in higher organisms in vivo, where we lack an appropriate vertebrate model system except for zebrafish.Beclin 1, an autophagic regulator, is essential for early embryonic development, and is a haploinsufficient tumor suppressor [17]. During starvation of cultured cells, the accumulation of large and long-lasting autolysosomes caused by Spns1 deficiency is attenuated by concurrent beclin 1 knockdown, suggesting dependence on autophagy induction and progression [16]. p53, the most extensively characterized tumor suppressor, is a master regulator with pleiotropic effects on genomic stability, cell cycle, proliferation, cell death, tumorigenesis, stress response, senescence and energy metabolism, and is also involved in autophagic regulation [18]. p53 had been exclusively considered as a positive regulator of autophagy [19], but was recently found also to act as an autophagic inhibitor [20], [21]. Thus, the role of p53 in autophagy regulation requires further study since it may underlie key aspects of metabolism, aging, and cancer biology.We examined the impact of Spns1 impairment on the autophagic process and on the induction of embryonic senescence in zebrafish, in order to clarify how autolysosomal processing is linked to these two tumor suppressors, Beclin 1 and p53. In this study, we found that inhibition of Beclin 1 can attenuate the yolk opacity and senescence caused by the Spns1 defect, whereas deficiency of “basal” p53 augments them (“basal” meaning in the absence of extrinsic genotoxic stress, e.g., ultraviolet light). Conversely, p53 “activated” by DNA damage apparently induced autophagy and apoptosis, intensifying the Spns1-deficient phenotype. Moreover, a chemical and genetic blockage of lysosomal acidification by inhibition of vacuolar-type H+-ATPase (v-ATPase) prevented the appearance of the hallmarks of Spns1 deficiency irrespective of the p53 state, while at the same time preventing autophagosome-lysosome fusion. Our findings thus suggest that Spns1 is critically involved in lysosomal acidification and trafficking during autophagy, and acts in the same pathway as Beclin 1 and p53 in the regulation of senescence.
Results
Accumulation of cytoplasmic membranous inclusions and LC3 puncta in spns1-mutant fish
Spin/Spns1 has been implicated in the regulation of autophagic lysosomal homeostasis in mammalian cells and flies [15], [16]. In fact, in zebrafish, electron microscopy revealed that compared with the wild-type control, spns1-mutant larvae accumulated cytoplasmic membranous inclusions corresponding to late endosomal, autophagic, and lysosomal structures in the hypodermal and retinal epithelial cells (). To verify that the autophagic process of spns1-deficient (spns1) vertebrates is fundamentally disturbed, we generated EGFP-tagged microtubule-associated protein 1 light chain 3 (LC3) transgenic zebrafish with the spns1-mutant background. In the resulting EGFP-LC3-transgenic spns1-mutant [Tg(CMV:EGFP-LC3); spns1] fish line, grossly enhanced EGFP intensity was observed throughout the body in comparison with the original Tg(CMV:EGFP-LC3) line [22], [23] (
). In addition, intracellular localization of EGFP-LC3 was detectable as aggregated puncta in periderm or basal epidermal cells of the skin (above the eye on the head or in the caudal fin) and epithelial cells of several other organs including yolk sac, retina, and liver (
), suggesting excessive autophagosome and/or autolysosome accumulation.
Figure 1
Aberrant autophagosome and autolysosome formation in spns1-mutant zebrafish.
(A) Yolk opaqueness and LC3 puncta formation in spns1-mutant zebrafish embryos. For EGFP-LC3 transgenic spns1-mutant [Tg(CMV:EGFP-LC3);spns1] fish siblings, bright-field and fluorescence images of wild-type (wt) control (upper) and spns1 mutant (spns1) (lower) embryos at 84 hpf are shown. The black arrow indicates the yolk-opaqueness phenotype in the spns1 mutant. The gross expression of EGFP-LC3 at head and trunk in the spns1-mutant animal is relatively stronger than in the wt animal. Occasionally, however, a high intensity signal can be observed at the liver region in the mutant (as seen in D). Scale bar, 250 µm. (B) EGFP-LC3 punctate compartments in the liver cells of the spns1 mutant. Through high magnification (×600) confocal microscopy, intracellular EGFP-LC3 puncta were visualized in live animals at 84 hpf. Nuclei were counterstained with Hoechest 33342 (blue), and peri-nuclear EGFP-LC3 puncta were evident in the spns1 mutant, but not in wt animals. Scale bar, 10 µm. (C) Immunoblotting to detect the conversion of LC3-I to LC-II. Using an anti-LC3 antibody, both endogenous LC3 and transgenic (exogenous) EGFP-LC3 expression was detected and an increase of LC3-II conversion/accumulation was seen in the spns1 mutant compared with wt fish at 84 hpf. (D–F) Identification of autophagosome and autolysosome/lysosome formation in the spns1 mutant. (D, E) LysoTracker (DND-99; red) staining of EGFP-LC3 transgenic spns1-mutant [Tg(CMV:EGFP-LC3); spns1] embryos was performed at 84 hpf. At the whole animal levels (D), the EGFP-LC3 signal is relatively higher throughout in the spns1 mutant than in wild type, and a particularly strong signal can be seen in the liver, as shown in (A). In the head and trunk portions of the animals (D), a distinctive increase in the intensity of LysoTracker can be observed in the spns1 mutant. At the intracellular level (E), several small LC3 spots and largely diffuse green signal in the cells and cytosolic LysoTracker staining is seen. A number of enlarged LC3- and LysoTracker-positive yellow punctate structures can be seen in the spns1 mutant by confocal microscopy at a higher magnification (inset; enlarged from dotted square area). (F) EGFP-LC3 and mCherry-LC3 double-transgenic [Tg(EGFP-LC3:mCherry-LC3)] zebrafish were used to monitor autolysosome formation in spns1 MO-injected embryos at 84 hpf. A number of enlarged yellow LC3 puncta were detected in the spns1 morphant, while only small yellow LC3 spots can be seen in control-injected embryos. Nuclei were counterstained with 4′, 6-diamidino-2-phenylindole, dihydrochloride (DAPI). Scale bar, 250 µm in (D). Scale bar, 10 µm in (E, F). Quantification of data presented in D (n = 12), E (n = 6), and F (n = 6) is shown in the right graph; the number (n) of animals is for each genotype. Three independent areas (periderm or basal epidermal cells above the eye) were selected from individual animals. (G) Transgenic expression of mCherry-Lamp1 in wt [Tg(CMV:EGFP-LC3)] and spns1-mutant [Tg(CMV:EGFP-LC3);spns1] animals 84 hpf. Scale bar, 10 µm. (H) Transgenic expression of EGFP-Vector (vector), EGFP-wild-type Spns1 (spns1 WT), or EGFP-mutant Spns1 (spns1 E153K) in [Tg(CMV:mCherry-LC3);spns1] animals at 84 hpf. Scale bar, 10 µm. Quantification of data presented in H is shown for ratio of yolk opaqueness phenotype (n = 48), mCherry intensity (red) (n = 6), and merge intensity of EGFP and mCherry (yellow) (n = 6) in the right graphs; the number (n) of animals is for each genotype. Three independent areas (periderm or basal epidermal cells above the eye) were selected from individual animals. Error bars represent the mean ± standard deviation (S.D.), *p<0.005; ns, not significant.
Aberrant autophagosome and autolysosome formation in spns1-mutant zebrafish.
(A) Yolk opaqueness and LC3 puncta formation in spns1-mutant zebrafish embryos. For EGFP-LC3 transgenic spns1-mutant [Tg(CMV:EGFP-LC3);spns1] fish siblings, bright-field and fluorescence images of wild-type (wt) control (upper) and spns1 mutant (spns1) (lower) embryos at 84 hpf are shown. The black arrow indicates the yolk-opaqueness phenotype in the spns1 mutant. The gross expression of EGFP-LC3 at head and trunk in the spns1-mutant animal is relatively stronger than in the wt animal. Occasionally, however, a high intensity signal can be observed at the liver region in the mutant (as seen in D). Scale bar, 250 µm. (B) EGFP-LC3 punctate compartments in the liver cells of the spns1 mutant. Through high magnification (×600) confocal microscopy, intracellular EGFP-LC3 puncta were visualized in live animals at 84 hpf. Nuclei were counterstained with Hoechest 33342 (blue), and peri-nuclear EGFP-LC3 puncta were evident in the spns1 mutant, but not in wt animals. Scale bar, 10 µm. (C) Immunoblotting to detect the conversion of LC3-I to LC-II. Using an anti-LC3 antibody, both endogenous LC3 and transgenic (exogenous) EGFP-LC3 expression was detected and an increase of LC3-II conversion/accumulation was seen in the spns1 mutant compared with wt fish at 84 hpf. (D–F) Identification of autophagosome and autolysosome/lysosome formation in the spns1 mutant. (D, E) LysoTracker (DND-99; red) staining of EGFP-LC3 transgenic spns1-mutant [Tg(CMV:EGFP-LC3); spns1] embryos was performed at 84 hpf. At the whole animal levels (D), the EGFP-LC3 signal is relatively higher throughout in the spns1 mutant than in wild type, and a particularly strong signal can be seen in the liver, as shown in (A). In the head and trunk portions of the animals (D), a distinctive increase in the intensity of LysoTracker can be observed in the spns1 mutant. At the intracellular level (E), several small LC3 spots and largely diffuse green signal in the cells and cytosolic LysoTracker staining is seen. A number of enlarged LC3- and LysoTracker-positive yellow punctate structures can be seen in the spns1 mutant by confocal microscopy at a higher magnification (inset; enlarged from dotted square area). (F) EGFP-LC3 and mCherry-LC3 double-transgenic [Tg(EGFP-LC3:mCherry-LC3)] zebrafish were used to monitor autolysosome formation in spns1 MO-injected embryos at 84 hpf. A number of enlarged yellow LC3 puncta were detected in the spns1 morphant, while only small yellow LC3 spots can be seen in control-injected embryos. Nuclei were counterstained with 4′, 6-diamidino-2-phenylindole, dihydrochloride (DAPI). Scale bar, 250 µm in (D). Scale bar, 10 µm in (E, F). Quantification of data presented in D (n = 12), E (n = 6), and F (n = 6) is shown in the right graph; the number (n) of animals is for each genotype. Three independent areas (periderm or basal epidermal cells above the eye) were selected from individual animals. (G) Transgenic expression of mCherry-Lamp1 in wt [Tg(CMV:EGFP-LC3)] and spns1-mutant [Tg(CMV:EGFP-LC3);spns1] animals 84 hpf. Scale bar, 10 µm. (H) Transgenic expression of EGFP-Vector (vector), EGFP-wild-type Spns1 (spns1 WT), or EGFP-mutant Spns1 (spns1E153K) in [Tg(CMV:mCherry-LC3);spns1] animals at 84 hpf. Scale bar, 10 µm. Quantification of data presented in H is shown for ratio of yolk opaqueness phenotype (n = 48), mCherry intensity (red) (n = 6), and merge intensity of EGFP and mCherry (yellow) (n = 6) in the right graphs; the number (n) of animals is for each genotype. Three independent areas (periderm or basal epidermal cells above the eye) were selected from individual animals. Error bars represent the mean ± standard deviation (S.D.), *p<0.005; ns, not significant.To gain additional information concerning the site of action of Spns1, we examined LC3 conversion as a hallmark of autophagy induction in whole zebrafish embryos by immunoblotting to distinguish the autophagosome-associated phosphatidylethanolamine-conjugated LC3-II from the cytosolic LC3-I form by showing the increased mobility of LC3-II. In spns1 mutants, both endogenous LC3-II and exogenous EGFP-LC3-II were detected at higher levels (
).Extending our analysis to a second animal model, we also examined autophagy activity in Caenorhabditis elegans containing a loss-of function mutation in the gene homologous to spin-1 (C13C4.5) [24]. Similar to our results in zebrafish, the C. elegansspin-1 mutation conferred augmented autophagic induction, as demonstrated by the increased expression and cytoplasmic aggregation of the EGFP::LGG-1 reporter gene product (LGG-1 is the ortholog of LC3) in seam cells of mutant animals (). We found the spin-1 mutant worms were more sensitive to starvation-induced death (), consistent with defective autophagy. In addition, decrease of Spns1 in heterozygous zebrafish as well as loss of Spin-1 in homozygous worms resulted in significant reductions in their adult lifespan (). These data suggest that across these different species, the defects in the spns1/spin-1 gene induce autophagic abnormality with excessive autophagosomes and/or autolysosomes, potentially leading to the accumulation of undegraded macromolecules and organelles in cells of mutant animals, which subsequently have a shortened life expectancy.
Lysosomal, but not mitochondrial, abnormalities in the pathogenesis of spns1 mutants
Spin/Spns1 is a multi-pass transmembrane protein localized in late endosomes and lysosomes [15], [25]. In mammalian cells, however, Spns1 has been reported to occasionally localize to mitochondria [26]. To elucidate a potential relationship between lysosomal and mitochondrial biogenesis with the pathogenesis induced by the Spns1-defective animals in vivo, we performed double staining of these two organelles by using LysoTracker (red) and MitoTracker (green) probes. In whole animal images, we found prominent increases of LysoTracker intensity in spns1-mutant fish, whereas no significant difference was detected by MitoTracker staining (). By further utilizing Tg(CMV:EGFP-LC3);spns1 animals, concurrent LysoTracker staining revealed significant numbers of intracellular yellow (both green- and red-positive) puncta. Since the EGFP green signal is normally lost by quenching in acidic compartments such as the lysosome [27], this finding suggests the existence of insufficiently acidic autolysosomes (
). In contrast, staining with a mitochondrial superoxide indicator, MitoSOX, revealed no critical abnormality of superoxide generated in the mitochondria (). These results suggest that Spns1 deficiency fundamentally leads to impaired lysosomal and/or autolysosomal acidification, but not to any significant modulation of mitochondrial biogenesis and oxidative stress.
Formation of enlarged mal-acidic cellular deposits caused by the Spns1 defect
Autophagosomes subsequently fuse with lysosomes to degrade their contents. The Spns1 defect causes excessively enlarged undegraded deposits of autolysosomal compartments in cells [16]. The inability of spns1 mutants to degrade protein aggregates, despite the apparent induction of autophagosomes, prompted us to ask whether Spns1 is required for degradation of autophagic cargos by ensuring proper acidification in autolysosomes. To address this question, we generated EGFP-LC3;mCherry-LC3 double-transgenic zebrafish [Tg(CMV:EGFP-LC3;mCherry-LC3); spns1] to determine the acidification efficiency. As EGFP fluorescence is lost in acidic compartments, but mCherry red fluorescence is not, the coexpression of EGFP-LC3 and mCherry-LC3 can label insufficiently acidified autolysosomes as well as non-acidic autophagosomes to produce yellow fluorescence (positive for both green EGFP and red mCherry), whereas acidic autolysosomes would only show a red fluorescent signal.To first validate that the EGFP signal was decreased or lost by quenching in acidic autolysosomes of wild-type animals, we utilized two lysosomal protease inhibitors, pepstatin A, an inhibitor of cathepsins D and E, and E-64-d, an inhibitor of cathepsins B, H and L. Because these inhibitors can target the proteases without altering autolysosomal acidity, we anticipated that the EGFP signal would only be reduced in truly acidic vesicles. In wild-type animals, as expected, only the large punctate signals of EGFP-LC3 were faded, whereas neither the LysoTracker nor mCherry-LC3 signals were affected (). On the other hand, as shown in
, once spns1morpholino antisense oligonucleotide (MO) was injected into the GFP- and mCherry-LC3-double transgenic fish embryos to knockdown the gene expression, we observed a prominent increase in the number of yellow-fluorescent enlarged intracellular vesicles as compared with those in standard control MO-injected animals, consistent with the accumulation of insufficiently acidified autolysosomes. The EGFP-LC3-positive vesicles in the spns1 mutants were further confirmed to be autolysosomes by the co-expression of a mCherry-tagged lysosomal membrane marker, lysosomal-associated membrane protein 1 (Lamp1) (
). mCherry-LC3-positive enlarged vesicular aggregations that accumulated in the spns1-mutant fish were suppressed by expression of EGFP-tagged Spns1 vector (Spns1 WT) but not by that of an empty EGFP vector or an EGFP-tagged mutant Spns1 vector (Spns1E153K; presumably disrupted for the transporter activity) [15], [16] (
).In addition, the vast majority of EGFP-LC3-positive vesicles in spns1 mutants were found to be still positive for a fluorogenic lysosomal substrate DQ Red BSA at the earlier phenotypic stages (∼60 hours post fertilization; hpf) (). DQ Red BSA fluoresces upon lysosomal degradation due to dequenching; the released peptide fragments are brightly fluorescent. Thus, the autolysosomes of spns1-mutant fish appeared to still contain hydrolytic activity at least in early autolysosomes, indicating that the primary reason for the retained EGFP-LC3 signal is probably due to suboptimal acidity at later stages. Therefore, the observed increase in both EGFP-LC3 and mCherry-LC3 double-positive yellow fluorescent intracellular vesicles in spns1-mutant fish could be attributed to ineffective or insufficient acidification (“mal-acidification”) at the late autolysosomal stage.
Rescue of the Spns1 deficit in zebrafish by suppression of Beclin 1
Based on a recent report of an autophagy-dependent effect of spns1 knockdown in a mammalian cell culture [16] and our current observations described above in the zebrafish model, we assumed that inhibition of the early stages of autophagy by blocking the class III phosphatidylinositol 3-kinase (PtdIns3K) complex containing Vps34/Pik3c3 and Beclin 1 would reduce aggregated LC3 puncta in cells of spns1 mutants and ameliorate yolk opaque abnormalities induced by the Spns1 deficiency. We therefore designed a splice-block morpholino antisense oligonucleotide (MO) targeting the zebrafishbeclin 1 (becn1; zbeclin 1) gene at the 5′ end of exon 4 (
). RT-PCR and DNA sequencing results showed this splice-block MO (beclin 1 MO) generated a loss of exon 4 and a premature stop codon, resulting in a truncated protein lacking the entire Bcl2 homology domain 3 (BH3 domain) (
). The phenotype induced by the knockdown of beclin 1 by the MO during early development was not particularly evident at the gross morphology level apart from some minor developmental retardation at 24 hpf, without any obvious abnormality later on (). In contrast, the concurrent suppression of both spns1 and beclin 1 by MO targeting strikingly diminished the yolk opaqueness seen with the spns1 morphants and produced an increased number of viable larvae that survive beyond 72 hpf (
). We also performed beclin 1 MO injections into spns1-mutant embryos, and reproducibly confirmed the ameliorated yolk phenotype through 3 dpf (), but mutant animals subsequently relapsed into deterioration, presumably due to the persistent impact of the Spns1 mutation and/or transient activity of the beclin 1 MO. These results indicate that suppression of the early stage of autophagy by beclin 1 knockdown can offset the deleterious effect of Spns1 deficiency that occurs at the late stage of autophagy.
Figure 2
Knockdown of beclin 1 suppresses the Spns1 deficiency in zebrafish.
(A) Schematic representation of the zebrafish beclin 1 (zbeclin 1) gene, its mRNA and protein products. A splice-blocking beclin 1 MO was designed to overlap the intron-exon boundary at the 5′-splice junction of exon 4 in the zebrafish beclin 1 gene. To detect aberrantly spliced RNA products, two forward primers were designed for exon 3 (EX3 primer) and exon 4 (EX4 primer), and one reverse primer was designed for exon 7 (EX7 primer) within the beclin 1 gene. The zebrafish beclin 1 gene has a total of 11 exons having three unique domains [BH3 domain, coiled-coil (CCD) domain, and evolutionarily conserved (ECD) domain], and the beclin 1 MO was anticipated to disrupt the BH3 domain encoded by exon 4 and exon 5. (B) Splicing detection of zbeclin 1 mRNA by RT-PCR. Amplified PCR fragments show the intact sizes of the two amplicons for EX3-EX7 and EX4-EX7 following control (water) injection or only spns1 MO injection. Either beclin 1 MO (12 ng/embryo) injection or coinjection of spns1 MO (4 ng/embryo) and beclin 1 MO (12 ng/embryo) generated a skipping of exon 4 (beclin 1Δexon4). This was detected by the presence of an altered EX3-EX7 amplicon and undetectable EX4-EX7 product. The deletion of exon 4 was confirmed by sequencing. Injected embryos were harvested for total RNA isolation at 54 hpf. (C and D) Rescue of the spns1 morphant by beclin 1 knockdown. (C) The yolk opaqueness phenotype appearance in control-injected (water), spns1 MO-injected, and spns1 and beclin 1 MOs-coinjected embryos was followed through 72 hpf. At 24 hpf, opaqueness commenced from the yolk extension region, which had almost disappeared or was severely damaged (more than 95% of spns1 MO-injected animals) with an extension of opacity to the entire yolk at 48 hpf. By 72 hpf, yolk opaqueness became highly dense throughout most of the spns1 MO-injected embryos, which usually died within another 24 h. Scale bar, 250 µm. (D) Clarification of the yolk opaqueness phenotype in spns1 morphants at 72 hpf. As described in (C), more than 95% of the spns1 MO-injected embryos showed a ‘mostly opaque’ yolk at 48 hpf, and such embryos subsequently died. Animals showing a ‘partially opaque’ yolk could sometimes be recovered and subsequently survived 96 h and beyond. beclin 1 MO coinjection dramatically increased (more than 10 times) the animal numbers with the partial yolk opaque phenotype. (E) Survival curve for spns1 morphant and spns1;beclin 1-double morphant larvae (log rank test: χ2 = 162.5 on one degree of freedom; p<0.0001).
Knockdown of beclin 1 suppresses the Spns1 deficiency in zebrafish.
(A) Schematic representation of the zebrafishbeclin 1 (zbeclin 1) gene, its mRNA and protein products. A splice-blocking beclin 1 MO was designed to overlap the intron-exon boundary at the 5′-splice junction of exon 4 in the zebrafishbeclin 1 gene. To detect aberrantly spliced RNA products, two forward primers were designed for exon 3 (EX3 primer) and exon 4 (EX4 primer), and one reverse primer was designed for exon 7 (EX7 primer) within the beclin 1 gene. The zebrafishbeclin 1 gene has a total of 11 exons having three unique domains [BH3 domain, coiled-coil (CCD) domain, and evolutionarily conserved (ECD) domain], and the beclin 1 MO was anticipated to disrupt the BH3 domain encoded by exon 4 and exon 5. (B) Splicing detection of zbeclin 1 mRNA by RT-PCR. Amplified PCR fragments show the intact sizes of the two amplicons for EX3-EX7 and EX4-EX7 following control (water) injection or only spns1 MO injection. Either beclin 1 MO (12 ng/embryo) injection or coinjection of spns1 MO (4 ng/embryo) and beclin 1 MO (12 ng/embryo) generated a skipping of exon 4 (beclin 1Δexon4). This was detected by the presence of an altered EX3-EX7 amplicon and undetectable EX4-EX7 product. The deletion of exon 4 was confirmed by sequencing. Injected embryos were harvested for total RNA isolation at 54 hpf. (C and D) Rescue of the spns1 morphant by beclin 1 knockdown. (C) The yolk opaqueness phenotype appearance in control-injected (water), spns1 MO-injected, and spns1 and beclin 1 MOs-coinjected embryos was followed through 72 hpf. At 24 hpf, opaqueness commenced from the yolk extension region, which had almost disappeared or was severely damaged (more than 95% of spns1 MO-injected animals) with an extension of opacity to the entire yolk at 48 hpf. By 72 hpf, yolk opaqueness became highly dense throughout most of the spns1 MO-injected embryos, which usually died within another 24 h. Scale bar, 250 µm. (D) Clarification of the yolk opaqueness phenotype in spns1 morphants at 72 hpf. As described in (C), more than 95% of the spns1 MO-injected embryos showed a ‘mostly opaque’ yolk at 48 hpf, and such embryos subsequently died. Animals showing a ‘partially opaque’ yolk could sometimes be recovered and subsequently survived 96 h and beyond. beclin 1 MO coinjection dramatically increased (more than 10 times) the animal numbers with the partial yolk opaque phenotype. (E) Survival curve for spns1 morphant and spns1;beclin 1-double morphant larvae (log rank test: χ2 = 162.5 on one degree of freedom; p<0.0001).We next examined whether the enlarged aggregations of LC3 in spns1 morphants and mutants can be restored by Beclin 1 knockdown. spns1 MO and/or beclin 1 MO were introduced into Tg(CMV:EGFP-LC3) fish embryos and resultant specimens were observed by confocal microscopy at the cellular level. The appearance of punctate vesicle-like intracellular aggregates and deposits observed in spns1 morphants was diminished by the beclin 1 knockdown (
). LC3 has several functional homologs, including gamma-aminobutyric acid A (GABA)-receptor associated protein (GABARAP) and GABARAPL2/GATE-16. It has been reported that both LC3 and GABARAP are indispensable for the autophagic process in mammalian cells [21]. The restorative effect of beclin 1 knockdown was also demonstrated in spns1-depleted Tg(CMV:EGFP-GABARAP;mCherry-LC3) fish. The concomitant microinjection of spns1 MO and beclin 1 MO showed consistently similar outcomes in terms of the obvious reduction of both EGFP-GABARAP and mCherry-LC3 puncta (
), as observed with the EGFP-LC3 puncta (
).
Figure 3
Knockdown of beclin 1 suppresses abnormal autolysosomal puncta formation and embryonic senescence caused by Spns1 deficiency in zebrafish.
(A) Effect of beclin 1 knockdown on EGFP-LC3 puncta formation in spns1-depleted zebrafish embryos. Injection of control (water) injection, spns1 MO (4 ng/embryo) or coinjection of spns1 MO (4 ng/embryo) and beclin 1 MO (12 ng/embryo) into Tg(CMV:EGFP-LC3) fish was performed to assess whether the beclin 1 knockdown reduces or eliminates aggregated LC3 puncta induced by Spns1 depletion at 84 hpf. Scale bar, 10 µm. Quantification of data presented in panel A (n = 12) is shown in the right graph; the number (n) of animals is for each morphant or water-injected control. Three independent areas (periderm or basal epidermal cells above the eye) were selected from individual animals. (B) Effect of beclin 1 knockdown on EGFP-GABARAP as well as mCherry-LC3 puncta formation in spns1-depleted zebrafish embryos. Injection of control (water), spns1 MO or coinjection of spns1 MO and beclin 1 MO into Tg(CMV:EGFP-GABARAP;mCherry-LC3) fish was performed to evaluate whether the beclin 1 knockdown reduces or eliminates the aggregation of GFP-GABARAP puncta in comparison with those of LC3 caused by the Spns1 depletion at 84 hpf. Scale bar, 10 µm. Quantification of data presented in the top row (green; EGFP) (n = 9), middle row (red; mCherry) (n = 12), and bottom row (yellow; merge of EGFP and mCherry) (n = 9) in panel B is shown in the right graphs; the number (n) of animals is for each morphant or water-injected control. Three independent areas (periderm or basal epidermal cells above the eye) were selected from individual animals. (C) Effect of beclin 1 knockdown on embryonic senescence in spns1 morphant. By using the same injection samples [injection of control (water), spns1 MO or coinjection of spns1 MO and beclin 1 MO into Tg(CMV:EGFP-GABARAP;mCherry-LC3) fish], SA-β-gal staining was performed to assess whether the beclin 1 knockdown has any impact on the embryonic senescence caused by Spns1 depletion at 84 hpf. Representative images of individual fish by bright field (BF, live samples) and SA-β-gal (SABG) staining are shown in the upper and middle panels, respectively. Scale bar, 250 µm. Lower panels are larger magnification images of corresponding SA-β-gal samples shown in the middle panels and the fluorescence images of nuclei counterstained with DAPI. Scale bar, 10 µm. Quantification of data presented in the middle row (SABG) in panel C (n = 12) is shown in the right graph; the number (n) of animals is for each morphant or water-injected control. Error bars represent the mean ± S.D., *p<0.005.
Knockdown of beclin 1 suppresses abnormal autolysosomal puncta formation and embryonic senescence caused by Spns1 deficiency in zebrafish.
(A) Effect of beclin 1 knockdown on EGFP-LC3 puncta formation in spns1-depleted zebrafish embryos. Injection of control (water) injection, spns1 MO (4 ng/embryo) or coinjection of spns1 MO (4 ng/embryo) and beclin 1 MO (12 ng/embryo) into Tg(CMV:EGFP-LC3) fish was performed to assess whether the beclin 1 knockdown reduces or eliminates aggregated LC3 puncta induced by Spns1 depletion at 84 hpf. Scale bar, 10 µm. Quantification of data presented in panel A (n = 12) is shown in the right graph; the number (n) of animals is for each morphant or water-injected control. Three independent areas (periderm or basal epidermal cells above the eye) were selected from individual animals. (B) Effect of beclin 1 knockdown on EGFP-GABARAP as well as mCherry-LC3 puncta formation in spns1-depleted zebrafish embryos. Injection of control (water), spns1 MO or coinjection of spns1 MO and beclin 1 MO into Tg(CMV:EGFP-GABARAP;mCherry-LC3) fish was performed to evaluate whether the beclin 1 knockdown reduces or eliminates the aggregation of GFP-GABARAP puncta in comparison with those of LC3 caused by the Spns1 depletion at 84 hpf. Scale bar, 10 µm. Quantification of data presented in the top row (green; EGFP) (n = 9), middle row (red; mCherry) (n = 12), and bottom row (yellow; merge of EGFP and mCherry) (n = 9) in panel B is shown in the right graphs; the number (n) of animals is for each morphant or water-injected control. Three independent areas (periderm or basal epidermal cells above the eye) were selected from individual animals. (C) Effect of beclin 1 knockdown on embryonic senescence in spns1 morphant. By using the same injection samples [injection of control (water), spns1 MO or coinjection of spns1 MO and beclin 1 MO into Tg(CMV:EGFP-GABARAP;mCherry-LC3) fish], SA-β-gal staining was performed to assess whether the beclin 1 knockdown has any impact on the embryonic senescence caused by Spns1 depletion at 84 hpf. Representative images of individual fish by bright field (BF, live samples) and SA-β-gal (SABG) staining are shown in the upper and middle panels, respectively. Scale bar, 250 µm. Lower panels are larger magnification images of corresponding SA-β-gal samples shown in the middle panels and the fluorescence images of nuclei counterstained with DAPI. Scale bar, 10 µm. Quantification of data presented in the middle row (SABG) in panel C (n = 12) is shown in the right graph; the number (n) of animals is for each morphant or water-injected control. Error bars represent the mean ± S.D., *p<0.005.Another hallmark of spns1-mutant fish is the striking induction of senescence-associated β-galactosidase (SA-β-gal), which is an endogenous lysosomal β-D-galactosidase detectable at pH 6.0 [12], [28]. Previously we demonstrated that an embryonic (or larval) senescence phenotype caused by specific gene mutations (or MO-mediated knockdowns) and also by stress is readily detectable via SA-β-gal staining of zebrafish embryos and larvae [12]. Additionally, we also tested another lysosomal hydrolase/glycosidase, α-L-fucosidase (α-fuc) that has been reported in mammalian cells as a novel sensitive biomarker, senescence-associated α-fuc (SA-α-fuc) [29]. We found that higher activity of SA-α-fuc, as well as of SA-β-gal, was detected in spns1-mutant fish, compared with wild-type control fish, with SA-β-gal being the more sensitive assay (; see also ). We therefore examined the effect of beclin 1 MO by staining with SA-β-gal in both spns1 morphants and mutants. Consistent with the restored yolk clarity and reduced LC3 puncta observed with beclin 1 knockdown in conditions of Spns1 deficiency, the beclin 1 MO markedly decreased the intensity of SA-β-gal at 3.5 dpf (
and ), whereas control injections (water and standard control MO) did not significantly affect the SA-β-gal activity in spns1 morphant and mutant animals (
and ). These results suggest that the aberrant SA-β-gal activity in spns1-defective animals coincides with autophagic initiation and its progression, and is accompanied by an increase in autolysosomes at the late autophagy stage.While the excessive accumulation of autophagosomes and autolysosomes was observed in spns1-deficient animals, we anticipated that induction of apoptosis may be accompanied or preceded by the autophagic abnormality. We found, however, that such apoptotic induction was undetectable in spns1 mutants and morphants (; see also ). Acridine orange (AO) staining, which can correspond to the detection of acidified compartments [30], [31] as well as of apoptotic and necrotic cell death [32], [33], showed positive signals co-stained by LysoTracker in spns1 mutants (). However, when we performed a TUNEL assay for detecting DNA fragmentation associated with apoptosis, we found no staining upon knockdown of spns1 (), while the positive control of ultraviolet light (UV) irradiation produced a TUNEL-positive signal, as reported previously [34]. The UV irradiation-mediated apoptosis was slightly but not significantly inhibited by beclin 1 knockdown (), which can fully suppress autophagy induced by UV (), suggesting that Beclin 1 plays a critical role in initiating autophagy, but is potentially dispensable for the induction of UV-mediated apoptosis in zebrafish embryos.
Impact of the p53 status on Spns1 deficiency in zebrafish
It has been reported that cells deficient in Beclin 1 exhibit an elevated DNA damage response [35], along with an increase in reactive oxygen species (ROS) [36]. In addition, a reduction of p53 by proteasomal degradation has been documented under the condition of beclin 1 knockdown [37]. The stress-responsive function of p53 still remains poorly understood with regard to how it is linked to autophagy impairment. In fact, although activated nuclear p53 can induce autophagy [38], it has also been reported that a removal of basal cytosolic p53 can stimulate autophagy [20]. We wondered which state of p53, if either, is involved in the Spns1 impairment. Moreover, since p53 activation is ordinarily thought to induce cellular senescence, which is also the case for zebrafish embryonic senescence [33], we suspected that the suppression of senescence by Beclin 1 depletion might be due to an intrinsic reduction in p53 [37]. We therefore investigated the requirement of p53 in the Spns1 deficiency-mediated senescence in zebrafish embryos under various experimental conditions through the genetic manipulations described below.First, we examined the potential contribution of Spns1 and p53 separately in spns1 and p53 mutant fish backgrounds. We tested spns1 MO and p53 MO in p53 mutants and spns1 mutants, respectively (). Unexpectedly, either p53 mutation or knockdown enhanced, rather than suppressed, the senescence phenotype under the Spns1-defective conditions. This increased SA-β-gal activity that is induced by p53 suppression was further demonstrated by coinjection of p53 MO and spns1 MO into normal wild-type animals to rule out any background influence in the mutants (
, upper panels and B).
Figure 4
p53 depletion does not suppress but rather exacerbates Spns1 deficiency.
(A) Effect of p53 knockdown on embryonic senescence and autolysosome formation in spns1 morphants. The impact of transient p53 knockdown on SA-β-gal (SABG) induction, as well as on EGFP-LC3 and LysoTracker (LysoT) puncta, was determined in spns1 morphants at 84 hpf, followed by the MO (4 ng/embryo) injections. Inverse-sequence p53 MO (inv. p53 MO) was used as a negative control for the original p53 MO. Scale bar, 250 µm in the SABG images. Scale bar, 10 µm in the fluorescence images. (B) Quantification of the SA-β-gal intensities in MO-injected animals, as shown for the SABG images in (A). Quantification of data presented in the top row (SABG) in B (n = 12) is shown; the number (n) of animals is for each morphant. (C) Quantification of EGFP-LC3 and LysoTracker puncta in MO-injected animals shown in (A) (n = 9); the number (n) of animals is for each morphant. Three independent areas (periderm or basal epidermal cells above the eye) were selected from individual animals. (D) Effect of a p53 mutation on embryonic SA-β-gal activity in the spns1 mutant. The heritable impact of p53 and Spns1 on SA-β-gal induction was tested in each single gene mutant [spns1 (spns1) or tp53 (p53)] and double mutant spns1 (spns1) compared with wild-type (wt) animals at 84 hpf. Scale bar, 250 µm. (E) Quantification of the SA-β-gal intensities in wt, tp53, spns1 and spns1 animals, shown in (D). Quantification of data presented in panel D (n = 12) is shown; the number (n) of animals is for each genotype. (F) Quantitative RT-PCR analyses of senescence marker and/or mediator expression as well as p53-downstream target genes in wt, tp53, spns1 and spns1 at 72 hpf. Data are mean ±SD [n = 4 samples (3 embryos/sample) per genotype]. Asterisks denote significant changes compared to wt values. *p<0.05. (G) LC3 conversions in p53 and spns1-mutant animals. Protein detection for the conversion/accumulation of LC3-I to LC-II was performed in the described mutant background animals in comparison with wt fish at 84 hpf. Western blot analysis using anti-LC3 antibody shows endogenous LC3 protein levels, which can confirm an increase of the total amount of LC3 in the p53 mutant compared with wt fish. Increased LC3-II conversion/accumulation was detected in p53 and spns1 double-mutants as well as in spns1 single-mutant fish. (H) The blotting band intensities of LC3-I, LC3-II and β-actin were quantified (n = 6), and the relative ratios between LC3-II/actin and LC3-I/actin are shown in the bar graph; the number (n) of animals is for each genotype. (I) wt, tp53, spns1 and spns1 embryos injected with beclin 1 MO or control MO (12 ng/embryo) were assayed for SA-β-gal at 84 hpf. beclin 1 MO-mediated suppression of SA-β-gal in spns1 animals was attenuated in the p53 mutant background. Scale bar, 250 µm. (J) Quantification of the SA-β-gal intensities shown in (I). Quantification of data presented in H (n = 12) is shown; the number (n) of animals is for each genotype with MO. Error bars represent the mean ± S.D., *p<0.005; ns, not significant.
p53 depletion does not suppress but rather exacerbates Spns1 deficiency.
(A) Effect of p53 knockdown on embryonic senescence and autolysosome formation in spns1 morphants. The impact of transient p53 knockdown on SA-β-gal (SABG) induction, as well as on EGFP-LC3 and LysoTracker (LysoT) puncta, was determined in spns1 morphants at 84 hpf, followed by the MO (4 ng/embryo) injections. Inverse-sequence p53 MO (inv. p53 MO) was used as a negative control for the original p53 MO. Scale bar, 250 µm in the SABG images. Scale bar, 10 µm in the fluorescence images. (B) Quantification of the SA-β-gal intensities in MO-injected animals, as shown for the SABG images in (A). Quantification of data presented in the top row (SABG) in B (n = 12) is shown; the number (n) of animals is for each morphant. (C) Quantification of EGFP-LC3 and LysoTracker puncta in MO-injected animals shown in (A) (n = 9); the number (n) of animals is for each morphant. Three independent areas (periderm or basal epidermal cells above the eye) were selected from individual animals. (D) Effect of a p53 mutation on embryonic SA-β-gal activity in the spns1 mutant. The heritable impact of p53 and Spns1 on SA-β-gal induction was tested in each single gene mutant [spns1 (spns1) or tp53 (p53)] and double mutant spns1 (spns1) compared with wild-type (wt) animals at 84 hpf. Scale bar, 250 µm. (E) Quantification of the SA-β-gal intensities in wt, tp53, spns1 and spns1 animals, shown in (D). Quantification of data presented in panel D (n = 12) is shown; the number (n) of animals is for each genotype. (F) Quantitative RT-PCR analyses of senescence marker and/or mediator expression as well as p53-downstream target genes in wt, tp53, spns1 and spns1 at 72 hpf. Data are mean ±SD [n = 4 samples (3 embryos/sample) per genotype]. Asterisks denote significant changes compared to wt values. *p<0.05. (G) LC3 conversions in p53 and spns1-mutant animals. Protein detection for the conversion/accumulation of LC3-I to LC-II was performed in the described mutant background animals in comparison with wt fish at 84 hpf. Western blot analysis using anti-LC3 antibody shows endogenous LC3 protein levels, which can confirm an increase of the total amount of LC3 in the p53 mutant compared with wt fish. Increased LC3-II conversion/accumulation was detected in p53 and spns1 double-mutants as well as in spns1 single-mutant fish. (H) The blotting band intensities of LC3-I, LC3-II and β-actin were quantified (n = 6), and the relative ratios between LC3-II/actin and LC3-I/actin are shown in the bar graph; the number (n) of animals is for each genotype. (I) wt, tp53, spns1 and spns1 embryos injected with beclin 1 MO or control MO (12 ng/embryo) were assayed for SA-β-gal at 84 hpf. beclin 1 MO-mediated suppression of SA-β-gal in spns1 animals was attenuated in the p53 mutant background. Scale bar, 250 µm. (J) Quantification of the SA-β-gal intensities shown in (I). Quantification of data presented in H (n = 12) is shown; the number (n) of animals is for each genotype with MO. Error bars represent the mean ± S.D., *p<0.005; ns, not significant.Next, we performed coinjections of p53 and spns1 MOs into Tg(CMV:EGFP-LC3) fish to concurrently monitor the autophagic process with EGFP-positive LC3 aggregate formation, in addition to subsequent senescence induction (
, middle and lower panels, and C). Upon transient knockdown, although the total EGFP fluorescence became brighter, the number of EGFP-LC3 puncta were only slightly increased by p53 MO, compared with the control injected fish (
, columns 1 and 2). On the one hand, enhanced LC3 puncta induction was observed when both MOs were coinjected, as similarly seen in the case of spns1 MO injection only (
, columns 3 and 4), suggesting that autophagy induction associated with Spns1 depletion does not require p53. On the other hand, there were more cumulative LysoTracker-positive aggregates (dysfunctional autolysosomes) colocalized with LC3 by the double knockdown than spns1 knockdown alone, as EGFP-LC3 and LysoTracker double-positive yellow puncta were obviously increased by the p53 suppression in spns1 morphants (
, middle panels, and C, columns 11 and 12). Moreover, the enhancing effect of p53 knockdown on senescence in spns1 morphants was obviously seen (
, upper panels, and ).We further generated spns1-mutant fish harboring a p53 mutation (tp53), spns1, and confirmed that there was no requirement of normal p53 inheritance for the induction of embryonic senescence resulting from Spns1 deficiency, but instead there was an enhancement of SA-β-gal activity caused by the constitutive loss of wild-type p53 (
). To further obtain robust hallmarks of senescence in zebrafish embryos, we examined the expression of other markers and/or mediators of senescence in spns1-defective animals. Quantitative RT-PCR (qPCR) as well as semi-qPCR in individual embryos demonstrated that the expression of p21 and plasminogen activator inhibitor-1 (pai-1), which are known downstream targets of the p53 pathway [39], were upregulated in spns1 morphants and mutants (
, and ; see also ). Senescence marker protein-30 (smp-30) was downregulated in spns1-deficient animals compared with the corresponding controls. While the induction of p21 as well as bax was apparently regulated in a p53-dependent manner, both the pai-1 induction and the smp-30 reduction in spns1 mutants were not influenced by the p53 defect.We extended the analysis by monitoring the conversion of LC3-I into LC3-II among normal wild-type, tp53, spns1, and spns1 fish through 4 dpf. Autophagy was minimally induced in tp53 fish based on detection of LC3-II conversion by immunoblotting, while the total amount of LC3 (LC3-I plus -II) was increased (
). In spns1 fish, the LC3-II conversion/accumulation was similar to that seen in spns1-mutant fish (
). These results suggest that either decrease or loss of basal p53 enhances the Spns1 impairment, potentially by augmenting autophagy progression (but not initiation) and/or lysosomal biogenesis (i.e., subsequent autolysosomal formation and maturation).We then proceeded to assess the epistasis among spns1, beclin 1 and p53. We first confirmed that Beclin 1 suppression had no significant impact on p53 morphants or tp53 fish (
, columns 1, 3, 5, and 7, and ). Conversely, p53 depletion prevented the ability of beclin 1 MO to suppress the appearance of the yolk opaqueness and senescence phenotypes of spns1 mutants (
, and ). Moreover, the beclin 1 knockdown significantly suppressed the SA-β-gal activity in spns1 fish to a similar extent as seen in standard control MO-injected spns1 fish (
, columns 2 and 8, and ). However, the reduction of the SA-β-gal activity was more obvious in beclin 1 MO-injected spns1 fish than in spns1 fish (
, columns 6 and 8, and ). Thus, basal p53 activity has a certain protective role(s) in preventing the deleterious phenotypes caused by genetic ablation of the spns1 gene, by competing with Beclin 1-mediated autophagy progression.Although basal p53 can contribute to attenuating the Spns1 deficiency conceivably through suppressing autophagic progression and lysosomal biogenesis, we also wondered whether “activated p53” in response to DNA damage (e.g., UV) has any impact on the Spns1 deficiency, based on the result that the UV irradiation activates and/or enhances autophagy in zebrafish embryos (). As anticipated, apoptosis was similarly induced in spns1 mutants, compared with wild-type animals after UV treatment, whereas such apoptotic induction was almost undetectable under the p53 mutant condition (; see also ). The UV exposure apparently augmented both autophagic progress (i.e., GFP-LC3 puncta formation) and lysosomal biogenesis (i.e., LysoTracker-stained puncta) in spns1 mutants only when functional p53 was present ().A DNA damage response can be visualized as persistent foci of damaged nuclear DNA and its interacting proteins such as the phosphorylated histone variant, γH2AX [40]. DNA damage induced by UV treatment and the subsequent cell-cycle arrest in S phase were demonstrated by an increase of γH2AX intensity and a decrease of 5-bromo-2-deoxyuridine (BrdU) incorporation, respectively (; see also ). spns1 mutants had a negligible difference in γH2AX levels but had a significant reduction of BrdU incorporation, irrespective of the p53 state (), which is indicative of a slowdown of cell proliferation without apparent DNA damage. The immunostaining of a mitotic marker, phosphorylated histone H3 (pH 3) also showed a significant reduction in tp53-spns1-mutant animals, even without UV treatment. There was a similar tendency of pH 3 reduction in non-irradiated spns1;tp53-double mutants, but it was not statistically significant (). Embryonic SA-β-gal activity was consistently increased by the UV stimulation in both wild-type and spns1-mutant animals in the presence of p53 ().Finally, we extended our analysis to examine the expression profiles of p21, pai-1, and smp-30 as potential markers and/or mediators of senescence in spns1-defective animals (
and ). beclin 1 morphants did not show any significantly detectable changes in expression of these genes (). Importantly, however, the suppression of beclin 1 significantly counteracted the impact of the spns1 depletion by restoring expression of the pai-1 and smp-30 genes (). As described above, even in the absence of p53, the altered regulation of these two critical senescence markers was still detectable in spns1-deficient animals (), indicating that p53-independent regulation may be responsible for the expression of these genes. In contrast, the induction of p21, bax, and mdm2 genes in the spns1-defective condition was apparently p53 dependent and UV responsive, as confirmed by the level of their expression in p53 mutants (). It is also important to note that expression of ink4ab (the zebrafish homolog of both p15 and p16) was induced by UV treatment but not by Spns1 loss (). Taken together, the upregulation of pai-1 and p21, and the downregulation of smp-30 in spns1-defective fish embryos are consistent with the induction of senescence characteristics in aging organisms [40], [41], [42], [43], [44], [45].
Chemical modulation and monitoring of the autolysosomal acidification in spns1-mutant fish
Chemical genetic approaches are emerging in the zebrafish model system, and increasing numbers of chemical compounds are currently available for examining autophagic regulation [46], [47], [48]. We determined the effects of several chemical compounds and selective modulators of autophagy on Spns1 deficiency to see if any chemical(s) ameliorates or exacerbates the Spns1 phenotypes of zebrafish embryos. Of the chemicals tested, bafilomycin A1 (BafA) and other proton pump inhibitors (PPIs) such as the acid reducer omeprazole stood out due to their apparent inhibitory effect on overall phenotypic deterioration in spns1 animals (
and ). BafA is a specific inhibitor of vacuolar-type H+-ATPase (v-ATPase), and inhibits lysosomal acidification, slowing or blocking degradation of LC3-II within autolysosomes as well as inhibiting the fusion between autophagosomes and lysosomes [49], [50], and subsequently it also enhances EGFP-LC3 puncta accumulation corresponding to mammalian autophagosomes [27]. Consistently, we found that BafA significantly increased the formation of cellular LC3 puncta as well as their gross EGFP intensity in wild-type zebrafish (
). Intriguingly, both the progression of yolk opacity and SA-β-gal activity in spns1 mutants during the time period of 36–60 hpf were entirely suppressed by BafA treatment (
). While EGFP-LC3 puncta signals in BafA-treated spns1 mutants did not appear significantly different compared with those in untreated counterparts, LysoTracker-positive compartments in cells were reduced by BafA treatment (
), similar to the result seen with whole animal staining (
). This is likely due to ‘prior’ alkalinization in lysosomes/autolysosomes and reduction of their biogenesis (
). Importantly, these effects of BafA on spns1-mutant animals were essentially unaltered under the p53-depleted condition. Thus, BafA-induced pre-alkalinization might compensate for vulnerability of the spns1 mutants lacking basal p53 activity (
).
Figure 5
Acidity-dependent lysosomal biogenesis is rate limiting in spns1-mutant zebrafish.
(A) Effect of bafilomycin A1 (BafA) on the yolk opaque phenotype (BF; bright field) and embryonic senescence (SABG; SA-β-gal) in the spns1 mutant in the presence or absence of p53 at 48 hpf. Normal wild-type (spns1), tp53 (p53), spns1 (spns1) and spns1 (spns1) embryos at 36 hpf were incubated with BafA (200 nM) for 12 h, and stained with LysoTracker at 48 hpf, followed by SA-β-gal staining at 60 hpf. Scale bar, 250 µm. (B) Quantification of the SA-β-gal intensities shown in (A). Quantification of data presented in panel A (n = 12) is shown; the number (n) of animals is for each genotype with DMSO or BafA. (C) Gross morphology, EGFP-LC3 and LysoTracker intensities in wild-type (wt) and spns1-mutant animals treated with BafA shown at 48 hpf (12 h treatment starting at 36 hpf). Scale bar, 250 µm. (D) Quantification of the EGFP-LC3 and LysoTracker fluorescence intensities shown in (C). Quantification of data presented in the middle and bottom rows (green; EGFP, red; mCherry) in panel C (n = 12) is shown; the number (n) of animals is for each genotype with DMSO or BafA. (E) Intracellular autolysosome formation and lysosomal biogenesis in the BafA-treated spns1 mutant. The samples analyzed in (C) were observed by using confocal microscopy at high magnification (×600). Scale bar, 10 µm. (F) Quantification of the EGFP-LC3 and LysoTracker fluorescence intensities shown in (E). Quantification of data presented for EGFP (green) and mCherry (red) signals in panel E (n = 6) is shown; the number (n) of animals is for each genotype with DMSO or BafA. Three independent areas (periderm or basal epidermal cells above the eye) were selected from individual animals. (G) Insufficient intracellular acidity constituent in the spns1 mutants. Using two different acidic-sensitive probes, LysoSensor 189 and neutral-sensitive LysoSensor 153 (green), in combination with LysoTracker (red), wt and spns1-mutant animals showed detectable signals when stained at 72 hpf. In spns1-mutant animals, autolysosomal and/or lysosomal compartments were more prominently detectable by LysoSensor 153 than by LysoSensor 189, at the cellular level with enhanced signal intensity of these enlarged compartments. In stark contrast, the cellular compartments in wt fish treated with pepstatin A and E-64-d (P/E) (12 h treatment from 60 hpf through 72 hpf) were more prominently detectable by LysoSensor 189 than by LysoSensor 153 under the identical LysoTracker staining conditions. Of note, these autolysosomal and lysosomal compartments in spns1 mutants, as well as in wt animals treated with pepstatin A and E-64-d, may still retain some weak (higher pH) and strong (lower pH) acidity, respectively, as short-term BafA treatment (for 1 h between 71 and 72 hpf) can abolish the acidic compartments stained by both LysoSensor and LysoTracker (). Scale bar, 10 µm. (H) Quantification of the LysoSensor (189 and 153) and LysoTracker fluorescence intensities shown in (G). Quantification of data presented for LysoSensor (green) and LysoTracker (red) signals in panel G (n = 6) is shown; the number (n) of animals is for each genotype with DMSO or pepstatin A and E-64-d (P/E). Three independent areas (periderm or basal epidermal cells above the eye) were selected from individual animals. Error bars represent the mean ± S.D., *p<0.005; ns, not significant.
Acidity-dependent lysosomal biogenesis is rate limiting in spns1-mutant zebrafish.
(A) Effect of bafilomycin A1 (BafA) on the yolk opaque phenotype (BF; bright field) and embryonic senescence (SABG; SA-β-gal) in the spns1 mutant in the presence or absence of p53 at 48 hpf. Normal wild-type (spns1), tp53 (p53), spns1 (spns1) and spns1 (spns1) embryos at 36 hpf were incubated with BafA (200 nM) for 12 h, and stained with LysoTracker at 48 hpf, followed by SA-β-gal staining at 60 hpf. Scale bar, 250 µm. (B) Quantification of the SA-β-gal intensities shown in (A). Quantification of data presented in panel A (n = 12) is shown; the number (n) of animals is for each genotype with DMSO or BafA. (C) Gross morphology, EGFP-LC3 and LysoTracker intensities in wild-type (wt) and spns1-mutant animals treated with BafA shown at 48 hpf (12 h treatment starting at 36 hpf). Scale bar, 250 µm. (D) Quantification of the EGFP-LC3 and LysoTracker fluorescence intensities shown in (C). Quantification of data presented in the middle and bottom rows (green; EGFP, red; mCherry) in panel C (n = 12) is shown; the number (n) of animals is for each genotype with DMSO or BafA. (E) Intracellular autolysosome formation and lysosomal biogenesis in the BafA-treated spns1 mutant. The samples analyzed in (C) were observed by using confocal microscopy at high magnification (×600). Scale bar, 10 µm. (F) Quantification of the EGFP-LC3 and LysoTracker fluorescence intensities shown in (E). Quantification of data presented for EGFP (green) and mCherry (red) signals in panel E (n = 6) is shown; the number (n) of animals is for each genotype with DMSO or BafA. Three independent areas (periderm or basal epidermal cells above the eye) were selected from individual animals. (G) Insufficient intracellular acidity constituent in the spns1 mutants. Using two different acidic-sensitive probes, LysoSensor 189 and neutral-sensitive LysoSensor 153 (green), in combination with LysoTracker (red), wt and spns1-mutant animals showed detectable signals when stained at 72 hpf. In spns1-mutant animals, autolysosomal and/or lysosomal compartments were more prominently detectable by LysoSensor 153 than by LysoSensor 189, at the cellular level with enhanced signal intensity of these enlarged compartments. In stark contrast, the cellular compartments in wt fish treated with pepstatin A and E-64-d (P/E) (12 h treatment from 60 hpf through 72 hpf) were more prominently detectable by LysoSensor 189 than by LysoSensor 153 under the identical LysoTracker staining conditions. Of note, these autolysosomal and lysosomal compartments in spns1 mutants, as well as in wt animals treated with pepstatin A and E-64-d, may still retain some weak (higher pH) and strong (lower pH) acidity, respectively, as short-term BafA treatment (for 1 h between 71 and 72 hpf) can abolish the acidic compartments stained by both LysoSensor and LysoTracker (). Scale bar, 10 µm. (H) Quantification of the LysoSensor (189 and 153) and LysoTracker fluorescence intensities shown in (G). Quantification of data presented for LysoSensor (green) and LysoTracker (red) signals in panel G (n = 6) is shown; the number (n) of animals is for each genotype with DMSO or pepstatin A and E-64-d (P/E). Three independent areas (periderm or basal epidermal cells above the eye) were selected from individual animals. Error bars represent the mean ± S.D., *p<0.005; ns, not significant.BafA specifically binds to subunit c of the v-ATPase and thereby inhibits its enzymatic and proton-pump activity, but it has been shown that the concentration used and the duration of treatment with this drug are fairly critical to observe this effect [49]. In addition, BafA may have other off-target effects [51]. Therefore, we specifically knocked down the v-ATPase subunit gene atp6v0c by using a MO, whose effectiveness had already been demonstrated [52]. We obtained comparably consistent outcomes for the ameliorative effect of atp6v0c knockdown on the Spns1 deficiency (). In addition, we found that three other PPIs (omeprazole, lansoprazole, and pantoprazole), which can all interfere with the v-ATPase [53], [54], could also suppress the senescence phenotype in spns1 mutants ().We further utilized LysoSensor dye to monitor acidification levels in lysosomes and autolysosomes, to verify that possible pre-alkalinization by BafA treatment or direct atp6v0c knockdown can efficiently suppress the spns1-mutant phenotypes. In contrast to the LysoTracker probes, which exhibit fluorescence that is largely independent of the pH level, the LysoSensor reagents can show a pH-dependent increase in fluorescence intensity upon acidification [55]. The neutral pH-sensitive LysoSensor 153 fluoresces optimally at pH 7.5, while the acidic pH-sensitive LysoSensor 189 fluoresces optimally at pH 5.2. When these probes (green) were used in combination with LysoTracker (red), we found a much stronger signal with LysoSensor 153 than with LysoSensor 189 in spns1-mutant animals (), which was also quite obvious at the cellular level (
). By contrast, treatment of wild-type animals with lysosomal protease inhibitors, pepstatin A and E-64-d, which allows the retention of intact autolysosomal/lysosomal acidity while preventing autolysosomal maturation and turnover, showed highly acidic vesicles stained by LysoSensor 189, rather than by LysoSensor 153 (
). Lysosomal compartments in spns1 mutants may still retain some weak acidification allowing lysosomal biogenesis and subsequent autophagosome-lysosome fusion, as short-term treatment (for 1 h) with BafA can completely abolish the acidic compartments stained by LysoSensor and significantly reduce the LysoTracker-positive signals ().Finally, we examined the colocalization of EGFP-LC3 puncta and lysosomes in wild-type fish in the presence of BafA or pepstatin A and E-64-d, compared to that in the spns1 fish (). In wild-type animals, BafA caused the accumulation of EGFP-LC3 and colocalization of EGFP-LC3-mCherry-LC3 signals (), but no accumulation of LysoTracker, indicating a block in fusion of autophagosomes with lysosomes (). Inhibition of lysosomal hydrolase activity with pepstatin A and E-64-d resulted in accumulation of lysosomes (red) and autolysosomes (yellow by overlapping EGFP-LC3 and LysoTracker) (). In contrast, the spns1 fish () and their cells () displayed both an accumulation of autolysosomes (yellow by overlapping EGFP-LC3 and LysoTracker) and autophagosomes (yellow by overlapping of EGFP-LC3 and mCherry-LC3) without any inhibitors, again indicating defects in both fusion of autophagosomes with lysosomes and autolysosomal maturation. Collectively, these results demonstrate that the appearance of deleterious changes in spns1 animals is due to aberrant autophagic progression caused by impaired suboptimal acidification in malformed autolysosomes, and that p53 may also be involved in the process of both lysosomal and autolysosomal pathogenesis in Spin1 deficiency.
Discussion
We demonstrated that loss of Spns1 leads to defects in autophagic and lysosomal homeostasis in zebrafish, and the tumor suppressors Beclin 1 and p53 are differentially involved in autophagy and senescence pathways regulated by Spns1. A reduction of Beclin 1 as an autophagy regulator can attenuate the Spns1 defect, whereas a decrease/loss of basal p53 activity, as well as activated p53 by DNA damage, augments it and exacerbates the deleterious phenotype in zebrafish. If both Spns1 and p53 were abrogated, the Beclin 1 reduction was no longer effective in suppressing the spns1-mutant phenotypes sufficiently, whereas v-ATPase reduction was robust enough to suppress the phenotypes regardless of p53 state.Importantly, we have successfully generated valuable zebrafish tools by crossing the fluorescent protein-tagged LC3- and GABARAP-transgenic lines with the spns1-mutant line to monitor real-time alterations of autophagic abnormalities in vivo. Vertebrates have approximately seven Atg8 homologs [56], and the best studied of these is LC3. GABARAP shows many similarities with LC3, but its conjugation is only mildly affected by starvation, and under certain conditions conjugation may be activated independent of target of rapamycin (TOR) inactivation [57], [58]. We have found, however, an indistinguishable behavior between LC3 and GABARAP in the transgenic animals harboring either spns1 mutation or depletion, although it has been suggested that LC3 and GABARAP differentially act in autophagosome biogenesis [59].The evolutionarily conserved autophagy gene beclin 1 (vps30/atg6) is frequently inactivated at one locus in several cancers [60], [61]. Studies in mice have also demonstrated that beclin 1 is a haploinsufficient tumor suppressor [17], [62]. It has been demonstrated that Spns1-loss-associated EGFP-LC3 puncta accumulation in cells, which reflects autophagic progression by autophagosome formation, is suppressed by the depletion of Beclin 1, Atg7, or Ulk1, as well as by treatment with a PtdIns3K inhibitor, 3-methyladenine [16]. Consistently, we also demonstrated that beclin 1 morphants were resistant to forming LC3 puncta induced by Spns1 deficiency in zebrafish. However, once both spns1 and p53 were depleted, the beclin 1 knockdown was no longer effective enough to suppress the punctate accumulation of LC3 as well as the mutant hallmarks of both yolk opaqueness and embryonic senescence characteristic of Spns1 deficiency in zebrafish.p53 is one of the most commonly mutated tumor suppressor genes found in many types of humancancers [63]. We found that the loss of basal p53 compromises the ability to properly adjust autolysosomal formation, and exacerbated the spns1 deficiency, while beclin 1 knockdown can ameliorate it by suppressing the early stage of autophagy. p53 has been linked to the regulation of autophagy, but the exact nature of its role still remains controversial. On the one hand, onocogenic and genotoxic stress events result in p53 stabilization and activation, which can stimulate autophagy through both transcription-independent mechanisms (e.g., AMP-activated protein kinase; AMPK activation and TOR inhibition) and transcription-dependent mechanisms (e.g., transcriptional upregulations of PTEN, tuberous sclerosis complex 1/TSC1 and damage-regulated autophagy modulator/DRAM1) [64]. On the other hand, it has been reported that genetic or chemical inhibition of basal cytoplasmic p53, or proteasomal depletion of p53 during starvation and/or endoplasmic reticulum stress, activates autophagy through transcription-independent mechanisms involving AMPK activation and TOR inhibition [20]. Loss of p53 may lead to homeostatic imbalance in cells, such as induction of bioenergetic compromise, increased ROS, and/or defective cell-cycle checkpoints, which can lead to autophagy induction. Thus, p53 depletion may promote or enhance autophagy indirectly as a result of imbalanced metabolic stress conditions. This therefore suggests that p53 maintains cellular homeostasis by adjusting the rate of autophagy in a context-dependent manner, as circumstances require.Intriguingly, Spns1-loss-induced embryonic senescence (SLIES) represents an atypical senescence response that is distinct from p53-induced senescence and can be suppressed by autophagy inhibition mediated through beclin 1 knockdown (
). Since the Beclin 1 suppression may lead to reduction in the level of p53 [37], and then might subsequently prevent SLIES, we intensively examined the effect of p53 depletion on SLIES. To our initial surprise, SLIES cannot be suppressed by the loss of p53 at all, but is rather enhanced. This seems to contradict the conventional role of p53 as an inducer of cellular senescence in various contexts including the zebrafish model [33], [65]. However, given recent evidence of a certain anti-aging mechanism by p53 in mice and p53-mediated suppression of senescence in cells [66], [67], it might not be surprising that p53 can also act both as a suppressor of senescence and of autophagy in some contexts, although the exact molecular mechanism remains elusive at this point. In addition, there remains a p53-independent cellular senescence mechanism that still depends on its authentic downstream target, p21Waf1/Cip1/Cdkn1a, among others, such as Arf and p27Kip1/Cdkn1b triggered by Skp2 inactivation [68]. Moreover, a recent report indicated that p21Waf1/Cip1/Cdkn1a also has a tissue-selective and context-dependent modulation of senescence in BubR1 progeroid mice [69]. In addition, most recently, SA-β-gal-positive “developmental senescence” observed in mice, which shares some, but not all, regulatory pathways detectable in adults, was shown to involve the activation of p21Waf1/Cip1/Cdkn1a in the absence of a DNA damage response and any alteration in p53, p16Ink4a, or p19Arf
[70], [71]. Interestingly, we found that in spns1-deficient fish embryos, the upregulation of p21 and pai-1 expression and the downregulation of smp-30 expression were detected without a DNA damage response. Further investigation and elucidation of their functional roles as senescence mediators or attenuators will be required to determine how they are responsible for SLIES.
Figure 6
Schematic model for Spns1 function under the control of the network module of autophagy-senescence signaling cascades differentially regulated through Beclin 1 and p53.
(A) Beclin 1 is essential for the early stage of autophagy and its depletion suppresses the Spns1 defect by blocking the ‘autophagic process’ and its progression. BafA can decelerate ‘lysosomal biogenesis’, which subsequently presumably prevents autophagosome-lysosome fusion, through the inhibition of the v-ATPase, and contributes to amelioration of the Spns1 defect at least temporarily. Basal p53 activity may suppress the intersection between the ‘autophagic progress’ and ‘lysosomal biogenesis’ where the Beclin 1 depletion was not sufficient, but the v-ATPase inhibition was still effective enough, to compete with the p53 loss to suppress the Spns1 deficiency. By switching the basal p53 state to the activated version with UV irradiation, p53 can promote autophagy. Spns1 might be a gatekeeper of autolysosomal maturation followed by lysosomal biogenesis. It remains unknown how p53 can mechanistically be linked to the lysosomal ‘efflux’ function of Spns1 as well as the lysosomal ‘influx’ function of v-ATPase, and further investigations will be required to explore this connection. (B) Roles of Spns1, p53 and Beclin 1 in senescence equilibrium. Loss of Spns1 leads to an imbalance in homeostasis and increased senescence. This effect can be ameliorated by concurrent knockdown of Beclin 1. p53 has a comparatively less dramatic impact on Spns1-loss-induced embryonic senescence. When in the “basal” state, p53 helps retain equilibrium. When p53 is “activated” by UV irradiation, a modest increase in senescence is observed. The higher level of senescence is seen during loss of Spns1 in the absence of basal p53 or in the presence of activated p53. During loss/knockdown of all three genes (spns1, p53 and beclin 1), a state of moderate senescence is observed. An increase in senescence is accompanied by a p53-dependent decrease in cellular proliferation.
Schematic model for Spns1 function under the control of the network module of autophagy-senescence signaling cascades differentially regulated through Beclin 1 and p53.
(A) Beclin 1 is essential for the early stage of autophagy and its depletion suppresses the Spns1 defect by blocking the ‘autophagic process’ and its progression. BafA can decelerate ‘lysosomal biogenesis’, which subsequently presumably prevents autophagosome-lysosome fusion, through the inhibition of the v-ATPase, and contributes to amelioration of the Spns1 defect at least temporarily. Basal p53 activity may suppress the intersection between the ‘autophagic progress’ and ‘lysosomal biogenesis’ where the Beclin 1 depletion was not sufficient, but the v-ATPase inhibition was still effective enough, to compete with the p53 loss to suppress the Spns1 deficiency. By switching the basal p53 state to the activated version with UV irradiation, p53 can promote autophagy. Spns1 might be a gatekeeper of autolysosomal maturation followed by lysosomal biogenesis. It remains unknown how p53 can mechanistically be linked to the lysosomal ‘efflux’ function of Spns1 as well as the lysosomal ‘influx’ function of v-ATPase, and further investigations will be required to explore this connection. (B) Roles of Spns1, p53 and Beclin 1 in senescence equilibrium. Loss of Spns1 leads to an imbalance in homeostasis and increased senescence. This effect can be ameliorated by concurrent knockdown of Beclin 1. p53 has a comparatively less dramatic impact on Spns1-loss-induced embryonic senescence. When in the “basal” state, p53 helps retain equilibrium. When p53 is “activated” by UV irradiation, a modest increase in senescence is observed. The higher level of senescence is seen during loss of Spns1 in the absence of basal p53 or in the presence of activated p53. During loss/knockdown of all three genes (spns1, p53 and beclin 1), a state of moderate senescence is observed. An increase in senescence is accompanied by a p53-dependent decrease in cellular proliferation.p53 is also well known for its pro-apoptotic cell death-inducing activities, but it can conversely possess pro-survival effects, particularly under mild stress conditions [72], [73], [74]. In zebrafish embryos, however, we determined that SLIES occurs regardless of p53-mediated impacts on apoptotic cell death and/or the cell-cycle checkpoint response as well. Thus, spns1-mutant animals show a new type of developmental senescence that can be triggered by autophagic initiation followed by autolysosomal fusion in the absence of the authentic senescence moderator p53, while basal p53 and activated p53 can play contrasting roles; attenuation in SLIES and mediation in apoptosis, respectively.“Activated p53” is not specifically involved in the spns1-ablated condition but can generally induce and/or augment the deleterious condition caused by the DNA damage response and apoptosis. In contrast, “basal p53” may have an antagonistic effect on lysosomal biogenesis (or autolysosomal maturation) rather than on the autophagic progress in the absence of Spns1. Alternatively, the p53 status may rather influence endosomal-lysosomal homeostasis where Spns1 is primarily involved. It should be noted that p53 may be involved in lysosomal stabilization [75], as well as in various metabolic changes and the regulation of energy metabolism including aerobic glycolysis (the Warburg effect) in which the lysosome is also engaged for degradation [38].Our preliminary observation suggests that SLIES and the yolk opaqueness hallmarks of spns1 embryos are only mildly affected by chemical (e.g., rapamycin)-mediated autophagy induction. This may be a reflection of the consistent outcome of already attenuated TOR (re)activation due to impaired autophagic lysosome reformation by Spns1 deficiency, as has been demonstrated in mammalian cells and flies [16], [76]. We are also wondering if basal p53 depletion may have any effect on autophagy enhancing activity independent of or different from the rapamycin-sensitive TOR pathway.Of note, rather than simple depletion of wild-type p53, the p53 mutant (tp53) fish used here retain an accumulation of the mutant p53 protein (p53M214K) [77], which corresponds to the human p53M246K mutant protein whose function is completely abolished [78]. A recent study suggests that this mutant p53 protein is degraded through chaperone-mediated autophagy (CMA) in a lysosome-dependent fashion [79]. Thus, the regulation of the stability of mutant p53 differs from that of wild-type p53. There is a possibility of activating the CMA pathway by inhibiting (macro)autophagy, to specifically promote the degradation of mutant p53, under a nutrient-starved condition. Therefore, it is also important to examine any involvement of the Spns1 function in the protein stability of mutant p53, whether the Spns1 defect selectively activates the CMA pathway for the removal of mutant p53 or not.Altogether, our present results support the notion that the interruption of the intrinsic nutrient supply through autophagy, supposedly from yolk in zebrafish embryos and larvae [80], may lead to profound energetic exhaustion under the aberrant autolysosomal condition resulting from Spns1 deficiency, and this effect is dependent on the p53 state.Since BafA can inhibit the import of H+ through the v-ATPase into the lysosome lumen, while the Spns1 defect presumably prohibits the symport of H+/sugar by loss of its function, it was anticipated that BafA might at least temporarily rescue the spns1-mutant animals, by restoring the balanced acidity condition of autolysosomes and/or lysosomes, as well as subsequent autophagosome-lysosome fusion. In fact, we found that BafA effectively inhibited the progression of both yolk opacity and embryonic senescence that appeared in spns1 mutants. Moreover, a direct depletion of the v-ATPase subunit c (a direct target of BafA) by MO recapitulated the restorative effect on the mutant animals. Importantly, the lysosomal pH of spns1 mutants was found to be less acidic, suggesting that protons may pass through the membrane via other H+-coupled transporters and/or channels such as lysosomal amino acid transporter 1 (LYAAT-1/SLC36A1) [81], chloride channel 7 (CLCN7) [82], and cystic fibrosis transmembrane conductance regulator (CFTR) [83].It should be noted that SA-β-gal is acid β-D-galactosidase, a lysosomal glycoside hydrolase (glycosidase), which catalyses the hydrolysis of β-galactosides into monosaccharides [28], and its substrates also include various glycoproteins, gangliosides (glycosphingolipids), lactose, and lactosylceramidases [84], [85]. The aberrant increase of the in situ SA-β-gal activity induced by Spns1 deficiency indicates that such a glycosidase product itself can be preserved in autolysosomes and/or lysosomes, but may not function properly in vivo without an essential permease(s) to transport degradation products that need to be delivered into the cytoplasm as energy sources.The extent to which our current observations of Spns1 functions during early development pertain to actual aging and age-related disease situations remains to be rigorously determined under both physiological and pathological conditions in animals. However, an increase in the abundance of the lysosomal hydrolases is presumably linked to the increased lysosomal biogenesis observed in senescent cells. Indeed, cumulative evidence suggests that an increased number of lysosomes and elevated lysosomal activity have been associated with replicative senescence [85]. Thus, the current finding suggests that temporal suppression of autophagy through Beclin 1 and/or v-ATPase by approved therapeutics (e.g., omeprazole) may be an effective therapeutic approach in the prevention of autophagic impairments similar to the Spns1 deficiency (
). Similar intervention has been demonstrated successfully in a mouse model of Pompe disease, a lysosomal glycogen storage disorder [86].
Materials and Methods
Zebrafish maintenance and ethics
Zebrafish (AB and casper strains) were maintained under a 14:10 h light/dark cycle and fed living brine shrimp twice daily. Brine shrimp were presented using 1 mL pipettes (about 0.75 mL brine shrimp per 20 fish). Flake food was also given every other day in proportion to the number of fish in the tanks. A continuously cycling aquarium system was used to maintain water quality (Aquatic Habitats Inc.). Zebrafish embryos were collected from pairwise matings of adults and raised at 28.5°C. The embryos to be used in the experiments were then staged by hours post fertilization (hpf) at 28.5°C and also by morphological appearance for experiments [87]. All animal experiments were approved by and conducted in accordance with the guidelines established by the Institutional Animal Care and Use Committee (IACUC) at The Scripps Research Institute, IACUC approval number 09-0009.
Confocal microscopy and imaging
Zebrafish embryos (in the case of the AB fish line) were transferred into 0.003% (w/v) 1-phenyl-2-thiourea (PTU) prior to 24 hpf to prevent pigmentation. Embryos or larvae were then mounted live in water containing 0.16 mg/ml tricaine (Sigma, A5040) for imaging. Images were taken using the FluoView 1000 confocal laser scanning microscope system (Olympus) with a 60× objective lens). Since EGFP- or mCherry-LC3 and EGFP-GABARAP showed both a uniform cytosolic signal and more intense spots, threshold values were set to reduce the cytosolic signal and identify the more intense dots. The same threshold value was applied for all samples in the indicated experiments. The extent of colocalization between LysoTracker and LysoSensor signals and EGFP- or mCherry-LC3 and EGFP-GABARAP dots was quantified in three independent visual fields from three independent embryos. All values are represented as mean ± standard deviation (S.D.). Mounted animals were photographed using each specific fluorescent signal by confocal laser microscopy. Fluorescence intensities were quantified using Adobe Photoshop over a color range that was chosen according to 25 additive color selections of regions that showed visually positive signals. For analyses of cells within the zebrafish embryos, these regions were selected in each actual embryo only and not in the yolk. Following pixel selection, a fuzziness setting of 64 was used, and the chosen pixel number was determined using the image histogram calculation.
Morpholino oligonucleotides
Morpholino oligonucleotides (MOs) were designed and synthesized by Gene Tools, LLC (Philomath, OR). The sequence of the beclin 1 MO is 5′-CATCCTGCAAAACACAAATGGCTTA-3′, which overlaps the intron-exon boundary at the 5′-splice junction of exon 4 in the zebrafishbeclin 1 gene. The sequence of the standard control MO is 5′-CCTCTTACCTCAGTTACAATTTATA-3′. MOs were resuspended in sterile water at a concentration of 1 mM as stock solutions. For microinjection into embryos, the stock solutions (1 mM) were diluted to 125, 250, 500, and 750 µM. A 10 nl volume of each MO solution was injected into the yolk during the one-cell stage. All other MO sequences have been reported previously [8], [12], [52], [88], except Inverse-sequence p53 MO (inv. p53 MO); 5′-GTTAAGAACGTTTCGTTACCGCG3′.
MitoTracker, LysoTracker, LysoSensor and DQ Red BSA staining
The vital mitochondrial and lysosomal dyes MitoTracker Green FM (Invitrogen; molecular probes, M7514), LysoTracker Red DND-99 (Invitrogen; molecular probes, L7528), LysoSensor Green DND-189 (Invitrogen; molecular probes, L7535) and LysoSensor Green DND-153 (Invitrogen; molecular probes, L7534) were diluted to final concentrations of 1 µM, 10 µM, 1 µM and 1 µM, respectively, in E3 medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, 0.33 mM MgSO4), and pre-warmed to 28.5°C. Each dye was then added to an equal volume of fresh water on embryos and incubated at 28.5°C in the dark for 30 min to 1 h. Embryos were then rinsed four times in fresh E3 medium before imaging. DQ Red BSA (Invitrogen; molecular probes, D12050) was diluted to a final concentration of 0.5 mg/ml in E3 medium, directly injected into the yolk sac at 72–84 hpf, and subjected animals were incubated for 4 h prior to observation by microscopy.
Transmission electron microscopy
Zebrafish larvae were fixed in 4% paraformaldehyde, 2.5% glutaraldehyde, 0.02% picric acid, 0.1 M Na cacodylate buffer, washed and fixed in 1% osmium tetroxide in 0.1 M Na cacodylate buffer. They were subsequently treated with 0.5% tannic acid followed by 1% sodium sulfate. The pellets were treated with propylene oxide and embedded in Epon/Araldite. Thin sections (70 nm) of the pelleted samples were cut on a Reichert Ultracut E (Leica, Deerfield, IL) using a diamond knife (Diatome, Electron Microscopy Sciences, Hatfield, PA), mounted on parlodion-coated copper slot grids and stained in uranyl acetate and lead citrate. Sections were examined on a Philips CM100 transmission electron microscope (FEI, Hillsbrough, OR). Images were documented and measurements were taken using a Megaview III CCD camera (Olympus Soft Imaging Solutions, Lakewood CO). Transverse sections were obtained through the trunk muscle region, the yolk and the eye region.
RNA isolation and RT-PCR analysis for zebrafish beclin 1
RT-PCR analysis of a single zebrafish embryo was performed to determine the effects of the splice-block MO for the zebrafishbeclin 1 gene. Total RNA was extracted from 24–48 hpf embryos injected with control MO, beclin 1 MO, or beclin 1 plus spns1 MO, using TRIzol reagent according to the manufacturer's protocol (Invitrogen). cDNA was synthesized using M-MLV reverse transcriptase (Promega), followed by PCR with ExTaq (Takara). For semi-quantitative analysis, the linear amplification ranges were then determined for each of the primer sets. PCR primers used to amplify the fragments of the zebrafishbeclin 1 gene were designed using a web-based primer design tool, PrimerQuest (Integrated DNA Technology, Inc.) (zbeclin 1 EX3 forward primer; 5′-CAAACAAGATGGCGTGGCTCGAAA-3′, zbeclin 1 EX4 forward primer; 5′-GTGGAACTATGGAGAACTTGAGTCGCA-3′, and zbeclin1 EX7 reverse primer; 5′-TCCAACTCCAGCTGCTGTCTCTT-3′). The amplified products were validated by sequencing. As controls for these PCR analyses, ef1α and β-actin were examined. The forward and reverse primers used to amplify ef1α were 5′-ACCACCGGCCATCTGATCTACAAA-3′ and 5′-ACGGATGTCCTT GACAGACACGTT-3′, respectively, and for β-actin were 5′-CCCAGACATCAGGGAGTGAT-3′ and 5′-CACCGATCCAGACGGAGTAT-3′, respectively. For amplification by PCR, the initial denaturing step at 94°C for 5 min was followed by 18–25 amplification cycles of 30 sec at 94°C; 30 sec at 60°C; 60 sec at 72°C, and a final extension period of 10 min at 72°C. Amplified products were separated on a 1.5% agarose gel stained with ethidium bromide and the bands were visualized and recorded using a Multi Image Light Cabinet (Cell Bioscience). Other PCR primers, parameters and conditions are summarized in Supplemental .
SA-β-gal assay and quantification
Zebrafish embryos and larvae at 48–72 dpf were washed three times in phosphate buffered saline (PBS) and fixed overnight in 4% paraformaldehyde with PBS at 4°C. After fixation, the samples were washed three times in PBS, pH 7.5, twice again in PBS, pH 6.0 at 4°C, and then incubated at 37°C (in the absence of CO2) for 12–16 h with SA-β-gal staining solution (5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 2 mM MgCl2 in PBS at pH 6.0). All animals were photographed under the same conditions using reflected light with a macro microscope, AZ100 (Nikon). SA-β-gal activity in each animal was quantified using a selection tool in Adobe Photoshop software for a color range that was chosen using 25 additive color selections of regions that showed visual SA-β-gal staining. For analyses of embryos, these regions were selected in each embryo proper only and not in the yolk in order to exclude variability in the initial yolk volume and yolk consumption levels over time. Since the yolk stains much more intense for SA-β-gal at all stages of development than any other embryonic tissues in general, it was desirable to eliminate this as a source of variability. Following pixel selection, a fuzziness setting of 14 was used, and the chosen pixel number was determined using the image histogram calculation.
Immunoblotting
Embryos were dechorionated, deyolked and homogenized in RIPA buffer. Protein concentrations of embryo lysates were determined using the bicinchoninic acid (BCA) protein assay. The lysates were mixed with equal volumes of 2× SDS sample buffer, heated at 95°C for 2 min, and resolved on 12.5% or 15% gels. After transfer, the polyvinylidene difluoride membranes were incubated with primary antibodies [anti-LC3A/B (Cell Signaling Technology, Inc., #4108), anti-β-actin (Cell Signaling Technology, #4967), or anti-GFP (Life Technologies, A11122) antibody], diluted in TBST overnight at 4°C. After washing, the blot was then incubated with a secondary anti-rabbithorseradish peroxidase-conjugated antibody (Cell Signaling Technology, #7074) at room temperature for 1 h and visualized using an ECL kit (Perkin Elmer) in accordance with the manufacturer's instructions.
Generating transgenic zebrafish
To generate transgenic zebrafish expressing mCherry-tagged LC3, the corresponding expression construct pminiTol2-mCherry-LC3 was generated using the QuikChange Site-Directed Mutagenesis Kit (Stratagene) in accordance with the manufacturer's instructions. pT3TS-Tol2 was linearized by XbaI and transcribed with T3 RNA polymerase using the Ambion mMESSAGE mMACHINE kit (Ambion, AM1348) to produce Tol2 transposase mRNA. Approximately 5 nl of the mixture of plasmid DNA (100 ng/µl) (pminiTol2-mCherry-LC3) and 50 pg of Tol2 transposase mRNA (100 ng/µl) were coinjected into newly fertilized embryos at the one-cell stage to produce transgenic fish. Injected embryos were raised to adulthood and out-crossed to wild-type fish to identify germline-transmitted transgenic founders (F0) as described previously [22]. Positive founders were determined by screening F1 embryos for visible mCherry expression. The mCherry-positive offspring were then allowed to grow to maturity for further experiments.
Chemical treatments
Bafilomycin A1 (BafA) (LC Laboratories, B-1080), omeprazole, lansoprazole, and pantoprazole (Sigma, O104, L8533, and P0021, respectively) treatment was performed from 36 through 48 hpf or 48 through 60 hpf in E3 medium at 28.5°C in 12- or 6-well plates. The chemicals dissolved in DMSO were added to the embryo water (E3 medium) at the final concentrations of 200 nM for BafA and 25 µM for lansoprazole, omeprazole and pantoprazole. Pepstatin A (Fisher BioReagent, BP26715) and E-64-d (Enzo Life Sciences, BML-PI107) treatment was administrated from 60 through 72 hpf for 12 h in E3 medium at 28.5°C in 12- or 6-well plates. These reagents were both dissolved in DMSO and added to the embryo water (E3 medium) at the final concentration of 5 µg/ml.
Quantitative analysis and statistics
Data processing and statistical analyses were performed using Statistical Package for the Social Sciences (SPSS) version 14.0. This software was used to generate each of the graphs shown in the text to perform statistical tests where appropriate.Autophagic abnormalities and survival in spns1-mutant fish and worms. (A) Representative transmission electron microscopy images of normal wt or spns1-mutant fish larvae at 84 hpf. Compared with wild-type (wt) control (left), the spns1 mutant (spns1) (right) accumulates abnormal cytoplasmic inclusions at the hypodermal regions adjacent to yolk sac (ys) (upper two panels) or melanophores (me) (middle two panels), and in the retinal pigment epithelium containing melanophores (me) (lower two panels). Arrows indicate cytoplasmic membranous inclusions. In the right-upper panel, the inset shows a magnified image of the cytoplasmic inclusion surrounded with a dotted square. Scale bar, 2 µm. (B) Modulation of autophagy activity by a mutation in the spns1 homolog (spin-1; C13C4.5) in C. elegans. Representative images of autophagosomes (EGFP::LGG-1 puncta) in seam cells are shown for wild-type {wt, adIs2122 [lgg-1p::GFP::lgg-1, rol-6(su1006)]} animals and for nematodes carrying a homozygous spin-1 deletion allele {spin-1(ok2087); adIs2122 [lgg-1p::GFP::lgg-1+rol-6(su1006)}. Arrows indicate autophagosomes only in the spin-1 animals. Scale bar, 5 µm. (C) Quantification of EGFP::LGG-1 puncta is shown for the indicated genetic backgrounds and conditions. The count of puncta per seam cell was 0.8936±0.0926 for wt and 1.9899±0.1396 for spin-1(ok2087) L4 larva, respectively [values are the mean ± standard error of mean (S.E.M.) for 94 (wt) and 99 [spin-1(ok2087)] seam cells; more than 20 animals were examined for each strain] (t-test: *p<0.0001). (D) The starvation sensitivity in spin-1(ok2087) mutant worms. Percent of worms surviving to adulthood on NGM plates with OP50 bacteria after incubation in M9 buffer in the absence of food at the L1 larval stage for the indicated times. Error bars are for standard errors of means estimated assuming a Poisson distribution, and similar results were obtained in three independent experiments. (E) Lifespan in spin-1(ok2087) mutant worms is demonstrated by Kaplan-Meier survival analysis. spin-1(ok2087) mutant worms are short lived compared with the wild-type N2 strain on HT115 bacteria. The median lifespan was 12 days for N2 and 10 days for spin-1(ok2087) (log rank test: χ2 = 8.834 on one degree of freedom; p = 0.003). Similar results were obtained in 2 experiments with 3 independent replicates each. (F) Shorter lifespan in heterozygous spns1 adult fish is demonstrated by Kaplan-Meier survival analysis (log rank test: χ2 = 54.05 on one degree of freedom; p<0.0001) and validated by Gompertz-Makeham model.(TIF)Click here for additional data file.Detection of lysosomal and mitochondrial biogenesis in spns1-mutant animals. (A) Whole-mount double staining of live embryos with LysoTracker (10 µM, DND-99; red) and MitoTracker (1 µM, green) at 72 hpf. Intense LysoTracker staining was detected only in spns1 mutants but not in wt animals. In contrast, MitoTracker detected equivalent signals between wt and spns1-mutant animals. Scale bar, 250 µm. (B) Whole-mount double staining of live embryos with MitoSox (5 µM, red) and MitoTracker (1 µM, green) at 72 hpf. Both of the probes detected equivalent signals between wt and spns1-mutant animals. Scale bar (black) in large image, 250 µm. Scale bar (white) in inset, 10 µm. (C) Acidity-dependent quenching of EGFP-LC3 at the LysoTracker-positive compartments in the cells from pepstatin A (5 µg/ml)- and E-64-d (5 µg/ml)-co-treated (P/E) zebrafish embryos at 72 hpf. Scale bar, 10 µm. (D) Acidity-dependent quenching of EGFP-LC3, but not mCherry-LC3, in cells from pepstatin A (5 µg/ml)- and E-64-d (5 µg/ml)-co-treated (P/E) zebrafish embryos at 72 hpf. Scale bar, 10 µm. (E) The degradation capacity of autolysosomes and lysosomes was examined by injection of a lysosomal substrate, DQ Red BSA (DQ-BSA; red) at 60 hpf. The enzyme-catalyzed hydrolysis of the intramolecular self-quenched DQ Red BSA by lysosomal proteases relieves the self-quenching, yielding brightly fluorescent reaction products. DQ Red BSA-injected wt control or spns1-mutant fish expressing EGFP-LC3 were observed at the cellular level by confocal microscopy. Scale bar, 10 µm. Quantification of data presented in E (n = 6), is shown in the right graph; the number (n) of animals is for each genotype. Three independent areas (periderm or basal epidermal cells above the eye) were selected from individual animals. Error bars represent the mean ± standard deviation (S.D.), *p<0.005.(TIF)Click here for additional data file.Impact of Beclin 1 depletion on the yolk opaque phenotype and embryonic senescence in spns1-mutant zebrafish. (A) Phenotype of beclin 1 morphant (beclin 1 MO, 12 ng/embryo) at 24, 48 and 72 hpf. Scale bar, 250 µm. (B) Effect of beclin 1 knockdown in the spns1 mutant on the phenotypes of yolk opacity (BF; bright field) and on embryonic senescence (SABG; SA-β-gal) in the spns1 mutant. Following injection of standard control MO or beclin 1 MO (12 ng/embryo) into Tg(CMV:EGFP-LC3); spns1 embryos, SA-β-gal staining was performed to determine whether the beclin 1 knockdown had any impact on embryonic senescence caused by Spns1 depletion at 84 hpf. Scale bar, 250 µm. Quantification of data presented in panel B (n = 12) is shown in the right graph; the number (n) of animals is for each morphant. (C) Parallel analyses of SA-β-gal and SA-α-fuc demonstrate the significant inductions of both activities in spns1-mutant animals at 84 hpf. As shown in the magnified panels, the caudal venous plexus (CVP) was the most prominently stained region. Staining for SA-β-gal was more intensive than for SA-α-fuc. Scale bar, 250 µm. Quantification of data presented in panel C (n = 12) is shown in the right graph; the number (n) of animals is for each morphant. Error bars represent the mean ± S.D., *p<0.005.(TIF)Click here for additional data file.Effect of UV irradiation on spns1-mutant zebrafish. (A) Acrdine orange (green) and Lysotracker (red) intensities, as well as gross morphology, in wild-type (wt) and spns1-mutant animals treated with UV. The UV (18 mj/cm2) treatment was done at 36 hpf, and phenotypes were observed at 48 hpf. Scale bar, 250 µm. Quantification of data presented in A (n = 9) is shown in the right graphs; the number (n) of animals is for each genotype with or without UV treatment. (B) Cellular characteristics in the animals shown in (A) were observed by using confocal microscopy at high magnification (×600). Scale bar, 10 µm. Quantification of data presented in B (n = 6) is shown in the right graphs; the number (n) of animals is for each genotype with or without UV treatment. Three independent areas (periderm or basal epidermal cells above the eye) were selected from individual animals. Error bars represent the mean ± S.D., *p<0.005; ns, not significant.(TIF)Click here for additional data file.Undetectable apoptosis in spns1 and/or beclin 1 morphants. (A) In spns1 and/or beclin 1 morphants stained with acridine orange (green) and LysoTracker (red) cellular characteristics were compared with UV-treated specimens by using confocal microscopy at high magnification (×600). Scale bar, 10 µm. Quantification of data presented in A (n = 6) is shown in the right graphs; the number (n) of animals is for each morphant and uninjected (Uninj.) animal with or without UV treatment. Three independent areas (periderm or basal epidermal cells above the eye) were selected from individual animals. (B) TUNEL assays demonstrate apoptosis induction in UV-treated zebrafish embryos, but not in spns1 and/or beclin 1 morphants. The UV (18 mj/cm2) treatment was done at 36 hpf, and phenotypes were observed at 48 hpf. Scale bar, 10 µm. Quantification of the fluorescence intensities is shown at the right-side graph. Quantification of data presented in B (n = 6) is shown in the right graphs; the number (n) of animals is for each morphant and uninjected (Uninj.) animal with or without UV treatment. Three independent areas (periderm or basal epidermal cells above the eye) were selected from individual animals. Error bars represent the mean ± S.D., *p<0.005.(TIF)Click here for additional data file.Impact of the beclin 1 knockdown on UV-induced apoptosis and autophagy. (A) Partial but significant suppression of UV-induced apoptosis in beclin 1 morphants. The UV (18 mj/cm2) treatment was done at 66 hpf, followed by the phenotype observations at 72 hpf. Scale bar in the large image, 250 µm. Scale bar in the inset, 10 µm. Quantification of data presented in A (n = 9) is shown in the right graphs; the number (n) of animals is for each morphant with or without UV treatment. Three independent areas (periderm or basal epidermal cells in the caudal fin) were selected from individual animals. (B) Sufficient suppression of UV-induced autophagy in beclin 1 morphants. The UV (18 mj/cm2) treatment was done at 69 hpf, followed by the phenotype observations at 72 hpf. Scale bar, 10 µm. Quantification of data presented in A (n = 9) is shown in the right graphs; the number (n) of animals is for each morphant with or without UV treatment. Three independent areas (periderm or basal epidermal cells above the eye) were selected from individual animals. Error bars represent the mean ± S.D., **p<0.005; *p<0.05 in (A), and *p<0.005; ns, not significant in (B).(TIF)Click here for additional data file.Effects of spns1 and p53 knockdowns on embryonic SA-β-gal activity in p53 and spns1 mutants, respectively. (A) Effect of spns1 knockdown on embryonic senescence in p53 mutants. The impact of transient spns1 knockdown on SA-β-gal induction was determined in spns1 MO-injected tp53 animals at 72 hpf. Standard control MO was used for control injections. Scale bar, 250 µm. (B) Effect of p53 knockdown on embryonic senescence in spns1 mutants. The impact of transient p53 knockdown on SA-β-gal induction was determined in p53 MO-injected spns1 animals at 72 hpf, followed by the MO injections. Inverse p53 MO (inv. p53 MO) was used for control injections. Scale bar, 10 µm. (C) Quantification of the SA-β-gal intensities shown in (A). Quantification of data presented in panel A (n = 12) is shown in the right graph; the number (n) of animals is for each genotype with MO. (D) Quantification of the SA-β-gal intensities shown in (B). Quantification of data presented in panel B (n = 12) is shown in the right graph; the number (n) of animals is for each morphant in genotype. Error bars represent the mean ± S.D., *p<0.005; ns, not significant.(TIF)Click here for additional data file.Impact of Beclin 1 depletion on Spns1 deficiency in the presence or absence of p53. (A) Yolk opaque phenotype of control MO-injected or beclin 1 MO-injected wild-type (spns1), tp53 (tp53), spns1 (spns1), and spns1 (spns1) animals is compared at 48 hpf. Opacity is greater in the p53 mutant background with Spns1 deficiency. The attenuated suppressive effect of beclin 1 MO (12 ng/embryo) yolk opacity in spns1 animals is shown. Scale bar, 250 µm. (B) spns1 animals coinjected with beclin 1 MO and p53 MO or beclin 1 MO and inverse-sequence p53 MO (inv. p53 MO; negative control) were assayed for the SA-β-gal detection at 84 hpf. The beclin 1 MO-mediated suppression of SA-β-gal in spns1 animals was attenuated by p53 MO injection. Scale bar, 250 µm. (C) Quantification of the SA-β-gal intensities shown in (B). Quantification of data presented in panel B (n = 10) is shown in the right graph; the number (n) of animals is for each morphant. Error bars represent the mean ± S.D., *p<0.005; ns, not significant.(TIF)Click here for additional data file.Impact of UV-induced apoptosis and autophagy on Spns1 deficiency in the presence or absence of p53. (A) UV-induced apoptosis can be detectable in either spns1 or spns1 animals in similar manners only under the normal p53 condition. The UV (18 mj/cm2) treatment was done at 60 hpf, followed by the phenotype observations in periderm or basal epidermal cells in the caudal eye at 72 hpf. Scale bar in image in top row, 250 µm. Scale bar in image in lower rows, 10 µm. (B) UV-induced autophagy enhances autolysosomal formation in spns1 animals in the presence of p53. The UV (18 mj/cm2) treatment was done at 69 hpf, followed by the phenotype observations in periderm or basal epidermal cells in the caudal fin at 72 hpf. Scale bar, 10 µm. (C) Quantification of the EGFP-LC3 and LysoTracker fluorescence intensities shown in (B). Quantification of data presented in panel B (n = 6) is shown in the right graph; the number (n) of animals is for each genotype with MO. Three independent areas (periderm or basal epidermal cells in the caudal fin) were selected from individual animals. Error bars represent the mean ± S.D., *p<0.005; ns, not significant.(TIF)Click here for additional data file.Detection of DNA damage response and DNA synthesis in spns1 mutants in the presence or absence of p53. (A) γH2AX- and BrdU detection in spns1 mutants in p53- and DNA damage-dependent manners. As shown in the green fluorescent panels, unaltered γH2AX intensities between spns1 and spns1 (spns1) were apparent irrespective of p53 status without UV irradiation. Increased γH2AX intensities in response to UV irradiation were observed in the presence of p53 regardless of Spns1 status. Of note, certain basal increases of γH2AX intensities were detected in the p53 mutant background. As shown in the red fluorescent panels, reduced BrdU incorporation in spns1 animals was detected in either normal or mutant p53 condition in the absence of UV treatment. UV-induced inhibition of DNA synthesis (reduction of BrdU signals) is apparently seen only in the normal p53 situation. The UV (18 mj/cm2) treatment was done at 68 hpf, followed by the phenotype observations at 72 hpf. Scale bar in the large image, 250 µm. Scale bar in the small merged image and inset, 10 µm. (B) Quantification of the γH2AX fluorescence intensities shown in (A). Quantification of data presented in panel A (n = 12) is shown in the right graph; the number (n) of animals is for each genotype. Three independent areas (periderm or basal epidermal cells in the trunk) were selected from individual animals. (C) Quantification of the BrdU-positive cells [in 25.6±2.2×104 µm areas; the trunk region starting from the rostral start point of the yolk extension (the distal end of the yolk) through the end of the caudal fin] shown in (A). Error bars represent the mean ± S.D., **p<0.005; *p<0.05; ns, not significant.(TIF)Click here for additional data file.Detection of mitotic cells in spns1 mutants in the presence or absence of p53. (A) Phosphorylated histone H3 (pH 3) staining in spns1-mutant animals with normal or mutant p53 backgrounds. The UV (18 mj/cm2) treatment was done at 68 hpf, followed by the phenotype observations at 72 hpf. Scale bar, 250 µm. (B) Quantification of the pH 3-positive cells [in 27.2±3.2×104 µm areas; the trunk region starting from the rostral start point of the yolk extension (the distal end of yolk) through the end of the caudal fin] shown in (A). Quantification of data presented in panel A (n = 9) is shown in the right graph; the number (n) of animals is for each genotype. Three independent areas (periderm or basal epidermal cells in the trunk) were selected from individual animals. Reduction of the pH 3 level was statistically significant in spns1 (spns1) animals in the presence of p53, and a reduced tendency (with no statistical significance) was also observed in spns1 mutants. Error bars represent the mean ± S.D., **p<0.05; *p<0.01; ns, not significant.(TIF)Click here for additional data file.Impact of UV irradiation on embryonic SA-β-gal activity in p53 and/or spns1 mutants. (A) Effect of UV treatment on embryonic SA-β-gal activity was validated in spns1-mutant animals with normal or mutant p53 backgrounds. The UV (18 mj/cm2) treatment was done at 68 hpf, followed by the phenotype observations at 72 hpf. Scale bar, 250 µm. (B) Quantification of the SA-β-gal intensities shown in (A). Quantification of data presented in panel A (n = 12) is shown in the right graph; the number (n) of animals is for each genotype. Error bars represent the mean ± S.D., **p<0.05; *p<0.01; ns, not significant.(TIF)Click here for additional data file.Semi-quantitative RT-PCR analyses of the expression of p21, pai-1, smp-30, and bax genes in spns1 and/or p53 mutants at 72 hpf. (A) A representative gel-loading pattern of each gene expression. (B) Quantification of the gene expression shown in (A). Data are mean ± SD [n = 6 samples (3 embryos/sample) per genotype]. Asterisks denote significant changes compared to wt values. *p<0.05.(TIF)Click here for additional data file.Gene-expression profiles of potential markers and/or mediators of senescence in spns1-defective zebrafish embryos. (A) Semi-quantitative RT-PCR analyses of senescence markers and/or mediators and of p53-downstream target genes in spns1 and/or beclin 1 morphants. The expression was detected at 72 hpf. Data are mean ± SD [n = 4 samples (3 embryos/sample) per morphant]. Asterisks denote significant changes from standard control MO injected values. *p<0.05. (B) Semi-quantitative RT-PCR analyses of senescence marker and/or mediator expression as well as p53-downstream target genes in spns1 and/or p53 mutants with or without UV treatment. The UV (18 mj/cm2) treatment was done at 66 hpf, and the expression was detected at 72 hpf. Data are mean ± SD [n = 6 samples (3 embryos/sample) per genotype]. Asterisks denote significant changes between values. *p<0.05.(TIF)Click here for additional data file.Semi-quantitative RT-PCR analyses of ink4ab gene expression in spns1 and/or p53 mutants with or without UV treatment. The UV (18 mj/cm2) treatment was done at 66 hpf, and the expression was detected at 72 hpf. Data are mean ± SD [n = 6 samples (3 embryos/sample) per genotype]. Asterisks denote significant changes from p53 without UV treatment (-) values. *p<0.05.(TIF)Click here for additional data file.Suppression of spns1-mutant phenotypes by BafA treatment in zebrafish embryos. Suppression of yolk opacity by treatment with BafA (200 nM; 12 h treatment from 48 hpf through 60 hpf) in pigmented (AB line) and unpigmented (casper line) zebrafish embryos is shown. Scale bar, 250 µm.(TIF)Click here for additional data file.Suppression of spns1-mutant phenotypes by knockdown of the atp6v0c gene in zebrafish embryos. (A) Gross morphology, EGFP-LC3 and LysoTracker intensities in wild-type (wt) and spns1-mutant animals injected with atp6v0c MO (4 ng/embryo) at 48 hpf. Suppression of yolk opacity and SA-β-gal (SABG) by injection of atp6v0c MO in zebrafish embryos was observed at 48 and 60 hpf, respectively. Scale bar, 250 µm. (B) Quantification of the SA-β-gal intensities shown in (A). Quantification of data presented in panel A (n = 10) is shown in the right graph; the number (n) of animals is for each genotype with MO. (C) Effect of the PPIs (omeprazole; OPZ, lansoprazole; LPZ, and pantoprazole; PPZ) on embryonic senescence (SABG; SA-β-gal) in the spns1 mutant at 48 hpf. The drug treatments were done for 12 h from 36 hpf through 48 hpf. Scale bar, 250 µm. Error bars represent the mean ± S.D., *p<0.005; ns, not significant.(TIF)Click here for additional data file.Validations of lysosomal biogenesis and acidity in zebrafish embryos. (A) Whole-mount double staining with LysoTracker (10 µM, DND-99; red) and LysoSensor 189 (1 µM, DND-189; green). Live animals at 72 hpf were counterstained with LysoTracker and acidic pH-sensitive LysoSensor 189, simultaneously. LysoSensor 189 weakly detects acidic lysosomal signals in the spns1-mutant animals. Scale bar, 250 µm. Quantification of data presented for LysoSensor 189 (green) and LysoTracker (red) signals in panel A (n = 12) is shown in the right graph; the number (n) of animals is for each genotype. (B) Whole-mount double staining with LysoTracker (10 µM, DND-99; red) and LysoSensor 153 (1 µM, DND-153; green). Animals at 72 hpf were simultaneously counterstained by LysoTracker and neutral pH-sensitive LysoSensor 153. LysoSensor 153 can detect relatively neutral lysosomal signals in the spns1-mutant animals. Scale bar, 250 µm. Quantification of data presented for LysoSensor 153 (green) and LysoTracker (red) signals in panel B (n = 12) is shown in the right graph; the number (n) of animals is for each genotype. (C) Acidic pH-sensitive LysoSensor 189 (1 µM, green) probe in combination with LysoTracker (10 µM, red) was used in wt and spns1-mutant animals, and detectable signals in cells were obtained at 72 hpf. In wt fish treated with pepstatin A and E-64-d (P/E) (5 µg/ml each for 12 h), autolysosomal and/or lysosomal compartments were more prominently detected by LysoSensor 189 at the cellular level with enhanced accumulation of enlarged compartments under the identical LysoTracker staining condition. In contrast, in spns1-mutant animals, the cellular compartments were only weakly detectable by LysoSensor 189. Importantly, the short-term BafA treatment (for 1 h) largely attenuated or abolished staining of acidic compartments by both LysoSensor and LysoTracker, indicating that these autolysosomal and lysosomal compartments in wt animals treated with pepstatin A and E-64-d may retain some strong (lower pH) acidity. Scale bar, 10 µm. Quantification of data presented for LysoSensor 189 (green) and LysoTracker (red) signals in panel C (n = 12) is shown; the number (n) of animals is for each genotype with DMSO, pepstatin A and E-64-d (P/E) and/or BafA (+BafA; 1 h treatment). Three independent areas (periderm or basal epidermal cells above the eye) were selected from individual animals. (D) Using neutral pH-sensitive LysoSensor 153 (green) probes in combination with LysoTracker (red), wt and spns1-mutant animals were examined for detectable signals in cells when stained at 72 hpf. In spns1-mutant animals, autolysosomal and/or lysosomal compartments were more prominently detected by LysoSensor 153 at the cellular level with enhanced accumulation of enlarged compartments. In stark contrast, the cellular compartments in wt fish treated with pepstatin A and E-64-d (P/E) (5 µg/ml each for 12 h) were less detectable by LysoSensor 153 under the same staining condition used with LysoTracker. The short-term BafA treatment (for 1 h) still abolished the acidic compartments stained by both LysoSensor and LysoTracker, suggesting that the autolysosomal and lysosomal compartments observed in spns1-mutants may still retain some weak (higher pH) acidity. Scale bar, 10 µm. Quantification of data presented for LysoSensor 153 (green) and LysoTracker (red) signals in panel D (n = 12) is shown; the number (n) of animals is for each genotype with DMSO, pepstatin A and E-64-d (P/E) and/or BafA (+BafA; 1 h treatment). Three independent areas (periderm or basal epidermal cells above the eye) were selected from individual animals. Error bars represent the mean ± S.D., *p<0.005; ns, not significant in (A), (B) and (D), and **p<0.005; *p<0.05; ns, not significant in (C).(TIF)Click here for additional data file.Validations of autolysosome formation and lysosomal biogenesis in zebrafish embryos. (A) Gross morphologies of BafA (100 nM)-treated or pepstatin A (5 µg/ml)- and E-64-d (5 µg/ml)-co-treated (P/E) wt [Tg(CMV:EGFP-LC3)] and spns1-mutant [Tg(CMV:EGFP-LC3); spns1] animals. Embryos at 60 hpf were incubated with BafA or P/E for 12 h, and stained with LysoTracker at 72 hpf. Scale bar, 250 µm. Quantification of data presented in the middle and bottom rows (green; EGFP, red; mCherry) in panel A (n = 12) is shown; the number (n) of animals is for each genotype with DMSO, BafA or pepstatin A and E-64-d (P/E). (B) Intracellular autolysosome formation and lysosomal biogenesis in vehicle (DMSO)-treated, BafA (100 nM)-treated or pepstatin A (5 µg/ml)- and E-64-d (5 µg/ml)-treated (P/E) wt [Tg(CMV:EGFP-LC3)] and spns1-mutant [Tg(CMV:EGFP-LC3);spns1] animals. Numerous large EGFP-LC3 puncta are evident in the BafA-treated embryos, with minimal LysoTracker staining. Some increased EGFP-LC3 speckles and strong enhancement of enlarged LysoTracker signals are evident in the cells from P/E-treated embryos. The same samples analyzed in (A) were observed by using confocal microscopy at a high magnification (×600). Scale bar, 10 µm. Quantification of data presented in the middle and bottom rows (green; EGFP, red; mCherry) in panel A (n = 6) is shown. The number (n) of animals is for each genotype with DMSO, BafA or pepstatin A and E-64-d (P/E). Three independent areas (periderm or basal epidermal cells above the eye) were selected from individual animals. (C) Impaired autolysosomal acidification in BafA-treated wt or in spns1-mutant embryos, but not in pepstatin A- and E-64-d-treated (P/E) wt embryos. EGFP-LC3 and mCherry-LC3 double-transgenic wt [Tg(CMV:EGFP-LC3:mCherry-LC3)] and spns1-mutant [Tg(CMV:EGFP-LC3:mCherry-LC3);spns1] zebrafish were used to monitor autolysosome formation. Embryos at 60 hpf were incubated with BafA (100 nM) or P/E (5 µg/ml each) for 12 h, to be observed later at 72 hpf. Quenching of EGFP-LC3 signals but not mCherry-LC3 signals is seen in the P/E-treated embryos, whereas unquenched EGFP-LC3 signals are evident in the BafA-treated as well as the spns1 MO-injected embryos. Whole-mount samples were observed by using confocal microscopy at a high magnification (×600). Scale bar, 10 µm. Quantification of data presented in the middle and bottom rows (green; EGFP, red; mCherry) in panel A (n = 6) is shown; the number (n) of animals is for each genotype with DMSO, BafA or pepstatin A and E-64-d (P/E). Three independent areas (periderm or basal epidermal cells above the eye) were selected from individual animals.(TIF)Click here for additional data file.List of primers used for qPCR.(DOC)Click here for additional data file.List of primers used for RT-PCR and list of PCR conditions.(DOC)Click here for additional data file.Supplemental data.(DOC)Click here for additional data file.Supplemental Materials and Methods.(DOC)Click here for additional data file.
Authors: Samuel Sidi; Takaomi Sanda; Richard D Kennedy; Andreas T Hagen; Cicely A Jette; Raymond Hoffmans; Jennifer Pascual; Shintaro Imamura; Shuji Kishi; James F Amatruda; John P Kanki; Douglas R Green; Alan A D'Andrea; A Thomas Look Journal: Cell Date: 2008-05-30 Impact factor: 41.582
Authors: Ander Matheu; Antonio Maraver; Peter Klatt; Ignacio Flores; Isabel Garcia-Cao; Consuelo Borras; Juana M Flores; Jose Viña; Maria A Blasco; Manuel Serrano Journal: Nature Date: 2007-07-19 Impact factor: 49.962
Authors: Shuji Kishi; Peter E Bayliss; Junzo Uchiyama; Eriko Koshimizu; Jie Qi; Purushothama Nanjappa; Shintaro Imamura; Asiful Islam; Donna Neuberg; Adam Amsterdam; Thomas M Roberts Journal: PLoS Genet Date: 2008-08-15 Impact factor: 5.917
Authors: Shintaro Imamura; Junzo Uchiyama; Eriko Koshimizu; Jun-Ichi Hanai; Christina Raftopoulou; Ryan D Murphey; Peter E Bayliss; Yoichi Imai; Caroline Erter Burns; Kenkichi Masutomi; Sarantis Gagos; Leonard I Zon; Thomas M Roberts; Shuji Kishi Journal: PLoS One Date: 2008-10-10 Impact factor: 3.240
Authors: Tomoyuki Sasaki; Shanshan Lian; Alam Khan; Jesse R Llop; Andrew V Samuelson; Wenbiao Chen; Daniel J Klionsky; Shuji Kishi Journal: Autophagy Date: 2016-11-22 Impact factor: 16.016
Authors: Menglan He; Alvin C Y Kuk; Mei Ding; Cheen Fei Chin; Dwight L A Galam; Jie Min Nah; Bryan C Tan; Hui Li Yeo; Geok Lin Chua; Peter I Benke; Markus R Wenk; Lena Ho; Federico Torta; David L Silver Journal: Proc Natl Acad Sci U S A Date: 2022-09-26 Impact factor: 12.779
Authors: Natalya V Kaverina; Zaira G Kadagidze; Anton V Borovjagin; Apollon I Karseladze; Chung Kwon Kim; Maciej S Lesniak; Jason Miska; Peng Zhang; Maria A Baryshnikova; Ting Xiao; David Ornelles; Charles Cobbs; Andrey Khramtsov; Ilya V Ulasov Journal: Oncogene Date: 2018-07-10 Impact factor: 9.867
Authors: Daniel J Klionsky; Amal Kamal Abdel-Aziz; Sara Abdelfatah; Mahmoud Abdellatif; Asghar Abdoli; Steffen Abel; Hagai Abeliovich; Marie H Abildgaard; Yakubu Princely Abudu; Abraham Acevedo-Arozena; Iannis E Adamopoulos; Khosrow Adeli; Timon E Adolph; Annagrazia Adornetto; Elma Aflaki; Galila Agam; Anupam Agarwal; Bharat B Aggarwal; Maria Agnello; Patrizia Agostinis; Javed N Agrewala; Alexander Agrotis; Patricia V Aguilar; S Tariq Ahmad; Zubair M Ahmed; Ulises Ahumada-Castro; Sonja Aits; Shu Aizawa; Yunus Akkoc; Tonia Akoumianaki; Hafize Aysin Akpinar; Ahmed M Al-Abd; Lina Al-Akra; Abeer Al-Gharaibeh; Moulay A Alaoui-Jamali; Simon Alberti; Elísabet Alcocer-Gómez; Cristiano Alessandri; Muhammad Ali; M Abdul Alim Al-Bari; Saeb Aliwaini; Javad Alizadeh; Eugènia Almacellas; Alexandru Almasan; Alicia Alonso; Guillermo D Alonso; Nihal Altan-Bonnet; Dario C Altieri; Élida M C Álvarez; Sara Alves; Cristine Alves da Costa; Mazen M Alzaharna; Marialaura Amadio; Consuelo Amantini; Cristina Amaral; Susanna Ambrosio; Amal O Amer; Veena Ammanathan; Zhenyi An; Stig U Andersen; Shaida A Andrabi; Magaiver Andrade-Silva; Allen M Andres; Sabrina Angelini; David Ann; Uche C Anozie; Mohammad Y Ansari; Pedro Antas; Adam Antebi; Zuriñe Antón; Tahira Anwar; Lionel Apetoh; Nadezda Apostolova; Toshiyuki Araki; Yasuhiro Araki; Kohei Arasaki; Wagner L Araújo; Jun Araya; Catherine Arden; Maria-Angeles Arévalo; Sandro Arguelles; Esperanza Arias; Jyothi Arikkath; Hirokazu Arimoto; Aileen R Ariosa; Darius Armstrong-James; Laetitia Arnauné-Pelloquin; Angeles Aroca; Daniela S Arroyo; Ivica Arsov; Rubén Artero; Dalia Maria Lucia Asaro; Michael Aschner; Milad Ashrafizadeh; Osnat Ashur-Fabian; Atanas G Atanasov; Alicia K Au; Patrick Auberger; Holger W Auner; Laure Aurelian; Riccardo Autelli; Laura Avagliano; Yenniffer Ávalos; Sanja Aveic; Célia Alexandra Aveleira; Tamar Avin-Wittenberg; Yucel Aydin; Scott Ayton; Srinivas Ayyadevara; Maria Azzopardi; Misuzu Baba; Jonathan M Backer; Steven K Backues; Dong-Hun Bae; Ok-Nam Bae; Soo Han Bae; Eric H Baehrecke; Ahruem Baek; Seung-Hoon Baek; Sung Hee Baek; Giacinto Bagetta; Agnieszka Bagniewska-Zadworna; Hua Bai; Jie Bai; Xiyuan Bai; Yidong Bai; Nandadulal Bairagi; Shounak Baksi; Teresa Balbi; Cosima T Baldari; Walter Balduini; Andrea Ballabio; Maria Ballester; Salma Balazadeh; Rena Balzan; Rina Bandopadhyay; Sreeparna Banerjee; Sulagna Banerjee; Ágnes Bánréti; Yan Bao; Mauricio S Baptista; Alessandra Baracca; Cristiana Barbati; Ariadna Bargiela; Daniela Barilà; Peter G Barlow; Sami J Barmada; Esther Barreiro; George E Barreto; Jiri Bartek; Bonnie Bartel; Alberto Bartolome; Gaurav R Barve; Suresh H Basagoudanavar; Diane C Bassham; Robert C Bast; Alakananda Basu; Henri Batoko; Isabella Batten; Etienne E Baulieu; Bradley L Baumgarner; Jagadeesh Bayry; Rupert Beale; Isabelle Beau; Florian Beaumatin; Luiz R G Bechara; George R Beck; Michael F Beers; Jakob Begun; Christian Behrends; Georg M N Behrens; Roberto Bei; Eloy Bejarano; Shai Bel; Christian Behl; Amine Belaid; Naïma Belgareh-Touzé; Cristina Bellarosa; Francesca Belleudi; Melissa Belló Pérez; Raquel Bello-Morales; Jackeline Soares de Oliveira Beltran; Sebastián Beltran; Doris Mangiaracina Benbrook; Mykolas Bendorius; Bruno A Benitez; Irene Benito-Cuesta; Julien Bensalem; Martin W Berchtold; Sabina Berezowska; Daniele Bergamaschi; Matteo Bergami; Andreas Bergmann; Laura Berliocchi; Clarisse Berlioz-Torrent; Amélie Bernard; Lionel Berthoux; Cagri G Besirli; Sebastien Besteiro; Virginie M Betin; Rudi Beyaert; Jelena S Bezbradica; Kiran Bhaskar; Ingrid Bhatia-Kissova; Resham Bhattacharya; Sujoy Bhattacharya; Shalmoli Bhattacharyya; Md Shenuarin Bhuiyan; Sujit Kumar Bhutia; Lanrong Bi; Xiaolin Bi; Trevor J Biden; Krikor Bijian; Viktor A Billes; Nadine Binart; Claudia Bincoletto; Asa B Birgisdottir; Geir Bjorkoy; Gonzalo Blanco; Ana Blas-Garcia; Janusz Blasiak; Robert Blomgran; Klas Blomgren; Janice S Blum; Emilio Boada-Romero; Mirta Boban; Kathleen Boesze-Battaglia; Philippe Boeuf; Barry Boland; Pascale Bomont; Paolo Bonaldo; Srinivasa Reddy Bonam; Laura Bonfili; Juan S Bonifacino; Brian A Boone; Martin D Bootman; Matteo Bordi; Christoph Borner; Beat C Bornhauser; Gautam Borthakur; Jürgen Bosch; Santanu Bose; Luis M Botana; Juan Botas; Chantal M Boulanger; Michael E Boulton; Mathieu Bourdenx; Benjamin Bourgeois; Nollaig M Bourke; Guilhem Bousquet; Patricia Boya; Peter V Bozhkov; Luiz H M Bozi; Tolga O Bozkurt; Doug E Brackney; Christian H Brandts; Ralf J Braun; Gerhard H Braus; Roberto Bravo-Sagua; José M Bravo-San Pedro; Patrick Brest; Marie-Agnès Bringer; Alfredo Briones-Herrera; V Courtney Broaddus; Peter Brodersen; Jeffrey L Brodsky; Steven L Brody; Paola G Bronson; Jeff M Bronstein; Carolyn N Brown; Rhoderick E Brown; Patricia C Brum; John H Brumell; Nicola Brunetti-Pierri; Daniele Bruno; Robert J Bryson-Richardson; Cecilia Bucci; Carmen Buchrieser; Marta Bueno; Laura Elisa Buitrago-Molina; Simone Buraschi; Shilpa Buch; J Ross Buchan; Erin M Buckingham; Hikmet Budak; Mauricio Budini; Geert Bultynck; Florin Burada; Joseph R Burgoyne; M Isabel Burón; Victor Bustos; Sabrina Büttner; Elena Butturini; Aaron Byrd; Isabel Cabas; Sandra Cabrera-Benitez; Ken Cadwell; Jingjing Cai; Lu Cai; Qian Cai; Montserrat Cairó; Jose A Calbet; Guy A Caldwell; Kim A Caldwell; Jarrod A Call; Riccardo Calvani; Ana C Calvo; Miguel Calvo-Rubio Barrera; Niels Os Camara; Jacques H Camonis; Nadine Camougrand; Michelangelo Campanella; Edward M Campbell; François-Xavier Campbell-Valois; Silvia Campello; Ilaria Campesi; Juliane C Campos; Olivier Camuzard; Jorge Cancino; Danilo Candido de Almeida; Laura Canesi; Isabella Caniggia; Barbara Canonico; Carles Cantí; Bin Cao; Michele Caraglia; Beatriz Caramés; Evie H Carchman; Elena Cardenal-Muñoz; Cesar Cardenas; Luis Cardenas; Sandra M Cardoso; Jennifer S Carew; Georges F Carle; Gillian Carleton; Silvia Carloni; Didac Carmona-Gutierrez; Leticia A Carneiro; Oliana Carnevali; Julian M Carosi; Serena Carra; Alice Carrier; Lucie Carrier; Bernadette Carroll; A Brent Carter; Andreia Neves Carvalho; Magali Casanova; Caty Casas; Josefina Casas; Chiara Cassioli; Eliseo F Castillo; Karen Castillo; Sonia Castillo-Lluva; Francesca Castoldi; Marco Castori; Ariel F Castro; Margarida Castro-Caldas; Javier Castro-Hernandez; Susana Castro-Obregon; Sergio D Catz; Claudia Cavadas; Federica Cavaliere; Gabriella Cavallini; Maria Cavinato; Maria L Cayuela; Paula Cebollada Rica; Valentina Cecarini; Francesco Cecconi; Marzanna Cechowska-Pasko; Simone Cenci; Victòria Ceperuelo-Mallafré; João J Cerqueira; Janete M Cerutti; Davide Cervia; Vildan Bozok Cetintas; Silvia Cetrullo; Han-Jung Chae; Andrei S Chagin; Chee-Yin Chai; Gopal Chakrabarti; Oishee Chakrabarti; Tapas Chakraborty; Trinad Chakraborty; Mounia Chami; Georgios Chamilos; David W Chan; Edmond Y W Chan; Edward D Chan; H Y Edwin Chan; Helen H Chan; Hung Chan; Matthew T V Chan; Yau Sang Chan; Partha K Chandra; Chih-Peng Chang; Chunmei Chang; Hao-Chun Chang; Kai Chang; Jie Chao; Tracey Chapman; Nicolas Charlet-Berguerand; Samrat Chatterjee; Shail K Chaube; Anu Chaudhary; Santosh Chauhan; Edward Chaum; Frédéric Checler; Michael E Cheetham; Chang-Shi Chen; Guang-Chao Chen; Jian-Fu Chen; Liam L Chen; Leilei Chen; Lin Chen; Mingliang Chen; Mu-Kuan Chen; Ning Chen; Quan Chen; Ruey-Hwa Chen; Shi Chen; Wei Chen; Weiqiang Chen; Xin-Ming Chen; Xiong-Wen Chen; Xu Chen; Yan Chen; Ye-Guang Chen; Yingyu Chen; Yongqiang Chen; Yu-Jen Chen; Yue-Qin Chen; Zhefan Stephen Chen; Zhi Chen; Zhi-Hua Chen; Zhijian J Chen; Zhixiang Chen; Hanhua Cheng; Jun Cheng; Shi-Yuan Cheng; Wei Cheng; Xiaodong Cheng; Xiu-Tang Cheng; Yiyun Cheng; Zhiyong Cheng; Zhong Chen; Heesun Cheong; Jit Kong Cheong; Boris V Chernyak; Sara Cherry; Chi Fai Randy Cheung; Chun Hei Antonio Cheung; King-Ho Cheung; Eric Chevet; Richard J Chi; Alan Kwok Shing Chiang; Ferdinando Chiaradonna; Roberto Chiarelli; Mario Chiariello; Nathalia Chica; Susanna Chiocca; Mario Chiong; Shih-Hwa Chiou; Abhilash I Chiramel; Valerio Chiurchiù; Dong-Hyung Cho; Seong-Kyu Choe; Augustine M K Choi; Mary E Choi; Kamalika Roy Choudhury; Norman S Chow; Charleen T Chu; Jason P Chua; John Jia En Chua; Hyewon Chung; Kin Pan Chung; Seockhoon Chung; So-Hyang Chung; Yuen-Li Chung; Valentina Cianfanelli; Iwona A Ciechomska; Mariana Cifuentes; Laura Cinque; Sebahattin Cirak; Mara Cirone; Michael J Clague; Robert Clarke; Emilio Clementi; Eliana M Coccia; Patrice Codogno; Ehud Cohen; Mickael M Cohen; Tania Colasanti; Fiorella Colasuonno; Robert A Colbert; Anna Colell; Miodrag Čolić; Nuria S Coll; Mark O Collins; María I Colombo; Daniel A Colón-Ramos; Lydie Combaret; Sergio Comincini; Márcia R Cominetti; Antonella Consiglio; Andrea Conte; Fabrizio Conti; Viorica Raluca Contu; Mark R Cookson; Kevin M Coombs; Isabelle Coppens; Maria Tiziana Corasaniti; Dale P Corkery; Nils Cordes; Katia Cortese; Maria do Carmo Costa; Sarah Costantino; Paola Costelli; Ana Coto-Montes; Peter J Crack; Jose L Crespo; Alfredo Criollo; Valeria Crippa; Riccardo Cristofani; Tamas Csizmadia; Antonio Cuadrado; Bing Cui; Jun Cui; Yixian Cui; Yong Cui; Emmanuel Culetto; Andrea C Cumino; Andrey V Cybulsky; Mark J Czaja; Stanislaw J Czuczwar; Stefania D'Adamo; Marcello D'Amelio; Daniela D'Arcangelo; Andrew C D'Lugos; Gabriella D'Orazi; James A da Silva; Hormos Salimi Dafsari; Ruben K Dagda; Yasin Dagdas; Maria Daglia; Xiaoxia Dai; Yun Dai; Yuyuan Dai; Jessica Dal Col; Paul Dalhaimer; Luisa Dalla Valle; Tobias Dallenga; Guillaume Dalmasso; Markus Damme; Ilaria Dando; Nico P Dantuma; April L Darling; Hiranmoy Das; Srinivasan Dasarathy; Santosh K Dasari; Srikanta Dash; Oliver Daumke; Adrian N Dauphinee; Jeffrey S Davies; Valeria A Dávila; Roger J Davis; Tanja Davis; Sharadha Dayalan Naidu; Francesca De Amicis; Karolien De Bosscher; Francesca De Felice; Lucia De Franceschi; Chiara De Leonibus; Mayara G de Mattos Barbosa; Guido R Y De Meyer; Angelo De Milito; Cosimo De Nunzio; Clara De Palma; Mauro De Santi; Claudio De Virgilio; Daniela De Zio; Jayanta Debnath; Brian J DeBosch; Jean-Paul Decuypere; Mark A Deehan; Gianluca Deflorian; James DeGregori; Benjamin Dehay; Gabriel Del Rio; Joe R Delaney; Lea M D Delbridge; Elizabeth Delorme-Axford; M Victoria Delpino; Francesca Demarchi; Vilma Dembitz; Nicholas D Demers; Hongbin Deng; Zhiqiang Deng; Joern Dengjel; Paul Dent; Donna Denton; Melvin L DePamphilis; Channing J Der; Vojo Deretic; Albert Descoteaux; Laura Devis; Sushil Devkota; Olivier Devuyst; Grant Dewson; Mahendiran Dharmasivam; Rohan Dhiman; Diego di Bernardo; Manlio Di Cristina; Fabio Di Domenico; Pietro Di Fazio; Alessio Di Fonzo; Giovanni Di Guardo; Gianni M Di Guglielmo; Luca Di Leo; Chiara Di Malta; Alessia Di Nardo; Martina Di Rienzo; Federica Di Sano; George Diallinas; Jiajie Diao; Guillermo Diaz-Araya; Inés Díaz-Laviada; Jared M Dickinson; Marc Diederich; Mélanie Dieudé; Ivan Dikic; Shiping Ding; Wen-Xing Ding; Luciana Dini; Jelena Dinić; Miroslav Dinic; Albena T Dinkova-Kostova; Marc S Dionne; Jörg H W Distler; Abhinav Diwan; Ian M C Dixon; Mojgan Djavaheri-Mergny; Ina Dobrinski; Oxana Dobrovinskaya; Radek Dobrowolski; Renwick C J Dobson; Jelena Đokić; Serap Dokmeci Emre; Massimo Donadelli; Bo Dong; Xiaonan Dong; Zhiwu Dong; Gerald W Dorn Ii; Volker Dotsch; Huan Dou; Juan Dou; Moataz Dowaidar; Sami Dridi; Liat Drucker; Ailian Du; Caigan Du; Guangwei Du; Hai-Ning Du; Li-Lin Du; André du Toit; Shao-Bin Duan; Xiaoqiong Duan; Sónia P Duarte; Anna Dubrovska; Elaine A Dunlop; Nicolas Dupont; Raúl V Durán; Bilikere S Dwarakanath; Sergey A Dyshlovoy; Darius Ebrahimi-Fakhari; Leopold Eckhart; Charles L Edelstein; Thomas Efferth; Eftekhar Eftekharpour; Ludwig Eichinger; Nabil Eid; Tobias Eisenberg; N Tony Eissa; Sanaa Eissa; Miriam Ejarque; Abdeljabar El Andaloussi; Nazira El-Hage; Shahenda El-Naggar; Anna Maria Eleuteri; Eman S El-Shafey; Mohamed Elgendy; Aristides G Eliopoulos; María M Elizalde; Philip M Elks; Hans-Peter Elsasser; Eslam S Elsherbiny; Brooke M Emerling; N C Tolga Emre; Christina H Eng; Nikolai Engedal; Anna-Mart Engelbrecht; Agnete S T Engelsen; Jorrit M Enserink; Ricardo Escalante; Audrey Esclatine; Mafalda Escobar-Henriques; Eeva-Liisa Eskelinen; Lucile Espert; Makandjou-Ola Eusebio; Gemma Fabrias; Cinzia Fabrizi; Antonio Facchiano; Francesco Facchiano; Bengt Fadeel; Claudio Fader; Alex C Faesen; W Douglas Fairlie; Alberto Falcó; Bjorn H Falkenburger; Daping Fan; Jie Fan; Yanbo Fan; Evandro F Fang; Yanshan Fang; Yognqi Fang; Manolis Fanto; Tamar Farfel-Becker; Mathias Faure; Gholamreza Fazeli; Anthony O Fedele; Arthur M Feldman; Du Feng; Jiachun Feng; Lifeng Feng; Yibin Feng; Yuchen Feng; Wei Feng; Thais Fenz Araujo; Thomas A Ferguson; Álvaro F Fernández; Jose C Fernandez-Checa; Sonia Fernández-Veledo; Alisdair R Fernie; Anthony W Ferrante; Alessandra Ferraresi; Merari F Ferrari; Julio C B Ferreira; Susan Ferro-Novick; Antonio Figueras; Riccardo Filadi; Nicoletta Filigheddu; Eduardo Filippi-Chiela; Giuseppe Filomeni; Gian Maria Fimia; Vittorio Fineschi; Francesca Finetti; Steven Finkbeiner; Edward A Fisher; Paul B Fisher; Flavio Flamigni; Steven J Fliesler; Trude H Flo; Ida Florance; Oliver Florey; Tullio Florio; Erika Fodor; Carlo Follo; Edward A Fon; Antonella Forlino; Francesco Fornai; Paola Fortini; Anna Fracassi; Alessandro Fraldi; Brunella Franco; Rodrigo Franco; Flavia Franconi; Lisa B Frankel; Scott L Friedman; Leopold F Fröhlich; Gema Frühbeck; Jose M Fuentes; Yukio Fujiki; Naonobu Fujita; Yuuki Fujiwara; Mitsunori Fukuda; Simone Fulda; Luc Furic; Norihiko Furuya; Carmela Fusco; Michaela U Gack; Lidia Gaffke; Sehamuddin Galadari; Alessia Galasso; Maria F Galindo; Sachith Gallolu Kankanamalage; Lorenzo Galluzzi; Vincent Galy; Noor Gammoh; Boyi Gan; Ian G Ganley; Feng Gao; Hui Gao; Minghui Gao; Ping Gao; Shou-Jiang Gao; Wentao Gao; Xiaobo Gao; Ana Garcera; Maria Noé Garcia; Verónica E Garcia; Francisco García-Del Portillo; Vega Garcia-Escudero; Aracely Garcia-Garcia; Marina Garcia-Macia; Diana García-Moreno; Carmen Garcia-Ruiz; Patricia García-Sanz; Abhishek D Garg; Ricardo Gargini; Tina Garofalo; Robert F Garry; Nils C Gassen; Damian Gatica; Liang Ge; Wanzhong Ge; Ruth Geiss-Friedlander; Cecilia Gelfi; Pascal Genschik; Ian E Gentle; Valeria Gerbino; Christoph Gerhardt; Kyla Germain; Marc Germain; David A Gewirtz; Elham Ghasemipour Afshar; Saeid Ghavami; Alessandra Ghigo; Manosij Ghosh; Georgios Giamas; Claudia Giampietri; Alexandra Giatromanolaki; Gary E Gibson; Spencer B Gibson; Vanessa Ginet; Edward Giniger; Carlotta Giorgi; Henrique Girao; Stephen E Girardin; Mridhula Giridharan; Sandy Giuliano; Cecilia Giulivi; Sylvie Giuriato; Julien Giustiniani; Alexander Gluschko; Veit Goder; Alexander Goginashvili; Jakub Golab; David C Goldstone; Anna Golebiewska; Luciana R Gomes; Rodrigo Gomez; Rubén Gómez-Sánchez; Maria Catalina Gomez-Puerto; Raquel Gomez-Sintes; Qingqiu Gong; Felix M Goni; Javier González-Gallego; Tomas Gonzalez-Hernandez; Rosa A Gonzalez-Polo; Jose A Gonzalez-Reyes; Patricia González-Rodríguez; Ing Swie Goping; Marina S Gorbatyuk; Nikolai V Gorbunov; Kıvanç Görgülü; Roxana M Gorojod; Sharon M Gorski; Sandro Goruppi; Cecilia Gotor; Roberta A Gottlieb; Illana Gozes; Devrim Gozuacik; Martin Graef; Markus H Gräler; Veronica Granatiero; Daniel Grasso; Joshua P Gray; Douglas R Green; Alexander Greenhough; Stephen L Gregory; Edward F Griffin; Mark W Grinstaff; Frederic Gros; Charles Grose; Angelina S Gross; Florian Gruber; Paolo Grumati; Tilman Grune; Xueyan Gu; Jun-Lin Guan; Carlos M Guardia; Kishore Guda; Flora Guerra; Consuelo Guerri; Prasun Guha; Carlos Guillén; Shashi Gujar; Anna Gukovskaya; Ilya Gukovsky; Jan Gunst; Andreas Günther; Anyonya R Guntur; Chuanyong Guo; Chun Guo; Hongqing Guo; Lian-Wang Guo; Ming Guo; Pawan Gupta; Shashi Kumar Gupta; Swapnil Gupta; Veer Bala Gupta; Vivek Gupta; Asa B Gustafsson; David D Gutterman; Ranjitha H B; Annakaisa Haapasalo; James E Haber; Aleksandra Hać; Shinji Hadano; Anders J Hafrén; Mansour Haidar; Belinda S Hall; Gunnel Halldén; Anne Hamacher-Brady; Andrea Hamann; Maho Hamasaki; Weidong Han; Malene Hansen; Phyllis I Hanson; Zijian Hao; Masaru Harada; Ljubica Harhaji-Trajkovic; Nirmala Hariharan; Nigil Haroon; James Harris; Takafumi Hasegawa; Noor Hasima Nagoor; Jeffrey A Haspel; Volker Haucke; Wayne D Hawkins; Bruce A Hay; Cole M Haynes; Soren B Hayrabedyan; Thomas S Hays; Congcong He; Qin He; Rong-Rong He; You-Wen He; Yu-Ying He; Yasser Heakal; Alexander M Heberle; J Fielding Hejtmancik; Gudmundur Vignir Helgason; Vanessa Henkel; Marc Herb; Alexander Hergovich; Anna Herman-Antosiewicz; Agustín Hernández; Carlos Hernandez; Sergio Hernandez-Diaz; Virginia Hernandez-Gea; Amaury Herpin; Judit Herreros; Javier H Hervás; Daniel Hesselson; Claudio Hetz; Volker T Heussler; Yujiro Higuchi; Sabine Hilfiker; Joseph A Hill; William S Hlavacek; Emmanuel A Ho; Idy H T Ho; Philip Wing-Lok Ho; Shu-Leong Ho; Wan Yun Ho; G Aaron Hobbs; Mark Hochstrasser; Peter H M Hoet; Daniel Hofius; Paul Hofman; Annika Höhn; Carina I Holmberg; Jose R Hombrebueno; Chang-Won Hong Yi-Ren Hong; Lora V Hooper; Thorsten Hoppe; Rastislav Horos; Yujin Hoshida; I-Lun Hsin; Hsin-Yun Hsu; Bing Hu; Dong Hu; Li-Fang Hu; Ming Chang Hu; Ronggui Hu; Wei Hu; Yu-Chen Hu; Zhuo-Wei Hu; Fang Hua; Jinlian Hua; Yingqi Hua; Chongmin Huan; Canhua Huang; Chuanshu Huang; Chuanxin Huang; Chunling Huang; Haishan Huang; Kun Huang; Michael L H Huang; Rui Huang; Shan Huang; Tianzhi Huang; Xing Huang; Yuxiang Jack Huang; Tobias B Huber; Virginie Hubert; Christian A Hubner; Stephanie M Hughes; William E Hughes; Magali Humbert; Gerhard Hummer; James H Hurley; Sabah Hussain; Salik Hussain; Patrick J Hussey; Martina Hutabarat; Hui-Yun Hwang; Seungmin Hwang; Antonio Ieni; Fumiyo Ikeda; Yusuke Imagawa; Yuzuru Imai; Carol Imbriano; Masaya Imoto; Denise M Inman; Ken Inoki; Juan Iovanna; Renato V Iozzo; Giuseppe Ippolito; Javier E Irazoqui; Pablo Iribarren; Mohd Ishaq; Makoto Ishikawa; Nestor Ishimwe; Ciro Isidoro; Nahed Ismail; Shohreh Issazadeh-Navikas; Eisuke Itakura; Daisuke Ito; Davor Ivankovic; Saška Ivanova; Anand Krishnan V Iyer; José M Izquierdo; Masanori Izumi; Marja Jäättelä; Majid Sakhi Jabir; William T Jackson; Nadia Jacobo-Herrera; Anne-Claire Jacomin; Elise Jacquin; Pooja Jadiya; Hartmut Jaeschke; Chinnaswamy Jagannath; Arjen J Jakobi; Johan Jakobsson; Bassam Janji; Pidder Jansen-Dürr; Patric J Jansson; Jonathan Jantsch; Sławomir Januszewski; Alagie Jassey; Steve Jean; Hélène Jeltsch-David; Pavla Jendelova; Andreas Jenny; Thomas E Jensen; Niels Jessen; Jenna L Jewell; Jing Ji; Lijun Jia; Rui Jia; Liwen Jiang; Qing Jiang; Richeng Jiang; Teng Jiang; Xuejun Jiang; Yu Jiang; Maria Jimenez-Sanchez; Eun-Jung Jin; Fengyan Jin; Hongchuan Jin; Li Jin; Luqi Jin; Meiyan Jin; Si Jin; Eun-Kyeong Jo; Carine Joffre; Terje Johansen; Gail V W Johnson; Simon A Johnston; Eija Jokitalo; Mohit Kumar Jolly; Leo A B Joosten; Joaquin Jordan; Bertrand Joseph; Dianwen Ju; Jeong-Sun Ju; Jingfang Ju; Esmeralda Juárez; Delphine Judith; Gábor Juhász; Youngsoo Jun; Chang Hwa Jung; Sung-Chul Jung; Yong Keun Jung; Heinz Jungbluth; Johannes Jungverdorben; Steffen Just; Kai Kaarniranta; Allen Kaasik; Tomohiro Kabuta; Daniel Kaganovich; Alon Kahana; Renate Kain; Shinjo Kajimura; Maria Kalamvoki; Manjula Kalia; Danuta S Kalinowski; Nina Kaludercic; Ioanna Kalvari; Joanna Kaminska; Vitaliy O Kaminskyy; Hiromitsu Kanamori; Keizo Kanasaki; Chanhee Kang; Rui Kang; Sang Sun Kang; Senthilvelrajan Kaniyappan; Tomotake Kanki; Thirumala-Devi Kanneganti; Anumantha G Kanthasamy; Arthi Kanthasamy; Marc Kantorow; Orsolya Kapuy; Michalis V Karamouzis; Md Razaul Karim; Parimal Karmakar; Rajesh G Katare; Masaru Kato; Stefan H E Kaufmann; Anu Kauppinen; Gur P Kaushal; Susmita Kaushik; Kiyoshi Kawasaki; Kemal Kazan; Po-Yuan Ke; Damien J Keating; Ursula Keber; John H Kehrl; Kate E Keller; Christian W Keller; Jongsook Kim Kemper; Candia M Kenific; Oliver Kepp; Stephanie Kermorgant; Andreas Kern; Robin Ketteler; Tom G Keulers; Boris Khalfin; Hany Khalil; Bilon Khambu; Shahid Y Khan; Vinoth Kumar Megraj Khandelwal; Rekha Khandia; Widuri Kho; Noopur V Khobrekar; Sataree Khuansuwan; Mukhran Khundadze; Samuel A Killackey; Dasol Kim; Deok Ryong Kim; Do-Hyung Kim; Dong-Eun Kim; Eun Young Kim; Eun-Kyoung Kim; Hak-Rim Kim; Hee-Sik Kim; Jeong Hun Kim; Jin Kyung Kim; Jin-Hoi Kim; Joungmok Kim; Ju Hwan Kim; Keun Il Kim; Peter K Kim; Seong-Jun Kim; Scot R Kimball; Adi Kimchi; Alec C Kimmelman; Tomonori Kimura; Matthew A King; Kerri J Kinghorn; Conan G Kinsey; Vladimir Kirkin; Lorrie A Kirshenbaum; Sergey L Kiselev; Shuji Kishi; Katsuhiko Kitamoto; Yasushi Kitaoka; Kaio Kitazato; Richard N Kitsis; Josef T Kittler; Ole Kjaerulff; Peter S Klein; Thomas Klopstock; Jochen Klucken; Helene Knævelsrud; Roland L Knorr; Ben C B Ko; Fred Ko; Jiunn-Liang Ko; Hotaka Kobayashi; Satoru Kobayashi; Ina Koch; Jan C Koch; Ulrich Koenig; Donat Kögel; Young Ho Koh; Masato Koike; Sepp D Kohlwein; Nur M Kocaturk; Masaaki Komatsu; Jeannette König; Toru Kono; Benjamin T Kopp; Tamas Korcsmaros; Gözde Korkmaz; Viktor I Korolchuk; Mónica Suárez Korsnes; Ali Koskela; Janaiah Kota; Yaichiro Kotake; Monica L Kotler; Yanjun Kou; Michael I Koukourakis; Evangelos Koustas; Attila L Kovacs; Tibor Kovács; Daisuke Koya; Tomohiro Kozako; Claudine Kraft; Dimitri Krainc; Helmut Krämer; Anna D Krasnodembskaya; Carole Kretz-Remy; Guido Kroemer; Nicholas T Ktistakis; Kazuyuki Kuchitsu; Sabine Kuenen; Lars Kuerschner; Thomas Kukar; Ajay Kumar; Ashok Kumar; Deepak Kumar; Dhiraj Kumar; Sharad Kumar; Shinji Kume; Caroline Kumsta; Chanakya N Kundu; Mondira Kundu; Ajaikumar B Kunnumakkara; Lukasz Kurgan; Tatiana G Kutateladze; Ozlem Kutlu; SeongAe Kwak; Ho Jeong Kwon; Taeg Kyu Kwon; Yong Tae Kwon; Irene Kyrmizi; Albert La Spada; Patrick Labonté; Sylvain Ladoire; Ilaria Laface; Frank Lafont; Diane C Lagace; Vikramjit Lahiri; Zhibing Lai; Angela S Laird; Aparna Lakkaraju; Trond Lamark; Sheng-Hui Lan; Ane Landajuela; Darius J R Lane; Jon D Lane; Charles H Lang; Carsten Lange; Ülo Langel; Rupert Langer; Pierre Lapaquette; Jocelyn Laporte; Nicholas F LaRusso; Isabel Lastres-Becker; Wilson Chun Yu Lau; Gordon W Laurie; Sergio Lavandero; Betty Yuen Kwan Law; Helen Ka-Wai Law; Rob Layfield; Weidong Le; Herve Le Stunff; Alexandre Y Leary; Jean-Jacques Lebrun; Lionel Y W Leck; Jean-Philippe Leduc-Gaudet; Changwook Lee; Chung-Pei Lee; Da-Hye Lee; Edward B Lee; Erinna F Lee; Gyun Min Lee; He-Jin Lee; Heung Kyu Lee; Jae Man Lee; Jason S Lee; Jin-A Lee; Joo-Yong Lee; Jun Hee Lee; Michael Lee; Min Goo Lee; Min Jae Lee; Myung-Shik Lee; Sang Yoon Lee; Seung-Jae Lee; Stella Y Lee; Sung Bae Lee; Won Hee Lee; Ying-Ray Lee; Yong-Ho Lee; Youngil Lee; Christophe Lefebvre; Renaud Legouis; Yu L Lei; Yuchen Lei; Sergey Leikin; Gerd Leitinger; Leticia Lemus; Shuilong Leng; Olivia Lenoir; Guido Lenz; Heinz Josef Lenz; Paola Lenzi; Yolanda León; Andréia M Leopoldino; Christoph Leschczyk; Stina Leskelä; Elisabeth Letellier; Chi-Ting Leung; Po Sing Leung; Jeremy S Leventhal; Beth Levine; Patrick A Lewis; Klaus Ley; Bin Li; Da-Qiang Li; Jianming Li; Jing Li; Jiong Li; Ke Li; Liwu Li; Mei Li; Min Li; Min Li; Ming Li; Mingchuan Li; Pin-Lan Li; Ming-Qing Li; Qing Li; Sheng Li; Tiangang Li; Wei Li; Wenming Li; Xue Li; Yi-Ping Li; Yuan Li; Zhiqiang Li; Zhiyong Li; Zhiyuan Li; Jiqin Lian; Chengyu Liang; Qiangrong Liang; Weicheng Liang; Yongheng Liang; YongTian Liang; Guanghong Liao; Lujian Liao; Mingzhi Liao; Yung-Feng Liao; Mariangela Librizzi; Pearl P Y Lie; Mary A Lilly; Hyunjung J Lim; Thania R R Lima; Federica Limana; Chao Lin; Chih-Wen Lin; Dar-Shong Lin; Fu-Cheng Lin; Jiandie D Lin; Kurt M Lin; Kwang-Huei Lin; Liang-Tzung Lin; Pei-Hui Lin; Qiong Lin; Shaofeng Lin; Su-Ju Lin; Wenyu Lin; Xueying Lin; Yao-Xin Lin; Yee-Shin Lin; Rafael Linden; Paula Lindner; Shuo-Chien Ling; Paul Lingor; Amelia K Linnemann; Yih-Cherng Liou; Marta M Lipinski; Saška Lipovšek; Vitor A Lira; Natalia Lisiak; Paloma B Liton; Chao Liu; Ching-Hsuan Liu; Chun-Feng Liu; Cui Hua Liu; Fang Liu; Hao Liu; Hsiao-Sheng Liu; Hua-Feng Liu; Huifang Liu; Jia Liu; Jing Liu; Julia Liu; Leyuan Liu; Longhua Liu; Meilian Liu; Qin Liu; Wei Liu; Wende Liu; Xiao-Hong Liu; Xiaodong Liu; Xingguo Liu; Xu Liu; Xuedong Liu; Yanfen Liu; Yang Liu; Yang Liu; Yueyang Liu; Yule Liu; J Andrew Livingston; Gerard Lizard; Jose M Lizcano; Senka Ljubojevic-Holzer; Matilde E LLeonart; David Llobet-Navàs; Alicia Llorente; Chih Hung Lo; Damián Lobato-Márquez; Qi Long; Yun Chau Long; Ben Loos; Julia A Loos; Manuela G López; Guillermo López-Doménech; José Antonio López-Guerrero; Ana T López-Jiménez; Óscar López-Pérez; Israel López-Valero; Magdalena J Lorenowicz; Mar Lorente; Peter Lorincz; Laura Lossi; Sophie Lotersztajn; Penny E Lovat; Jonathan F Lovell; Alenka Lovy; Péter Lőw; Guang Lu; Haocheng Lu; Jia-Hong Lu; Jin-Jian Lu; Mengji Lu; Shuyan Lu; Alessandro Luciani; John M Lucocq; Paula Ludovico; Micah A Luftig; Morten Luhr; Diego Luis-Ravelo; Julian J Lum; Liany Luna-Dulcey; Anders H Lund; Viktor K Lund; Jan D Lünemann; Patrick Lüningschrör; Honglin Luo; Rongcan Luo; Shouqing Luo; Zhi Luo; Claudio Luparello; Bernhard Lüscher; Luan Luu; Alex Lyakhovich; Konstantin G Lyamzaev; Alf Håkon Lystad; Lyubomyr Lytvynchuk; Alvin C Ma; Changle Ma; Mengxiao Ma; Ning-Fang Ma; Quan-Hong Ma; Xinliang Ma; Yueyun Ma; Zhenyi Ma; Ormond A MacDougald; Fernando Macian; Gustavo C MacIntosh; Jeffrey P MacKeigan; Kay F Macleod; Sandra Maday; Frank Madeo; Muniswamy Madesh; Tobias Madl; Julio Madrigal-Matute; Akiko Maeda; Yasuhiro Maejima; Marta Magarinos; Poornima Mahavadi; Emiliano Maiani; Kenneth Maiese; Panchanan Maiti; Maria Chiara Maiuri; Barbara Majello; Michael B Major; Elena Makareeva; Fayaz Malik; Karthik Mallilankaraman; Walter Malorni; Alina Maloyan; Najiba Mammadova; Gene Chi Wai Man; Federico Manai; Joseph D Mancias; Eva-Maria Mandelkow; Michael A Mandell; Angelo A Manfredi; Masoud H Manjili; Ravi Manjithaya; Patricio Manque; Bella B Manshian; Raquel Manzano; Claudia Manzoni; Kai Mao; Cinzia Marchese; Sandrine Marchetti; Anna Maria Marconi; Fabrizio Marcucci; Stefania Mardente; Olga A Mareninova; Marta Margeta; Muriel Mari; Sara Marinelli; Oliviero Marinelli; Guillermo Mariño; Sofia Mariotto; Richard S Marshall; Mark R Marten; Sascha Martens; Alexandre P J Martin; Katie R Martin; Sara Martin; Shaun Martin; Adrián Martín-Segura; Miguel A Martín-Acebes; Inmaculada Martin-Burriel; Marcos Martin-Rincon; Paloma Martin-Sanz; José A Martina; Wim Martinet; Aitor Martinez; Ana Martinez; Jennifer Martinez; Moises Martinez Velazquez; Nuria Martinez-Lopez; Marta Martinez-Vicente; Daniel O Martins; Joilson O Martins; Waleska K Martins; Tania Martins-Marques; Emanuele Marzetti; Shashank Masaldan; Celine Masclaux-Daubresse; Douglas G Mashek; Valentina Massa; Lourdes Massieu; Glenn R Masson; Laura Masuelli; Anatoliy I Masyuk; Tetyana V Masyuk; Paola Matarrese; Ander Matheu; Satoaki Matoba; Sachiko Matsuzaki; Pamela Mattar; Alessandro Matte; Domenico Mattoscio; José L Mauriz; Mario Mauthe; Caroline Mauvezin; Emanual Maverakis; Paola Maycotte; Johanna Mayer; Gianluigi Mazzoccoli; Cristina Mazzoni; Joseph R Mazzulli; Nami McCarty; Christine McDonald; Mitchell R McGill; Sharon L McKenna; BethAnn McLaughlin; Fionn McLoughlin; Mark A McNiven; Thomas G McWilliams; Fatima Mechta-Grigoriou; Tania Catarina Medeiros; Diego L Medina; Lynn A Megeney; Klara Megyeri; Maryam Mehrpour; Jawahar L Mehta; Alfred J Meijer; Annemarie H Meijer; Jakob Mejlvang; Alicia Meléndez; Annette Melk; Gonen Memisoglu; Alexandrina F Mendes; Delong Meng; Fei Meng; Tian Meng; Rubem Menna-Barreto; Manoj B Menon; Carol Mercer; Anne E Mercier; Jean-Louis Mergny; Adalberto Merighi; Seth D Merkley; Giuseppe Merla; Volker Meske; Ana Cecilia Mestre; Shree Padma Metur; Christian Meyer; Hemmo Meyer; Wenyi Mi; Jeanne Mialet-Perez; Junying Miao; Lucia Micale; Yasuo Miki; Enrico Milan; Małgorzata Milczarek; Dana L Miller; Samuel I Miller; Silke Miller; Steven W Millward; Ira Milosevic; Elena A Minina; Hamed Mirzaei; Hamid Reza Mirzaei; Mehdi Mirzaei; Amit Mishra; Nandita Mishra; Paras Kumar Mishra; Maja Misirkic Marjanovic; Roberta Misasi; Amit Misra; Gabriella Misso; Claire Mitchell; Geraldine Mitou; Tetsuji Miura; Shigeki Miyamoto; Makoto Miyazaki; Mitsunori Miyazaki; Taiga Miyazaki; Keisuke Miyazawa; Noboru Mizushima; Trine H Mogensen; Baharia Mograbi; Reza Mohammadinejad; Yasir Mohamud; Abhishek Mohanty; Sipra Mohapatra; Torsten Möhlmann; Asif Mohmmed; Anna Moles; Kelle H Moley; Maurizio Molinari; Vincenzo Mollace; Andreas Buch Møller; Bertrand Mollereau; Faustino Mollinedo; Costanza Montagna; Mervyn J Monteiro; Andrea Montella; L Ruth Montes; Barbara Montico; Vinod K Mony; Giacomo Monzio Compagnoni; Michael N Moore; Mohammad A Moosavi; Ana L Mora; Marina Mora; David Morales-Alamo; Rosario Moratalla; Paula I Moreira; Elena Morelli; Sandra Moreno; Daniel Moreno-Blas; Viviana Moresi; Benjamin Morga; Alwena H Morgan; Fabrice Morin; Hideaki Morishita; Orson L Moritz; Mariko Moriyama; Yuji Moriyasu; Manuela Morleo; Eugenia Morselli; Jose F Moruno-Manchon; Jorge Moscat; Serge Mostowy; Elisa Motori; Andrea Felinto Moura; Naima Moustaid-Moussa; Maria Mrakovcic; Gabriel Muciño-Hernández; Anupam Mukherjee; Subhadip Mukhopadhyay; Jean M Mulcahy Levy; Victoriano Mulero; Sylviane Muller; Christian Münch; Ashok Munjal; Pura Munoz-Canoves; Teresa Muñoz-Galdeano; Christian Münz; Tomokazu Murakawa; Claudia Muratori; Brona M Murphy; J Patrick Murphy; Aditya Murthy; Timo T Myöhänen; Indira U Mysorekar; Jennifer Mytych; Seyed Mohammad Nabavi; Massimo Nabissi; Péter Nagy; Jihoon Nah; Aimable Nahimana; Ichiro Nakagawa; Ken Nakamura; Hitoshi Nakatogawa; Shyam S Nandi; Meera Nanjundan; Monica Nanni; Gennaro Napolitano; Roberta Nardacci; Masashi Narita; Melissa Nassif; Ilana Nathan; Manabu Natsumeda; Ryno J Naude; Christin Naumann; Olaia Naveiras; Fatemeh Navid; Steffan T Nawrocki; Taras Y Nazarko; Francesca Nazio; Florentina Negoita; Thomas Neill; Amanda L Neisch; Luca M Neri; Mihai G Netea; Patrick Neubert; Thomas P Neufeld; Dietbert Neumann; Albert Neutzner; Phillip T Newton; Paul A Ney; Ioannis P Nezis; Charlene C W Ng; Tzi Bun Ng; Hang T T Nguyen; Long T Nguyen; Hong-Min Ni; Clíona Ní Cheallaigh; Zhenhong Ni; M Celeste Nicolao; Francesco Nicoli; Manuel Nieto-Diaz; Per Nilsson; Shunbin Ning; Rituraj Niranjan; Hiroshi Nishimune; Mireia Niso-Santano; Ralph A Nixon; Annalisa Nobili; Clevio Nobrega; Takeshi Noda; Uxía Nogueira-Recalde; Trevor M Nolan; Ivan Nombela; Ivana Novak; Beatriz Novoa; Takashi Nozawa; Nobuyuki Nukina; Carmen Nussbaum-Krammer; Jesper Nylandsted; Tracey R O'Donovan; Seónadh M O'Leary; Eyleen J O'Rourke; Mary P O'Sullivan; Timothy E O'Sullivan; Salvatore Oddo; Ina Oehme; Michinaga Ogawa; Eric Ogier-Denis; Margret H Ogmundsdottir; Besim Ogretmen; Goo Taeg Oh; Seon-Hee Oh; Young J Oh; Takashi Ohama; Yohei Ohashi; Masaki Ohmuraya; Vasileios Oikonomou; Rani Ojha; Koji Okamoto; Hitoshi Okazawa; Masahide Oku; Sara Oliván; Jorge M A Oliveira; Michael Ollmann; James A Olzmann; Shakib Omari; M Bishr Omary; Gizem Önal; Martin Ondrej; Sang-Bing Ong; Sang-Ging Ong; Anna Onnis; Juan A Orellana; Sara Orellana-Muñoz; Maria Del Mar Ortega-Villaizan; Xilma R Ortiz-Gonzalez; Elena Ortona; Heinz D Osiewacz; Abdel-Hamid K Osman; Rosario Osta; Marisa S Otegui; Kinya Otsu; Christiane Ott; Luisa Ottobrini; Jing-Hsiung James Ou; Tiago F Outeiro; Inger Oynebraten; Melek Ozturk; Gilles Pagès; Susanta Pahari; Marta Pajares; Utpal B Pajvani; Rituraj Pal; Simona Paladino; Nicolas Pallet; Michela Palmieri; Giuseppe Palmisano; Camilla Palumbo; Francesco Pampaloni; Lifeng Pan; Qingjun Pan; Wenliang Pan; Xin Pan; Ganna Panasyuk; Rahul Pandey; Udai B Pandey; Vrajesh Pandya; Francesco Paneni; Shirley Y Pang; Elisa Panzarini; Daniela L Papademetrio; Elena Papaleo; Daniel Papinski; Diana Papp; Eun Chan Park; Hwan Tae Park; Ji-Man Park; Jong-In Park; Joon Tae Park; Junsoo Park; Sang Chul Park; Sang-Youel Park; Abraham H Parola; Jan B Parys; Adrien Pasquier; Benoit Pasquier; João F Passos; Nunzia Pastore; Hemal H Patel; Daniel Patschan; Sophie Pattingre; Gustavo Pedraza-Alva; Jose Pedraza-Chaverri; Zully Pedrozo; Gang Pei; Jianming Pei; Hadas Peled-Zehavi; Joaquín M Pellegrini; Joffrey Pelletier; Miguel A Peñalva; Di Peng; Ying Peng; Fabio Penna; Maria Pennuto; Francesca Pentimalli; Cláudia Mf Pereira; Gustavo J S Pereira; Lilian C Pereira; Luis Pereira de Almeida; Nirma D Perera; Ángel Pérez-Lara; Ana B Perez-Oliva; María Esther Pérez-Pérez; Palsamy Periyasamy; Andras Perl; Cristiana Perrotta; Ida Perrotta; Richard G Pestell; Morten Petersen; Irina Petrache; Goran Petrovski; Thorsten Pfirrmann; Astrid S Pfister; Jennifer A Philips; Huifeng Pi; Anna Picca; Alicia M Pickrell; Sandy Picot; Giovanna M Pierantoni; Marina Pierdominici; Philippe Pierre; Valérie Pierrefite-Carle; Karolina Pierzynowska; Federico Pietrocola; Miroslawa Pietruczuk; Claudio Pignata; Felipe X Pimentel-Muiños; Mario Pinar; Roberta O Pinheiro; Ronit Pinkas-Kramarski; Paolo Pinton; Karolina Pircs; Sujan Piya; Paola Pizzo; Theo S Plantinga; Harald W Platta; Ainhoa Plaza-Zabala; Markus Plomann; Egor Y Plotnikov; Helene Plun-Favreau; Ryszard Pluta; Roger Pocock; Stefanie Pöggeler; Christian Pohl; Marc Poirot; Angelo Poletti; Marisa Ponpuak; Hana Popelka; Blagovesta Popova; Helena Porta; Soledad Porte Alcon; Eliana Portilla-Fernandez; Martin Post; Malia B Potts; Joanna Poulton; Ted Powers; Veena Prahlad; Tomasz K Prajsnar; Domenico Praticò; Rosaria Prencipe; Muriel Priault; Tassula Proikas-Cezanne; Vasilis J Promponas; Christopher G Proud; Rosa Puertollano; Luigi Puglielli; Thomas Pulinilkunnil; Deepika Puri; Rajat Puri; Julien Puyal; Xiaopeng Qi; Yongmei Qi; Wenbin Qian; Lei Qiang; Yu Qiu; Joe Quadrilatero; Jorge Quarleri; Nina Raben; Hannah Rabinowich; Debora Ragona; Michael J Ragusa; Nader Rahimi; Marveh Rahmati; Valeria Raia; Nuno Raimundo; Namakkal-Soorappan Rajasekaran; Sriganesh Ramachandra Rao; Abdelhaq Rami; Ignacio Ramírez-Pardo; David B Ramsden; Felix Randow; Pundi N Rangarajan; Danilo Ranieri; Hai Rao; Lang Rao; Rekha Rao; Sumit Rathore; J Arjuna Ratnayaka; Edward A Ratovitski; Palaniyandi Ravanan; Gloria Ravegnini; Swapan K Ray; Babak Razani; Vito Rebecca; Fulvio Reggiori; Anne Régnier-Vigouroux; Andreas S Reichert; David Reigada; Jan H Reiling; Theo Rein; Siegfried Reipert; Rokeya Sultana Rekha; Hongmei Ren; Jun Ren; Weichao Ren; Tristan Renault; Giorgia Renga; Karen Reue; Kim Rewitz; Bruna Ribeiro de Andrade Ramos; S Amer Riazuddin; Teresa M Ribeiro-Rodrigues; Jean-Ehrland Ricci; Romeo Ricci; Victoria Riccio; Des R Richardson; Yasuko Rikihisa; Makarand V Risbud; Ruth M Risueño; Konstantinos Ritis; Salvatore Rizza; Rosario Rizzuto; Helen C Roberts; Luke D Roberts; Katherine J Robinson; Maria Carmela Roccheri; Stephane Rocchi; George G Rodney; Tiago Rodrigues; Vagner Ramon Rodrigues Silva; Amaia Rodriguez; Ruth Rodriguez-Barrueco; Nieves Rodriguez-Henche; Humberto Rodriguez-Rocha; Jeroen Roelofs; Robert S Rogers; Vladimir V Rogov; Ana I Rojo; Krzysztof Rolka; Vanina Romanello; Luigina Romani; Alessandra Romano; Patricia S Romano; David Romeo-Guitart; Luis C Romero; Montserrat Romero; Joseph C Roney; Christopher Rongo; Sante Roperto; Mathias T Rosenfeldt; Philip Rosenstiel; Anne G Rosenwald; Kevin A Roth; Lynn Roth; Steven Roth; Kasper M A Rouschop; Benoit D Roussel; Sophie Roux; Patrizia Rovere-Querini; Ajit Roy; Aurore Rozieres; Diego Ruano; David C Rubinsztein; Maria P Rubtsova; Klaus Ruckdeschel; Christoph Ruckenstuhl; Emil Rudolf; Rüdiger Rudolf; Alessandra Ruggieri; Avnika Ashok Ruparelia; Paola Rusmini; Ryan R Russell; Gian Luigi Russo; Maria Russo; Rossella Russo; Oxana O Ryabaya; Kevin M Ryan; Kwon-Yul Ryu; Maria Sabater-Arcis; Ulka Sachdev; Michael Sacher; Carsten Sachse; Abhishek Sadhu; Junichi Sadoshima; Nathaniel Safren; Paul Saftig; Antonia P Sagona; Gaurav Sahay; Amirhossein Sahebkar; Mustafa Sahin; Ozgur Sahin; Sumit Sahni; Nayuta Saito; Shigeru Saito; Tsunenori Saito; Ryohei Sakai; Yasuyoshi Sakai; Jun-Ichi Sakamaki; Kalle Saksela; Gloria Salazar; Anna Salazar-Degracia; Ghasem H Salekdeh; Ashok K Saluja; Belém Sampaio-Marques; Maria Cecilia Sanchez; Jose A Sanchez-Alcazar; Victoria Sanchez-Vera; Vanessa Sancho-Shimizu; J Thomas Sanderson; Marco Sandri; Stefano Santaguida; Laura Santambrogio; Magda M Santana; Giorgio Santoni; Alberto Sanz; Pascual Sanz; Shweta Saran; Marco Sardiello; Timothy J Sargeant; Apurva Sarin; Chinmoy Sarkar; Sovan Sarkar; Maria-Rosa Sarrias; Surajit Sarkar; Dipanka Tanu Sarmah; Jaakko Sarparanta; Aishwarya Sathyanarayan; Ranganayaki Sathyanarayanan; K Matthew Scaglione; Francesca Scatozza; Liliana Schaefer; Zachary T Schafer; Ulrich E Schaible; Anthony H V Schapira; Michael Scharl; Hermann M Schatzl; Catherine H Schein; Wiep Scheper; David Scheuring; Maria Vittoria Schiaffino; Monica Schiappacassi; Rainer Schindl; Uwe Schlattner; Oliver Schmidt; Roland Schmitt; Stephen D Schmidt; Ingo Schmitz; Eran Schmukler; Anja Schneider; Bianca E Schneider; Romana Schober; Alejandra C Schoijet; Micah B Schott; Michael Schramm; Bernd Schröder; Kai Schuh; Christoph Schüller; Ryan J Schulze; Lea Schürmanns; Jens C Schwamborn; Melanie Schwarten; Filippo Scialo; Sebastiano Sciarretta; Melanie J Scott; Kathleen W Scotto; A Ivana Scovassi; Andrea Scrima; Aurora Scrivo; David Sebastian; Salwa Sebti; Simon Sedej; Laura Segatori; Nava Segev; Per O Seglen; Iban Seiliez; Ekihiro Seki; Scott B Selleck; Frank W Sellke; Joshua T Selsby; Michael Sendtner; Serif Senturk; Elena Seranova; Consolato Sergi; Ruth Serra-Moreno; Hiromi Sesaki; Carmine Settembre; Subba Rao Gangi Setty; Gianluca Sgarbi; Ou Sha; John J Shacka; Javeed A Shah; Dantong Shang; Changshun Shao; Feng Shao; Soroush Sharbati; Lisa M Sharkey; Dipali Sharma; Gaurav Sharma; Kulbhushan Sharma; Pawan Sharma; Surendra Sharma; Han-Ming Shen; Hongtao Shen; Jiangang Shen; Ming Shen; Weili Shen; Zheni Shen; Rui Sheng; Zhi Sheng; Zu-Hang Sheng; Jianjian Shi; Xiaobing Shi; Ying-Hong Shi; Kahori Shiba-Fukushima; Jeng-Jer Shieh; Yohta Shimada; Shigeomi Shimizu; Makoto Shimozawa; Takahiro Shintani; Christopher J Shoemaker; Shahla Shojaei; Ikuo Shoji; Bhupendra V Shravage; Viji Shridhar; Chih-Wen Shu; Hong-Bing Shu; Ke Shui; Arvind K Shukla; Timothy E Shutt; Valentina Sica; Aleem Siddiqui; Amanda Sierra; Virginia Sierra-Torre; Santiago Signorelli; Payel Sil; Bruno J de Andrade Silva; Johnatas D Silva; Eduardo Silva-Pavez; Sandrine Silvente-Poirot; Rachel E Simmonds; Anna Katharina Simon; Hans-Uwe Simon; Matias Simons; Anurag Singh; Lalit P Singh; Rajat Singh; Shivendra V Singh; Shrawan K Singh; Sudha B Singh; Sunaina Singh; Surinder Pal Singh; Debasish Sinha; Rohit Anthony Sinha; Sangita Sinha; Agnieszka Sirko; Kapil Sirohi; Efthimios L Sivridis; Panagiotis Skendros; Aleksandra Skirycz; Iva Slaninová; Soraya S Smaili; Andrei Smertenko; Matthew D Smith; Stefaan J Soenen; Eun Jung Sohn; Sophia P M Sok; Giancarlo Solaini; Thierry Soldati; Scott A Soleimanpour; Rosa M Soler; Alexei Solovchenko; Jason A Somarelli; Avinash Sonawane; Fuyong Song; Hyun Kyu Song; Ju-Xian Song; Kunhua Song; Zhiyin Song; Leandro R Soria; Maurizio Sorice; Alexander A Soukas; Sandra-Fausia Soukup; Diana Sousa; Nadia Sousa; Paul A Spagnuolo; Stephen A Spector; M M Srinivas Bharath; Daret St Clair; Venturina Stagni; Leopoldo Staiano; Clint A Stalnecker; Metodi V Stankov; Peter B Stathopulos; Katja Stefan; Sven Marcel Stefan; Leonidas Stefanis; Joan S Steffan; Alexander Steinkasserer; Harald Stenmark; Jared Sterneckert; Craig Stevens; Veronika Stoka; Stephan Storch; Björn Stork; Flavie Strappazzon; Anne Marie Strohecker; Dwayne G Stupack; Huanxing Su; Ling-Yan Su; Longxiang Su; Ana M Suarez-Fontes; Carlos S Subauste; Selvakumar Subbian; Paula V Subirada; Ganapasam Sudhandiran; Carolyn M Sue; Xinbing Sui; Corey Summers; Guangchao Sun; Jun Sun; Kang Sun; Meng-Xiang Sun; Qiming Sun; Yi Sun; Zhongjie Sun; Karen K S Sunahara; Eva Sundberg; Katalin Susztak; Peter Sutovsky; Hidekazu Suzuki; Gary Sweeney; J David Symons; Stephen Cho Wing Sze; Nathaniel J Szewczyk; Anna Tabęcka-Łonczynska; Claudio Tabolacci; Frank Tacke; Heinrich Taegtmeyer; Marco Tafani; Mitsuo Tagaya; Haoran Tai; Stephen W G Tait; Yoshinori Takahashi; Szabolcs Takats; Priti Talwar; Chit Tam; Shing Yau Tam; Davide Tampellini; Atsushi Tamura; Chong Teik Tan; Eng-King Tan; Ya-Qin Tan; Masaki Tanaka; Motomasa Tanaka; Daolin Tang; Jingfeng Tang; Tie-Shan Tang; Isei Tanida; Zhipeng Tao; Mohammed Taouis; Lars Tatenhorst; Nektarios Tavernarakis; Allen Taylor; Gregory A Taylor; Joan M Taylor; Elena Tchetina; Andrew R Tee; Irmgard Tegeder; David Teis; Natercia Teixeira; Fatima Teixeira-Clerc; Kumsal A Tekirdag; Tewin Tencomnao; Sandra Tenreiro; Alexei V Tepikin; Pilar S Testillano; Gianluca Tettamanti; Pierre-Louis Tharaux; Kathrin Thedieck; Arvind A Thekkinghat; Stefano Thellung; Josephine W Thinwa; V P Thirumalaikumar; Sufi Mary Thomas; Paul G Thomes; Andrew Thorburn; Lipi Thukral; Thomas Thum; Michael Thumm; Ling Tian; Ales Tichy; Andreas Till; Vincent Timmerman; Vladimir I Titorenko; Sokol V Todi; Krassimira Todorova; Janne M Toivonen; Luana Tomaipitinca; Dhanendra Tomar; Cristina Tomas-Zapico; Sergej Tomić; Benjamin Chun-Kit Tong; Chao Tong; Xin Tong; Sharon A Tooze; Maria L Torgersen; Satoru Torii; Liliana Torres-López; Alicia Torriglia; Christina G Towers; Roberto Towns; Shinya Toyokuni; Vladimir Trajkovic; Donatella Tramontano; Quynh-Giao Tran; Leonardo H Travassos; Charles B Trelford; Shirley Tremel; Ioannis P Trougakos; Betty P Tsao; Mario P Tschan; Hung-Fat Tse; Tak Fu Tse; Hitoshi Tsugawa; Andrey S Tsvetkov; David A Tumbarello; Yasin Tumtas; María J Tuñón; Sandra Turcotte; Boris Turk; Vito Turk; Bradley J Turner; Richard I Tuxworth; Jessica K Tyler; Elena V Tyutereva; Yasuo Uchiyama; Aslihan Ugun-Klusek; Holm H Uhlig; Marzena Ułamek-Kozioł; Ilya V Ulasov; Midori Umekawa; Christian Ungermann; Rei Unno; Sylvie Urbe; Elisabet Uribe-Carretero; Suayib Üstün; Vladimir N Uversky; Thomas Vaccari; Maria I Vaccaro; Björn F Vahsen; Helin Vakifahmetoglu-Norberg; Rut Valdor; Maria J Valente; Ayelén Valko; Richard B Vallee; Angela M Valverde; Greet Van den Berghe; Stijn van der Veen; Luc Van Kaer; Jorg van Loosdregt; Sjoerd J L van Wijk; Wim Vandenberghe; Ilse Vanhorebeek; Marcos A Vannier-Santos; Nicola Vannini; M Cristina Vanrell; Chiara Vantaggiato; Gabriele Varano; Isabel Varela-Nieto; Máté Varga; M Helena Vasconcelos; Somya Vats; Demetrios G Vavvas; Ignacio Vega-Naredo; Silvia Vega-Rubin-de-Celis; Guillermo Velasco; Ariadna P Velázquez; Tibor Vellai; Edo Vellenga; Francesca Velotti; Mireille Verdier; Panayotis Verginis; Isabelle Vergne; Paul Verkade; Manish Verma; Patrik Verstreken; Tim Vervliet; Jörg Vervoorts; Alexandre T Vessoni; Victor M Victor; Michel Vidal; Chiara Vidoni; Otilia V Vieira; Richard D Vierstra; Sonia Viganó; Helena Vihinen; Vinoy Vijayan; Miquel Vila; Marçal Vilar; José M Villalba; Antonio Villalobo; Beatriz Villarejo-Zori; Francesc Villarroya; Joan Villarroya; Olivier Vincent; Cecile Vindis; Christophe Viret; Maria Teresa Viscomi; Dora Visnjic; Ilio Vitale; David J Vocadlo; Olga V Voitsekhovskaja; Cinzia Volonté; Mattia Volta; Marta Vomero; Clarissa Von Haefen; Marc A Vooijs; Wolfgang Voos; Ljubica Vucicevic; Richard Wade-Martins; Satoshi Waguri; Kenrick A Waite; Shuji Wakatsuki; David W Walker; Mark J Walker; Simon A Walker; Jochen Walter; Francisco G Wandosell; Bo Wang; Chao-Yung Wang; Chen Wang; Chenran Wang; Chenwei Wang; Cun-Yu Wang; Dong Wang; Fangyang Wang; Feng Wang; Fengming Wang; Guansong Wang; Han Wang; Hao Wang; Hexiang Wang; Hong-Gang Wang; Jianrong Wang; Jigang Wang; Jiou Wang; Jundong Wang; Kui Wang; Lianrong Wang; Liming Wang; Maggie Haitian Wang; Meiqing Wang; Nanbu Wang; Pengwei Wang; Peipei Wang; Ping Wang; Ping Wang; Qing Jun Wang; Qing Wang; Qing Kenneth Wang; Qiong A Wang; Wen-Tao Wang; Wuyang Wang; Xinnan Wang; Xuejun Wang; Yan Wang; Yanchang Wang; Yanzhuang Wang; Yen-Yun Wang; Yihua Wang; Yipeng Wang; Yu Wang; Yuqi Wang; Zhe Wang; Zhenyu Wang; Zhouguang Wang; Gary Warnes; Verena Warnsmann; Hirotaka Watada; Eizo Watanabe; Maxinne Watchon; Anna Wawrzyńska; Timothy E Weaver; Grzegorz Wegrzyn; Ann M Wehman; Huafeng Wei; Lei Wei; Taotao Wei; Yongjie Wei; Oliver H Weiergräber; Conrad C Weihl; Günther Weindl; Ralf Weiskirchen; Alan Wells; Runxia H Wen; Xin Wen; Antonia Werner; Beatrice Weykopf; Sally P Wheatley; J Lindsay Whitton; Alexander J Whitworth; Katarzyna Wiktorska; Manon E Wildenberg; Tom Wileman; Simon Wilkinson; Dieter Willbold; Brett Williams; Robin S B Williams; Roger L Williams; Peter R Williamson; Richard A Wilson; Beate Winner; Nathaniel J Winsor; Steven S Witkin; Harald Wodrich; Ute Woehlbier; Thomas Wollert; Esther Wong; Jack Ho Wong; Richard W Wong; Vincent Kam Wai Wong; W Wei-Lynn Wong; An-Guo Wu; Chengbiao Wu; Jian Wu; Junfang Wu; Kenneth K Wu; Min Wu; Shan-Ying Wu; Shengzhou Wu; Shu-Yan Wu; Shufang Wu; William K K Wu; Xiaohong Wu; Xiaoqing Wu; Yao-Wen Wu; Yihua Wu; Ramnik J Xavier; Hongguang Xia; Lixin Xia; Zhengyuan Xia; Ge Xiang; Jin Xiang; Mingliang Xiang; Wei Xiang; Bin Xiao; Guozhi Xiao; Hengyi Xiao; Hong-Tao Xiao; Jian Xiao; Lan Xiao; Shi Xiao; Yin Xiao; Baoming Xie; Chuan-Ming Xie; Min Xie; Yuxiang Xie; Zhiping Xie; Zhonglin Xie; Maria Xilouri; Congfeng Xu; En Xu; Haoxing Xu; Jing Xu; JinRong Xu; Liang Xu; Wen Wen Xu; Xiulong Xu; Yu Xue; Sokhna M S Yakhine-Diop; Masamitsu Yamaguchi; Osamu Yamaguchi; Ai Yamamoto; Shunhei Yamashina; Shengmin Yan; Shian-Jang Yan; Zhen Yan; Yasuo Yanagi; Chuanbin Yang; Dun-Sheng Yang; Huan Yang; Huang-Tian Yang; Hui Yang; Jin-Ming Yang; Jing Yang; Jingyu Yang; Ling Yang; Liu Yang; Ming Yang; Pei-Ming Yang; Qian Yang; Seungwon Yang; Shu Yang; Shun-Fa Yang; Wannian Yang; Wei Yuan Yang; Xiaoyong Yang; Xuesong Yang; Yi Yang; Ying Yang; Honghong Yao; Shenggen Yao; Xiaoqiang Yao; Yong-Gang Yao; Yong-Ming Yao; Takahiro Yasui; Meysam Yazdankhah; Paul M Yen; Cong Yi; Xiao-Ming Yin; Yanhai Yin; Zhangyuan Yin; Ziyi Yin; Meidan Ying; Zheng Ying; Calvin K Yip; Stephanie Pei Tung Yiu; Young H Yoo; Kiyotsugu Yoshida; Saori R Yoshii; Tamotsu Yoshimori; Bahman Yousefi; Boxuan Yu; Haiyang Yu; Jun Yu; Jun Yu; Li Yu; Ming-Lung Yu; Seong-Woon Yu; Victor C Yu; W Haung Yu; Zhengping Yu; Zhou Yu; Junying Yuan; Ling-Qing Yuan; Shilin Yuan; Shyng-Shiou F Yuan; Yanggang Yuan; Zengqiang Yuan; Jianbo Yue; Zhenyu Yue; Jeanho Yun; Raymond L Yung; David N Zacks; Gabriele Zaffagnini; Vanessa O Zambelli; Isabella Zanella; Qun S Zang; Sara Zanivan; Silvia Zappavigna; Pilar Zaragoza; Konstantinos S Zarbalis; Amir Zarebkohan; Amira Zarrouk; Scott O Zeitlin; Jialiu Zeng; Ju-Deng Zeng; Eva Žerovnik; Lixuan Zhan; Bin Zhang; Donna D Zhang; Hanlin Zhang; Hong Zhang; Hong Zhang; Honghe Zhang; Huafeng Zhang; Huaye Zhang; Hui Zhang; Hui-Ling Zhang; Jianbin Zhang; Jianhua Zhang; Jing-Pu Zhang; Kalin Y B Zhang; Leshuai W Zhang; Lin Zhang; Lisheng Zhang; Lu Zhang; Luoying Zhang; Menghuan Zhang; Peng Zhang; Sheng Zhang; Wei Zhang; Xiangnan Zhang; Xiao-Wei Zhang; Xiaolei Zhang; Xiaoyan Zhang; Xin Zhang; Xinxin Zhang; Xu Dong Zhang; Yang Zhang; Yanjin Zhang; Yi Zhang; Ying-Dong Zhang; Yingmei Zhang; Yuan-Yuan Zhang; Yuchen Zhang; Zhe Zhang; Zhengguang Zhang; Zhibing Zhang; Zhihai Zhang; Zhiyong Zhang; Zili Zhang; Haobin Zhao; Lei Zhao; Shuang Zhao; Tongbiao Zhao; Xiao-Fan Zhao; Ying Zhao; Yongchao Zhao; Yongliang Zhao; Yuting Zhao; Guoping Zheng; Kai Zheng; Ling Zheng; Shizhong Zheng; Xi-Long Zheng; Yi Zheng; Zu-Guo Zheng; Boris Zhivotovsky; Qing Zhong; Ao Zhou; Ben Zhou; Cefan Zhou; Gang Zhou; Hao Zhou; Hong Zhou; Hongbo Zhou; Jie Zhou; Jing Zhou; Jing Zhou; Jiyong Zhou; Kailiang Zhou; Rongjia Zhou; Xu-Jie Zhou; Yanshuang Zhou; Yinghong Zhou; Yubin Zhou; Zheng-Yu Zhou; Zhou Zhou; Binglin Zhu; Changlian Zhu; Guo-Qing Zhu; Haining Zhu; Hongxin Zhu; Hua Zhu; Wei-Guo Zhu; Yanping Zhu; Yushan Zhu; Haixia Zhuang; Xiaohong Zhuang; Katarzyna Zientara-Rytter; Christine M Zimmermann; Elena Ziviani; Teresa Zoladek; Wei-Xing Zong; Dmitry B Zorov; Antonio Zorzano; Weiping Zou; Zhen Zou; Zhengzhi Zou; Steven Zuryn; Werner Zwerschke; Beate Brand-Saberi; X Charlie Dong; Chandra Shekar Kenchappa; Zuguo Li; Yong Lin; Shigeru Oshima; Yueguang Rong; Judith C Sluimer; Christina L Stallings; Chun-Kit Tong Journal: Autophagy Date: 2021-02-08 Impact factor: 13.391
Authors: Daniel J Klionsky; Kotb Abdelmohsen; Akihisa Abe; Md Joynal Abedin; Hagai Abeliovich; Abraham Acevedo Arozena; Hiroaki Adachi; Christopher M Adams; Peter D Adams; Khosrow Adeli; Peter J Adhihetty; Sharon G Adler; Galila Agam; Rajesh Agarwal; Manish K Aghi; Maria Agnello; Patrizia Agostinis; Patricia V Aguilar; Julio Aguirre-Ghiso; Edoardo M Airoldi; Slimane Ait-Si-Ali; Takahiko Akematsu; Emmanuel T Akporiaye; Mohamed Al-Rubeai; Guillermo M Albaiceta; Chris Albanese; Diego Albani; Matthew L Albert; Jesus Aldudo; Hana Algül; Mehrdad Alirezaei; Iraide Alloza; Alexandru Almasan; Maylin Almonte-Beceril; Emad S Alnemri; Covadonga Alonso; Nihal Altan-Bonnet; Dario C Altieri; Silvia Alvarez; Lydia Alvarez-Erviti; Sandro Alves; Giuseppina Amadoro; Atsuo Amano; Consuelo Amantini; Santiago Ambrosio; Ivano Amelio; Amal O Amer; Mohamed Amessou; Angelika Amon; Zhenyi An; Frank A Anania; Stig U Andersen; Usha P Andley; Catherine K Andreadi; Nathalie Andrieu-Abadie; Alberto Anel; David K Ann; Shailendra Anoopkumar-Dukie; Manuela Antonioli; Hiroshi Aoki; Nadezda Apostolova; Saveria Aquila; Katia Aquilano; Koichi Araki; Eli Arama; Agustin Aranda; Jun Araya; Alexandre Arcaro; Esperanza Arias; Hirokazu Arimoto; Aileen R Ariosa; Jane L Armstrong; Thierry Arnould; Ivica Arsov; Katsuhiko Asanuma; Valerie Askanas; Eric Asselin; Ryuichiro Atarashi; Sally S Atherton; Julie D Atkin; Laura D Attardi; Patrick Auberger; Georg Auburger; Laure Aurelian; Riccardo Autelli; Laura Avagliano; Maria Laura Avantaggiati; Limor Avrahami; Suresh Awale; Neelam Azad; Tiziana Bachetti; Jonathan M Backer; Dong-Hun Bae; Jae-Sung Bae; Ok-Nam Bae; Soo Han Bae; Eric H Baehrecke; Seung-Hoon Baek; Stephen Baghdiguian; Agnieszka Bagniewska-Zadworna; Hua Bai; Jie Bai; Xue-Yuan Bai; Yannick Bailly; Kithiganahalli Narayanaswamy Balaji; Walter Balduini; Andrea Ballabio; Rena Balzan; Rajkumar Banerjee; Gábor Bánhegyi; Haijun Bao; Benoit Barbeau; Maria D Barrachina; Esther Barreiro; Bonnie Bartel; Alberto Bartolomé; Diane C Bassham; Maria Teresa Bassi; Robert C Bast; Alakananda Basu; Maria Teresa Batista; Henri Batoko; Maurizio Battino; Kyle Bauckman; Bradley L Baumgarner; K Ulrich Bayer; Rupert Beale; Jean-François Beaulieu; George R Beck; Christoph Becker; J David Beckham; Pierre-André Bédard; Patrick J Bednarski; Thomas J Begley; Christian Behl; Christian Behrends; Georg Mn Behrens; Kevin E Behrns; Eloy Bejarano; Amine Belaid; Francesca Belleudi; Giovanni Bénard; Guy Berchem; Daniele Bergamaschi; Matteo Bergami; Ben Berkhout; Laura Berliocchi; Amélie Bernard; Monique Bernard; Francesca Bernassola; Anne Bertolotti; Amanda S Bess; Sébastien Besteiro; Saverio Bettuzzi; Savita Bhalla; Shalmoli Bhattacharyya; Sujit K Bhutia; Caroline Biagosch; Michele Wolfe Bianchi; Martine Biard-Piechaczyk; Viktor Billes; Claudia Bincoletto; Baris Bingol; Sara W Bird; Marc Bitoun; Ivana Bjedov; Craig Blackstone; Lionel Blanc; Guillermo A Blanco; Heidi Kiil Blomhoff; Emilio Boada-Romero; Stefan Böckler; Marianne Boes; Kathleen Boesze-Battaglia; Lawrence H Boise; Alessandra Bolino; Andrea Boman; Paolo Bonaldo; Matteo Bordi; Jürgen Bosch; Luis M Botana; Joelle Botti; German Bou; Marina Bouché; Marion Bouchecareilh; Marie-Josée Boucher; Michael E Boulton; Sebastien G Bouret; Patricia Boya; Michaël Boyer-Guittaut; Peter V Bozhkov; Nathan Brady; Vania Mm Braga; Claudio Brancolini; Gerhard H Braus; José M Bravo-San Pedro; Lisa A Brennan; Emery H Bresnick; Patrick Brest; Dave Bridges; Marie-Agnès Bringer; Marisa Brini; Glauber C Brito; Bertha Brodin; Paul S Brookes; Eric J Brown; Karen Brown; Hal E Broxmeyer; Alain Bruhat; Patricia Chakur Brum; John H Brumell; Nicola Brunetti-Pierri; Robert J Bryson-Richardson; Shilpa Buch; Alastair M Buchan; Hikmet Budak; Dmitry V Bulavin; Scott J Bultman; Geert Bultynck; Vladimir Bumbasirevic; Yan Burelle; Robert E Burke; Margit Burmeister; Peter Bütikofer; Laura Caberlotto; Ken Cadwell; Monika Cahova; Dongsheng Cai; Jingjing Cai; Qian Cai; Sara Calatayud; Nadine Camougrand; Michelangelo Campanella; Grant R Campbell; Matthew Campbell; Silvia Campello; Robin Candau; Isabella Caniggia; Lavinia Cantoni; Lizhi Cao; Allan B Caplan; Michele Caraglia; Claudio Cardinali; Sandra Morais Cardoso; Jennifer S Carew; Laura A Carleton; Cathleen R Carlin; Silvia Carloni; Sven R Carlsson; Didac Carmona-Gutierrez; Leticia Am Carneiro; Oliana Carnevali; Serena Carra; Alice Carrier; Bernadette Carroll; Caty Casas; Josefina Casas; Giuliana Cassinelli; Perrine Castets; Susana Castro-Obregon; Gabriella Cavallini; Isabella Ceccherini; Francesco Cecconi; Arthur I Cederbaum; Valentín Ceña; Simone Cenci; Claudia Cerella; Davide Cervia; Silvia Cetrullo; Hassan Chaachouay; Han-Jung Chae; Andrei S Chagin; Chee-Yin Chai; Gopal Chakrabarti; Georgios Chamilos; Edmond Yw Chan; Matthew Tv Chan; Dhyan Chandra; Pallavi Chandra; Chih-Peng Chang; Raymond Chuen-Chung Chang; Ta Yuan Chang; John C Chatham; Saurabh Chatterjee; Santosh Chauhan; Yongsheng Che; Michael E Cheetham; Rajkumar Cheluvappa; Chun-Jung Chen; Gang Chen; Guang-Chao Chen; Guoqiang Chen; Hongzhuan Chen; Jeff W Chen; Jian-Kang Chen; Min Chen; Mingzhou Chen; Peiwen Chen; Qi Chen; Quan Chen; Shang-Der Chen; Si Chen; Steve S-L Chen; Wei Chen; Wei-Jung Chen; Wen Qiang Chen; Wenli Chen; Xiangmei Chen; Yau-Hung Chen; Ye-Guang Chen; Yin Chen; Yingyu Chen; Yongshun Chen; Yu-Jen Chen; Yue-Qin Chen; Yujie Chen; Zhen Chen; Zhong Chen; Alan Cheng; Christopher Hk Cheng; Hua Cheng; Heesun Cheong; Sara Cherry; Jason Chesney; Chun Hei Antonio Cheung; Eric Chevet; Hsiang Cheng Chi; Sung-Gil Chi; Fulvio Chiacchiera; Hui-Ling Chiang; Roberto Chiarelli; Mario Chiariello; Marcello Chieppa; Lih-Shen Chin; Mario Chiong; Gigi Nc Chiu; Dong-Hyung Cho; Ssang-Goo Cho; William C Cho; Yong-Yeon Cho; Young-Seok Cho; Augustine Mk Choi; Eui-Ju Choi; Eun-Kyoung Choi; Jayoung Choi; Mary E Choi; Seung-Il Choi; Tsui-Fen Chou; Salem Chouaib; Divaker Choubey; Vinay Choubey; Kuan-Chih Chow; Kamal Chowdhury; Charleen T Chu; Tsung-Hsien Chuang; Taehoon Chun; Hyewon Chung; Taijoon Chung; Yuen-Li Chung; Yong-Joon Chwae; Valentina Cianfanelli; Roberto Ciarcia; Iwona A Ciechomska; Maria Rosa Ciriolo; Mara Cirone; Sofie Claerhout; Michael J Clague; Joan Clària; Peter Gh Clarke; Robert Clarke; Emilio Clementi; Cédric Cleyrat; Miriam Cnop; Eliana M Coccia; Tiziana Cocco; Patrice Codogno; Jörn Coers; Ezra Ew Cohen; David Colecchia; Luisa Coletto; Núria S Coll; Emma Colucci-Guyon; Sergio Comincini; Maria Condello; Katherine L Cook; Graham H Coombs; Cynthia D Cooper; J Mark Cooper; Isabelle Coppens; Maria Tiziana Corasaniti; Marco Corazzari; Ramon Corbalan; Elisabeth Corcelle-Termeau; Mario D Cordero; Cristina Corral-Ramos; Olga Corti; Andrea Cossarizza; Paola Costelli; Safia Costes; Susan L Cotman; Ana Coto-Montes; Sandra Cottet; Eduardo Couve; Lori R Covey; L Ashley Cowart; Jeffery S Cox; Fraser P Coxon; Carolyn B Coyne; Mark S Cragg; Rolf J Craven; Tiziana Crepaldi; Jose L Crespo; Alfredo Criollo; Valeria Crippa; Maria Teresa Cruz; Ana Maria Cuervo; Jose M Cuezva; Taixing Cui; Pedro R Cutillas; Mark J Czaja; Maria F Czyzyk-Krzeska; Ruben K Dagda; Uta Dahmen; Chunsun Dai; Wenjie Dai; Yun Dai; Kevin N Dalby; Luisa Dalla Valle; Guillaume Dalmasso; Marcello D'Amelio; Markus Damme; Arlette Darfeuille-Michaud; Catherine Dargemont; Victor M Darley-Usmar; Srinivasan Dasarathy; Biplab Dasgupta; Srikanta Dash; Crispin R Dass; Hazel Marie Davey; Lester M Davids; David Dávila; Roger J Davis; Ted M Dawson; Valina L Dawson; Paula Daza; Jackie de Belleroche; Paul de Figueiredo; Regina Celia Bressan Queiroz de Figueiredo; José de la Fuente; Luisa De Martino; Antonella De Matteis; Guido Ry De Meyer; Angelo De Milito; Mauro De Santi; Wanderley de Souza; Vincenzo De Tata; Daniela De Zio; Jayanta Debnath; Reinhard Dechant; Jean-Paul Decuypere; Shane Deegan; Benjamin Dehay; Barbara Del Bello; Dominic P Del Re; Régis Delage-Mourroux; Lea Md Delbridge; Louise Deldicque; Elizabeth Delorme-Axford; Yizhen Deng; Joern Dengjel; Melanie Denizot; Paul Dent; Channing J Der; Vojo Deretic; Benoît Derrien; Eric Deutsch; Timothy P Devarenne; Rodney J Devenish; Sabrina Di Bartolomeo; Nicola Di Daniele; Fabio Di Domenico; Alessia Di Nardo; Simone Di Paola; Antonio Di Pietro; Livia Di Renzo; Aaron DiAntonio; Guillermo Díaz-Araya; Ines Díaz-Laviada; Maria T Diaz-Meco; Javier Diaz-Nido; Chad A Dickey; Robert C Dickson; Marc Diederich; Paul Digard; Ivan Dikic; Savithrama P Dinesh-Kumar; Chan Ding; Wen-Xing Ding; Zufeng Ding; Luciana Dini; Jörg Hw Distler; Abhinav Diwan; Mojgan Djavaheri-Mergny; Kostyantyn Dmytruk; Renwick Cj Dobson; Volker Doetsch; Karol Dokladny; Svetlana Dokudovskaya; Massimo Donadelli; X Charlie Dong; Xiaonan Dong; Zheng Dong; Terrence M Donohue; Kelly S Doran; Gabriella D'Orazi; Gerald W Dorn; Victor Dosenko; Sami Dridi; Liat Drucker; Jie Du; Li-Lin Du; Lihuan Du; André du Toit; Priyamvada Dua; Lei Duan; Pu Duann; Vikash Kumar Dubey; Michael R Duchen; Michel A Duchosal; Helene Duez; Isabelle Dugail; Verónica I Dumit; Mara C Duncan; Elaine A Dunlop; William A Dunn; Nicolas Dupont; Luc Dupuis; Raúl V Durán; Thomas M Durcan; Stéphane Duvezin-Caubet; Umamaheswar Duvvuri; Vinay Eapen; Darius Ebrahimi-Fakhari; Arnaud Echard; Leopold Eckhart; Charles L Edelstein; Aimee L Edinger; Ludwig Eichinger; Tobias Eisenberg; Avital Eisenberg-Lerner; N Tony Eissa; Wafik S El-Deiry; Victoria El-Khoury; Zvulun Elazar; Hagit Eldar-Finkelman; Chris Jh Elliott; Enzo Emanuele; Urban Emmenegger; Nikolai Engedal; Anna-Mart Engelbrecht; Simone Engelender; Jorrit M Enserink; Ralf Erdmann; Jekaterina Erenpreisa; Rajaraman Eri; Jason L Eriksen; Andreja Erman; Ricardo Escalante; Eeva-Liisa Eskelinen; Lucile Espert; Lorena Esteban-Martínez; Thomas J Evans; Mario Fabri; Gemma Fabrias; Cinzia Fabrizi; Antonio Facchiano; Nils J Færgeman; Alberto Faggioni; W Douglas Fairlie; Chunhai Fan; Daping Fan; Jie Fan; Shengyun Fang; Manolis Fanto; Alessandro Fanzani; Thomas Farkas; Mathias Faure; Francois B Favier; Howard Fearnhead; Massimo Federici; Erkang Fei; Tania C Felizardo; Hua Feng; Yibin Feng; Yuchen Feng; Thomas A Ferguson; Álvaro F Fernández; Maite G Fernandez-Barrena; Jose C Fernandez-Checa; Arsenio Fernández-López; Martin E Fernandez-Zapico; Olivier Feron; Elisabetta Ferraro; Carmen Veríssima Ferreira-Halder; Laszlo Fesus; Ralph Feuer; Fabienne C Fiesel; Eduardo C Filippi-Chiela; Giuseppe Filomeni; Gian Maria Fimia; John H Fingert; Steven Finkbeiner; Toren Finkel; Filomena Fiorito; Paul B Fisher; Marc Flajolet; Flavio Flamigni; Oliver Florey; Salvatore Florio; R Andres Floto; Marco Folini; Carlo Follo; Edward A Fon; Francesco Fornai; Franco Fortunato; Alessandro Fraldi; Rodrigo Franco; Arnaud Francois; Aurélie François; Lisa B Frankel; Iain Dc Fraser; Norbert Frey; Damien G Freyssenet; Christian Frezza; Scott L Friedman; Daniel E Frigo; Dongxu Fu; José M Fuentes; Juan Fueyo; Yoshio Fujitani; Yuuki Fujiwara; Mikihiro Fujiya; Mitsunori Fukuda; Simone Fulda; Carmela Fusco; Bozena Gabryel; Matthias Gaestel; Philippe Gailly; Malgorzata Gajewska; Sehamuddin Galadari; Gad Galili; Inmaculada Galindo; Maria F Galindo; Giovanna Galliciotti; Lorenzo Galluzzi; Luca Galluzzi; Vincent Galy; Noor Gammoh; Sam Gandy; Anand K Ganesan; Swamynathan Ganesan; Ian G Ganley; Monique Gannagé; Fen-Biao Gao; Feng Gao; Jian-Xin Gao; Lorena García Nannig; Eleonora García Véscovi; Marina Garcia-Macía; Carmen Garcia-Ruiz; Abhishek D Garg; Pramod Kumar Garg; Ricardo Gargini; Nils Christian Gassen; Damián Gatica; Evelina Gatti; Julie Gavard; Evripidis Gavathiotis; Liang Ge; Pengfei Ge; Shengfang Ge; Po-Wu Gean; Vania Gelmetti; Armando A Genazzani; Jiefei Geng; Pascal Genschik; Lisa Gerner; Jason E Gestwicki; David A Gewirtz; Saeid Ghavami; Eric Ghigo; Debabrata Ghosh; Anna Maria Giammarioli; Francesca Giampieri; Claudia Giampietri; Alexandra Giatromanolaki; Derrick J Gibbings; Lara Gibellini; Spencer B Gibson; Vanessa Ginet; Antonio Giordano; Flaviano Giorgini; Elisa Giovannetti; Stephen E Girardin; Suzana Gispert; Sandy Giuliano; Candece L Gladson; Alvaro Glavic; Martin Gleave; Nelly Godefroy; Robert M Gogal; Kuppan Gokulan; Gustavo H Goldman; Delia Goletti; Michael S Goligorsky; Aldrin V Gomes; Ligia C Gomes; Hernando Gomez; Candelaria Gomez-Manzano; Rubén Gómez-Sánchez; Dawit Ap Gonçalves; Ebru Goncu; Qingqiu Gong; Céline Gongora; Carlos B Gonzalez; Pedro Gonzalez-Alegre; Pilar Gonzalez-Cabo; Rosa Ana González-Polo; Ing Swie Goping; Carlos Gorbea; Nikolai V Gorbunov; Daphne R Goring; Adrienne M Gorman; Sharon M Gorski; Sandro Goruppi; Shino Goto-Yamada; Cecilia Gotor; Roberta A Gottlieb; Illana Gozes; Devrim Gozuacik; Yacine Graba; Martin Graef; Giovanna E Granato; Gary Dean Grant; Steven Grant; Giovanni Luca Gravina; Douglas R Green; Alexander Greenhough; Michael T Greenwood; Benedetto Grimaldi; Frédéric Gros; Charles Grose; Jean-Francois Groulx; Florian Gruber; Paolo Grumati; Tilman Grune; Jun-Lin Guan; Kun-Liang Guan; Barbara Guerra; Carlos Guillen; Kailash Gulshan; Jan Gunst; Chuanyong Guo; Lei Guo; Ming Guo; Wenjie Guo; Xu-Guang Guo; Andrea A Gust; Åsa B Gustafsson; Elaine Gutierrez; Maximiliano G Gutierrez; Ho-Shin Gwak; Albert Haas; James E Haber; Shinji Hadano; Monica Hagedorn; David R Hahn; Andrew J Halayko; Anne Hamacher-Brady; Kozo Hamada; Ahmed Hamai; Andrea Hamann; Maho Hamasaki; Isabelle Hamer; Qutayba Hamid; Ester M Hammond; Feng Han; Weidong Han; James T Handa; John A Hanover; Malene Hansen; Masaru Harada; Ljubica Harhaji-Trajkovic; J Wade Harper; Abdel Halim Harrath; Adrian L Harris; James Harris; Udo Hasler; Peter Hasselblatt; Kazuhisa Hasui; Robert G Hawley; Teresa S Hawley; Congcong He; Cynthia Y He; Fengtian He; Gu He; Rong-Rong He; Xian-Hui He; You-Wen He; Yu-Ying He; Joan K Heath; Marie-Josée Hébert; Robert A Heinzen; Gudmundur Vignir Helgason; Michael Hensel; Elizabeth P Henske; Chengtao Her; Paul K Herman; Agustín Hernández; Carlos Hernandez; Sonia Hernández-Tiedra; Claudio Hetz; P Robin Hiesinger; Katsumi Higaki; Sabine Hilfiker; Bradford G Hill; Joseph A Hill; William D Hill; Keisuke Hino; Daniel Hofius; Paul Hofman; Günter U Höglinger; Jörg Höhfeld; Marina K Holz; Yonggeun Hong; David A Hood; Jeroen Jm Hoozemans; Thorsten Hoppe; Chin Hsu; Chin-Yuan Hsu; Li-Chung Hsu; Dong Hu; Guochang Hu; Hong-Ming Hu; Hongbo Hu; Ming Chang Hu; Yu-Chen Hu; Zhuo-Wei Hu; Fang Hua; Ya Hua; Canhua Huang; Huey-Lan Huang; Kuo-How Huang; Kuo-Yang Huang; Shile Huang; Shiqian Huang; Wei-Pang Huang; Yi-Ran Huang; Yong Huang; Yunfei Huang; Tobias B Huber; Patricia Huebbe; Won-Ki Huh; Juha J Hulmi; Gang Min Hur; James H Hurley; Zvenyslava Husak; Sabah Na Hussain; Salik Hussain; Jung Jin Hwang; Seungmin Hwang; Thomas Is Hwang; Atsuhiro Ichihara; Yuzuru Imai; Carol Imbriano; Megumi Inomata; Takeshi Into; Valentina Iovane; Juan L Iovanna; Renato V Iozzo; Nancy Y Ip; Javier E Irazoqui; Pablo Iribarren; Yoshitaka Isaka; Aleksandra J Isakovic; Harry Ischiropoulos; Jeffrey S Isenberg; Mohammad Ishaq; Hiroyuki Ishida; Isao Ishii; Jane E Ishmael; Ciro Isidoro; Ken-Ichi Isobe; Erika Isono; Shohreh Issazadeh-Navikas; Koji Itahana; Eisuke Itakura; Andrei I Ivanov; Anand Krishnan V Iyer; José M Izquierdo; Yotaro Izumi; Valentina Izzo; Marja Jäättelä; Nadia Jaber; Daniel John Jackson; William T Jackson; Tony George Jacob; Thomas S Jacques; Chinnaswamy Jagannath; Ashish Jain; Nihar Ranjan Jana; Byoung Kuk Jang; Alkesh Jani; Bassam Janji; Paulo Roberto Jannig; Patric J Jansson; Steve Jean; Marina Jendrach; Ju-Hong Jeon; Niels Jessen; Eui-Bae Jeung; Kailiang Jia; Lijun Jia; Hong Jiang; Hongchi Jiang; Liwen Jiang; Teng Jiang; Xiaoyan Jiang; Xuejun Jiang; Xuejun Jiang; Ying Jiang; Yongjun Jiang; Alberto Jiménez; Cheng Jin; Hongchuan Jin; Lei Jin; Meiyan Jin; Shengkan Jin; Umesh Kumar Jinwal; Eun-Kyeong Jo; Terje Johansen; Daniel E Johnson; Gail Vw Johnson; James D Johnson; Eric Jonasch; Chris Jones; Leo Ab Joosten; Joaquin Jordan; Anna-Maria Joseph; Bertrand Joseph; Annie M Joubert; Dianwen Ju; Jingfang Ju; Hsueh-Fen Juan; Katrin Juenemann; Gábor Juhász; Hye Seung Jung; Jae U Jung; Yong-Keun Jung; Heinz Jungbluth; Matthew J Justice; Barry Jutten; Nadeem O Kaakoush; Kai Kaarniranta; Allen Kaasik; Tomohiro Kabuta; Bertrand Kaeffer; Katarina Kågedal; Alon Kahana; Shingo Kajimura; Or Kakhlon; Manjula Kalia; Dhan V Kalvakolanu; Yoshiaki Kamada; Konstantinos Kambas; Vitaliy O Kaminskyy; Harm H Kampinga; Mustapha Kandouz; Chanhee Kang; Rui Kang; Tae-Cheon Kang; Tomotake Kanki; Thirumala-Devi Kanneganti; Haruo Kanno; Anumantha G Kanthasamy; Marc Kantorow; Maria Kaparakis-Liaskos; Orsolya Kapuy; Vassiliki Karantza; Md Razaul Karim; Parimal Karmakar; Arthur Kaser; Susmita Kaushik; Thomas Kawula; A Murat Kaynar; Po-Yuan Ke; Zun-Ji Ke; John H Kehrl; Kate E Keller; Jongsook Kim Kemper; Anne K Kenworthy; Oliver Kepp; Andreas Kern; Santosh Kesari; David Kessel; Robin Ketteler; Isis do Carmo Kettelhut; Bilon Khambu; Muzamil Majid Khan; Vinoth Km Khandelwal; Sangeeta Khare; Juliann G Kiang; Amy A Kiger; Akio Kihara; Arianna L Kim; Cheol Hyeon Kim; Deok Ryong Kim; Do-Hyung Kim; Eung Kweon Kim; Hye Young Kim; Hyung-Ryong Kim; Jae-Sung Kim; Jeong Hun Kim; Jin Cheon Kim; Jin Hyoung Kim; Kwang Woon Kim; Michael D Kim; Moon-Moo Kim; Peter K Kim; Seong Who Kim; Soo-Youl Kim; Yong-Sun Kim; Yonghyun Kim; Adi Kimchi; Alec C Kimmelman; Tomonori Kimura; Jason S King; Karla Kirkegaard; Vladimir Kirkin; Lorrie A Kirshenbaum; Shuji Kishi; Yasuo Kitajima; Katsuhiko Kitamoto; Yasushi Kitaoka; Kaio Kitazato; Rudolf A Kley; Walter T Klimecki; Michael Klinkenberg; Jochen Klucken; Helene Knævelsrud; Erwin Knecht; Laura Knuppertz; Jiunn-Liang Ko; Satoru Kobayashi; Jan C Koch; Christelle Koechlin-Ramonatxo; Ulrich Koenig; Young Ho Koh; Katja Köhler; Sepp D Kohlwein; Masato Koike; Masaaki Komatsu; Eiki Kominami; Dexin Kong; Hee Jeong Kong; Eumorphia G Konstantakou; Benjamin T Kopp; Tamas Korcsmaros; Laura Korhonen; Viktor I Korolchuk; Nadya V Koshkina; Yanjun Kou; Michael I Koukourakis; Constantinos Koumenis; Attila L Kovács; Tibor Kovács; Werner J Kovacs; Daisuke Koya; Claudine Kraft; Dimitri Krainc; Helmut Kramer; Tamara Kravic-Stevovic; Wilhelm Krek; Carole Kretz-Remy; Roswitha Krick; Malathi Krishnamurthy; Janos Kriston-Vizi; Guido Kroemer; Michael C Kruer; Rejko Kruger; Nicholas T Ktistakis; Kazuyuki Kuchitsu; Christian Kuhn; Addanki Pratap Kumar; Anuj Kumar; Ashok Kumar; Deepak Kumar; Dhiraj Kumar; Rakesh Kumar; Sharad Kumar; Mondira Kundu; Hsing-Jien Kung; Atsushi Kuno; Sheng-Han Kuo; Jeff Kuret; Tino Kurz; Terry Kwok; Taeg Kyu Kwon; Yong Tae Kwon; Irene Kyrmizi; Albert R La Spada; Frank Lafont; Tim Lahm; Aparna Lakkaraju; Truong Lam; Trond Lamark; Steve Lancel; Terry H Landowski; Darius J R Lane; Jon D Lane; Cinzia Lanzi; Pierre Lapaquette; Louis R Lapierre; Jocelyn Laporte; Johanna Laukkarinen; Gordon W Laurie; Sergio Lavandero; Lena Lavie; Matthew J LaVoie; Betty Yuen Kwan Law; Helen Ka-Wai Law; Kelsey B Law; Robert Layfield; Pedro A Lazo; Laurent Le Cam; Karine G Le Roch; Hervé Le Stunff; Vijittra Leardkamolkarn; Marc Lecuit; Byung-Hoon Lee; Che-Hsin Lee; Erinna F Lee; Gyun Min Lee; He-Jin Lee; Hsinyu Lee; Jae Keun Lee; Jongdae Lee; Ju-Hyun Lee; Jun Hee Lee; Michael Lee; Myung-Shik Lee; Patty J Lee; Sam W Lee; Seung-Jae Lee; Shiow-Ju Lee; Stella Y Lee; Sug Hyung Lee; Sung Sik Lee; Sung-Joon Lee; Sunhee Lee; Ying-Ray Lee; Yong J Lee; Young H Lee; Christiaan Leeuwenburgh; Sylvain Lefort; Renaud Legouis; Jinzhi Lei; Qun-Ying Lei; David A Leib; Gil Leibowitz; Istvan Lekli; Stéphane D Lemaire; John J Lemasters; Marius K Lemberg; Antoinette Lemoine; Shuilong Leng; Guido Lenz; Paola Lenzi; Lilach O Lerman; Daniele Lettieri Barbato; Julia I-Ju Leu; Hing Y Leung; Beth Levine; Patrick A Lewis; Frank Lezoualc'h; Chi Li; Faqiang Li; Feng-Jun Li; Jun Li; Ke Li; Lian Li; Min Li; Min Li; Qiang Li; Rui Li; Sheng Li; Wei Li; Wei Li; Xiaotao Li; Yumin Li; Jiqin Lian; Chengyu Liang; Qiangrong Liang; Yulin Liao; Joana Liberal; Pawel P Liberski; Pearl Lie; Andrew P Lieberman; Hyunjung Jade Lim; Kah-Leong Lim; Kyu Lim; Raquel T Lima; Chang-Shen Lin; Chiou-Feng Lin; Fang Lin; Fangming Lin; Fu-Cheng Lin; Kui Lin; Kwang-Huei Lin; Pei-Hui Lin; Tianwei Lin; Wan-Wan Lin; Yee-Shin Lin; Yong Lin; Rafael Linden; Dan Lindholm; Lisa M Lindqvist; Paul Lingor; Andreas Linkermann; Lance A Liotta; Marta M Lipinski; Vitor A Lira; Michael P Lisanti; Paloma B Liton; Bo Liu; Chong Liu; Chun-Feng Liu; Fei Liu; Hung-Jen Liu; Jianxun Liu; Jing-Jing Liu; Jing-Lan Liu; Ke Liu; Leyuan Liu; Liang Liu; Quentin Liu; Rong-Yu Liu; Shiming Liu; Shuwen Liu; Wei Liu; Xian-De Liu; Xiangguo Liu; Xiao-Hong Liu; Xinfeng Liu; Xu Liu; Xueqin Liu; Yang Liu; Yule Liu; Zexian Liu; Zhe Liu; Juan P Liuzzi; Gérard Lizard; Mila Ljujic; Irfan J Lodhi; Susan E Logue; Bal L Lokeshwar; Yun Chau Long; Sagar Lonial; Benjamin Loos; Carlos López-Otín; Cristina López-Vicario; Mar Lorente; Philip L Lorenzi; Péter Lõrincz; Marek Los; Michael T Lotze; Penny E Lovat; Binfeng Lu; Bo Lu; Jiahong Lu; Qing Lu; She-Min Lu; Shuyan Lu; Yingying Lu; Frédéric Luciano; Shirley Luckhart; John Milton Lucocq; Paula Ludovico; Aurelia Lugea; Nicholas W Lukacs; Julian J Lum; Anders H Lund; Honglin Luo; Jia Luo; Shouqing Luo; Claudio Luparello; Timothy Lyons; Jianjie Ma; Yi Ma; Yong Ma; Zhenyi Ma; Juliano Machado; Glaucia M Machado-Santelli; Fernando Macian; Gustavo C MacIntosh; Jeffrey P MacKeigan; Kay F Macleod; John D MacMicking; Lee Ann MacMillan-Crow; Frank Madeo; Muniswamy Madesh; Julio Madrigal-Matute; Akiko Maeda; Tatsuya Maeda; Gustavo Maegawa; Emilia Maellaro; Hannelore Maes; Marta Magariños; Kenneth Maiese; Tapas K Maiti; Luigi Maiuri; Maria Chiara Maiuri; Carl G Maki; Roland Malli; Walter Malorni; Alina Maloyan; Fathia Mami-Chouaib; Na Man; Joseph D Mancias; Eva-Maria Mandelkow; Michael A Mandell; Angelo A Manfredi; Serge N Manié; Claudia Manzoni; Kai Mao; Zixu Mao; Zong-Wan Mao; Philippe Marambaud; Anna Maria Marconi; Zvonimir Marelja; Gabriella Marfe; Marta Margeta; Eva Margittai; Muriel Mari; Francesca V Mariani; Concepcio Marin; Sara Marinelli; Guillermo Mariño; Ivanka Markovic; Rebecca Marquez; Alberto M Martelli; Sascha Martens; Katie R Martin; Seamus J Martin; Shaun Martin; Miguel A Martin-Acebes; Paloma Martín-Sanz; Camille Martinand-Mari; Wim Martinet; Jennifer Martinez; Nuria Martinez-Lopez; Ubaldo Martinez-Outschoorn; Moisés Martínez-Velázquez; Marta Martinez-Vicente; Waleska Kerllen Martins; Hirosato Mashima; James A Mastrianni; Giuseppe Matarese; Paola Matarrese; Roberto Mateo; Satoaki Matoba; Naomichi Matsumoto; Takehiko Matsushita; Akira Matsuura; Takeshi Matsuzawa; Mark P Mattson; Soledad Matus; Norma Maugeri; Caroline Mauvezin; Andreas Mayer; Dusica Maysinger; Guillermo D Mazzolini; Mary Kate McBrayer; Kimberly McCall; Craig McCormick; Gerald M McInerney; Skye C McIver; Sharon McKenna; John J McMahon; Iain A McNeish; Fatima Mechta-Grigoriou; Jan Paul Medema; Diego L Medina; Klara Megyeri; Maryam Mehrpour; Jawahar L Mehta; Yide Mei; Ute-Christiane Meier; Alfred J Meijer; Alicia Meléndez; Gerry Melino; Sonia Melino; Edesio Jose Tenorio de Melo; Maria A Mena; Marc D Meneghini; Javier A Menendez; Regina Menezes; Liesu Meng; Ling-Hua Meng; Songshu Meng; Rossella Menghini; A Sue Menko; Rubem Fs Menna-Barreto; Manoj B Menon; Marco A Meraz-Ríos; Giuseppe Merla; Luciano Merlini; Angelica M Merlot; Andreas Meryk; Stefania Meschini; Joel N Meyer; Man-Tian Mi; Chao-Yu Miao; Lucia Micale; Simon Michaeli; Carine Michiels; Anna Rita Migliaccio; Anastasia Susie Mihailidou; Dalibor Mijaljica; Katsuhiko Mikoshiba; Enrico Milan; Leonor Miller-Fleming; Gordon B Mills; Ian G Mills; Georgia Minakaki; Berge A Minassian; Xiu-Fen Ming; Farida Minibayeva; Elena A Minina; Justine D Mintern; Saverio Minucci; Antonio Miranda-Vizuete; Claire H Mitchell; Shigeki Miyamoto; Keisuke Miyazawa; Noboru Mizushima; Katarzyna Mnich; Baharia Mograbi; Simin Mohseni; Luis Ferreira Moita; Marco Molinari; Maurizio Molinari; Andreas Buch Møller; Bertrand Mollereau; Faustino Mollinedo; Marco Mongillo; Martha M Monick; Serena Montagnaro; Craig Montell; Darren J Moore; Michael N Moore; Rodrigo Mora-Rodriguez; Paula I Moreira; Etienne Morel; Maria Beatrice Morelli; Sandra Moreno; Michael J Morgan; Arnaud Moris; Yuji Moriyasu; Janna L Morrison; Lynda A Morrison; Eugenia Morselli; Jorge Moscat; Pope L Moseley; Serge Mostowy; Elisa Motori; Denis Mottet; Jeremy C Mottram; Charbel E-H Moussa; Vassiliki E Mpakou; Hasan Mukhtar; Jean M Mulcahy Levy; Sylviane Muller; Raquel Muñoz-Moreno; Cristina Muñoz-Pinedo; Christian Münz; Maureen E Murphy; James T Murray; Aditya Murthy; Indira U Mysorekar; Ivan R Nabi; Massimo Nabissi; Gustavo A Nader; Yukitoshi Nagahara; Yoshitaka Nagai; Kazuhiro Nagata; Anika Nagelkerke; Péter Nagy; Samisubbu R Naidu; Sreejayan Nair; Hiroyasu Nakano; Hitoshi Nakatogawa; Meera Nanjundan; Gennaro Napolitano; Naweed I Naqvi; Roberta Nardacci; Derek P Narendra; Masashi Narita; Anna Chiara Nascimbeni; Ramesh Natarajan; Luiz C Navegantes; Steffan T Nawrocki; Taras Y Nazarko; Volodymyr Y Nazarko; Thomas Neill; Luca M Neri; Mihai G Netea; Romana T Netea-Maier; Bruno M Neves; Paul A Ney; Ioannis P Nezis; Hang Tt Nguyen; Huu Phuc Nguyen; Anne-Sophie Nicot; Hilde Nilsen; Per Nilsson; Mikio Nishimura; Ichizo Nishino; Mireia Niso-Santano; Hua Niu; Ralph A Nixon; Vincent Co Njar; Takeshi Noda; Angelika A Noegel; Elsie Magdalena Nolte; Erik Norberg; Koenraad K Norga; Sakineh Kazemi Noureini; Shoji Notomi; Lucia Notterpek; Karin Nowikovsky; Nobuyuki Nukina; Thorsten Nürnberger; Valerie B O'Donnell; Tracey O'Donovan; Peter J O'Dwyer; Ina Oehme; Clara L Oeste; Michinaga Ogawa; Besim Ogretmen; Yuji Ogura; Young J Oh; Masaki Ohmuraya; Takayuki Ohshima; Rani Ojha; Koji Okamoto; Toshiro Okazaki; F Javier Oliver; Karin Ollinger; Stefan Olsson; Daniel P Orban; Paulina Ordonez; Idil Orhon; Laszlo Orosz; Eyleen J O'Rourke; Helena Orozco; Angel L Ortega; Elena Ortona; Laura D Osellame; Junko Oshima; Shigeru Oshima; Heinz D Osiewacz; Takanobu Otomo; Kinya Otsu; Jing-Hsiung James Ou; Tiago F Outeiro; Dong-Yun Ouyang; Hongjiao Ouyang; Michael Overholtzer; Michelle A Ozbun; P Hande Ozdinler; Bulent Ozpolat; Consiglia Pacelli; Paolo Paganetti; Guylène Page; Gilles Pages; Ugo Pagnini; Beata Pajak; Stephen C Pak; Karolina Pakos-Zebrucka; Nazzy Pakpour; Zdena Palková; Francesca Palladino; Kathrin Pallauf; Nicolas Pallet; Marta Palmieri; Søren R Paludan; Camilla Palumbo; Silvia Palumbo; Olatz Pampliega; Hongming Pan; Wei Pan; Theocharis Panaretakis; Aseem Pandey; Areti Pantazopoulou; Zuzana Papackova; Daniela L Papademetrio; Issidora Papassideri; Alessio Papini; Nirmala Parajuli; Julian Pardo; Vrajesh V Parekh; Giancarlo Parenti; Jong-In Park; Junsoo Park; Ohkmae K Park; Roy Parker; Rosanna Parlato; Jan B Parys; Katherine R Parzych; Jean-Max Pasquet; Benoit Pasquier; Kishore Bs Pasumarthi; Daniel Patschan; Cam Patterson; Sophie Pattingre; Scott Pattison; Arnim Pause; Hermann Pavenstädt; Flaminia Pavone; Zully Pedrozo; Fernando J Peña; Miguel A Peñalva; Mario Pende; Jianxin Peng; Fabio Penna; Josef M Penninger; Anna Pensalfini; Salvatore Pepe; Gustavo Js Pereira; Paulo C Pereira; Verónica Pérez-de la Cruz; María Esther Pérez-Pérez; Diego Pérez-Rodríguez; Dolores Pérez-Sala; Celine Perier; Andras Perl; David H Perlmutter; Ida Perrotta; Shazib Pervaiz; Maija Pesonen; Jeffrey E Pessin; Godefridus J Peters; Morten Petersen; Irina Petrache; Basil J Petrof; Goran Petrovski; James M Phang; Mauro Piacentini; Marina Pierdominici; Philippe Pierre; Valérie Pierrefite-Carle; Federico Pietrocola; Felipe X Pimentel-Muiños; Mario Pinar; Benjamin Pineda; Ronit Pinkas-Kramarski; Marcello Pinti; Paolo Pinton; Bilal Piperdi; James M Piret; Leonidas C Platanias; Harald W Platta; Edward D Plowey; Stefanie Pöggeler; Marc Poirot; Peter Polčic; Angelo Poletti; Audrey H Poon; Hana Popelka; Blagovesta Popova; Izabela Poprawa; Shibu M Poulose; Joanna Poulton; Scott K Powers; Ted Powers; Mercedes Pozuelo-Rubio; Krisna Prak; Reinhild Prange; Mark Prescott; Muriel Priault; Sharon Prince; Richard L Proia; Tassula Proikas-Cezanne; Holger Prokisch; Vasilis J Promponas; Karin Przyklenk; Rosa Puertollano; Subbiah Pugazhenthi; Luigi Puglielli; Aurora Pujol; Julien Puyal; Dohun Pyeon; Xin Qi; Wen-Bin Qian; Zheng-Hong Qin; Yu Qiu; Ziwei Qu; Joe Quadrilatero; Frederick Quinn; Nina Raben; Hannah Rabinowich; Flavia Radogna; Michael J Ragusa; Mohamed Rahmani; Komal Raina; Sasanka Ramanadham; Rajagopal Ramesh; Abdelhaq Rami; Sarron Randall-Demllo; Felix Randow; Hai Rao; V Ashutosh Rao; Blake B Rasmussen; Tobias M Rasse; Edward A Ratovitski; Pierre-Emmanuel Rautou; Swapan K Ray; Babak Razani; Bruce H Reed; Fulvio Reggiori; Markus Rehm; Andreas S Reichert; Theo Rein; David J Reiner; Eric Reits; Jun Ren; Xingcong Ren; Maurizio Renna; Jane Eb Reusch; Jose L Revuelta; Leticia Reyes; Alireza R Rezaie; Robert I Richards; Des R Richardson; Clémence Richetta; Michael A Riehle; Bertrand H Rihn; Yasuko Rikihisa; Brigit E Riley; Gerald Rimbach; Maria Rita Rippo; Konstantinos Ritis; Federica Rizzi; Elizete Rizzo; Peter J Roach; Jeffrey Robbins; Michel Roberge; Gabriela Roca; Maria Carmela Roccheri; Sonia Rocha; Cecilia Mp Rodrigues; Clara I Rodríguez; Santiago Rodriguez de Cordoba; Natalia Rodriguez-Muela; Jeroen Roelofs; Vladimir V Rogov; Troy T Rohn; Bärbel Rohrer; Davide Romanelli; Luigina Romani; Patricia Silvia Romano; M Isabel G Roncero; Jose Luis Rosa; Alicia Rosello; Kirill V Rosen; Philip Rosenstiel; Magdalena Rost-Roszkowska; Kevin A Roth; Gael Roué; Mustapha Rouis; Kasper M Rouschop; Daniel T Ruan; Diego Ruano; David C Rubinsztein; Edmund B Rucker; Assaf Rudich; Emil Rudolf; Ruediger Rudolf; Markus A Ruegg; Carmen Ruiz-Roldan; Avnika Ashok Ruparelia; Paola Rusmini; David W Russ; Gian Luigi Russo; Giuseppe Russo; Rossella Russo; Tor Erik Rusten; Victoria Ryabovol; Kevin M Ryan; Stefan W Ryter; David M Sabatini; Michael Sacher; Carsten Sachse; Michael N Sack; Junichi Sadoshima; Paul Saftig; Ronit Sagi-Eisenberg; Sumit Sahni; Pothana Saikumar; Tsunenori Saito; Tatsuya Saitoh; Koichi Sakakura; Machiko Sakoh-Nakatogawa; Yasuhito Sakuraba; María Salazar-Roa; Paolo Salomoni; Ashok K Saluja; Paul M Salvaterra; Rosa Salvioli; Afshin Samali; Anthony Mj Sanchez; José A Sánchez-Alcázar; Ricardo Sanchez-Prieto; Marco Sandri; Miguel A Sanjuan; Stefano Santaguida; Laura Santambrogio; Giorgio Santoni; Claudia Nunes Dos Santos; Shweta Saran; Marco Sardiello; Graeme Sargent; Pallabi Sarkar; Sovan Sarkar; Maria Rosa Sarrias; Minnie M Sarwal; Chihiro Sasakawa; Motoko Sasaki; Miklos Sass; Ken Sato; Miyuki Sato; Joseph Satriano; Niramol Savaraj; Svetlana Saveljeva; Liliana Schaefer; Ulrich E Schaible; Michael Scharl; Hermann M Schatzl; Randy Schekman; Wiep Scheper; Alfonso Schiavi; Hyman M Schipper; Hana Schmeisser; Jens Schmidt; Ingo Schmitz; Bianca E Schneider; E Marion Schneider; Jaime L Schneider; Eric A Schon; Miriam J Schönenberger; Axel H Schönthal; Daniel F Schorderet; Bernd Schröder; Sebastian Schuck; Ryan J Schulze; Melanie Schwarten; Thomas L Schwarz; Sebastiano Sciarretta; Kathleen Scotto; A Ivana Scovassi; Robert A Screaton; Mark Screen; Hugo Seca; Simon Sedej; Laura Segatori; Nava Segev; Per O Seglen; Jose M Seguí-Simarro; Juan Segura-Aguilar; Ekihiro Seki; Christian Sell; Iban Seiliez; Clay F Semenkovich; Gregg L Semenza; Utpal Sen; Andreas L Serra; Ana Serrano-Puebla; Hiromi Sesaki; Takao Setoguchi; Carmine Settembre; John J Shacka; Ayesha N Shajahan-Haq; Irving M Shapiro; Shweta Sharma; Hua She; C-K James Shen; Chiung-Chyi Shen; Han-Ming Shen; Sanbing Shen; Weili Shen; Rui Sheng; Xianyong Sheng; Zu-Hang Sheng; Trevor G Shepherd; Junyan Shi; Qiang Shi; Qinghua Shi; Yuguang Shi; Shusaku Shibutani; Kenichi Shibuya; Yoshihiro Shidoji; Jeng-Jer Shieh; Chwen-Ming Shih; Yohta Shimada; Shigeomi Shimizu; Dong Wook Shin; Mari L Shinohara; Michiko Shintani; Takahiro Shintani; Tetsuo Shioi; Ken Shirabe; Ronit Shiri-Sverdlov; Orian Shirihai; Gordon C Shore; Chih-Wen Shu; Deepak Shukla; Andriy A Sibirny; Valentina Sica; Christina J Sigurdson; Einar M Sigurdsson; Puran Singh Sijwali; Beata Sikorska; Wilian A Silveira; Sandrine Silvente-Poirot; Gary A Silverman; Jan Simak; Thomas Simmet; Anna Katharina Simon; Hans-Uwe Simon; Cristiano Simone; Matias Simons; Anne Simonsen; Rajat Singh; Shivendra V Singh; Shrawan K Singh; Debasish Sinha; Sangita Sinha; Frank A Sinicrope; Agnieszka Sirko; Kapil Sirohi; Balindiwe Jn Sishi; Annie Sittler; Parco M Siu; Efthimios Sivridis; Anna Skwarska; Ruth Slack; Iva Slaninová; Nikolai Slavov; Soraya S Smaili; Keiran Sm Smalley; Duncan R Smith; Stefaan J Soenen; Scott A Soleimanpour; Anita Solhaug; Kumaravel Somasundaram; Jin H Son; Avinash Sonawane; Chunjuan Song; Fuyong Song; Hyun Kyu Song; Ju-Xian Song; Wei Song; Kai Y Soo; Anil K Sood; Tuck Wah Soong; Virawudh Soontornniyomkij; Maurizio Sorice; Federica Sotgia; David R Soto-Pantoja; Areechun Sotthibundhu; Maria João Sousa; Herman P Spaink; Paul N Span; Anne Spang; Janet D Sparks; Peter G Speck; Stephen A Spector; Claudia D Spies; Wolfdieter Springer; Daret St Clair; Alessandra Stacchiotti; Bart Staels; Michael T Stang; Daniel T Starczynowski; Petro Starokadomskyy; Clemens Steegborn; John W Steele; Leonidas Stefanis; Joan Steffan; Christine M Stellrecht; Harald Stenmark; Tomasz M Stepkowski; Stęphan T Stern; Craig Stevens; Brent R Stockwell; Veronika Stoka; Zuzana Storchova; Björn Stork; Vassilis Stratoulias; Dimitrios J Stravopodis; Pavel Strnad; Anne Marie Strohecker; Anna-Lena Ström; Per Stromhaug; Jiri Stulik; Yu-Xiong Su; Zhaoliang Su; Carlos S Subauste; Srinivasa Subramaniam; Carolyn M Sue; Sang Won Suh; Xinbing Sui; Supawadee Sukseree; David Sulzer; Fang-Lin Sun; Jiaren Sun; Jun Sun; Shi-Yong Sun; Yang Sun; Yi Sun; Yingjie Sun; Vinod Sundaramoorthy; Joseph Sung; Hidekazu Suzuki; Kuninori Suzuki; Naoki Suzuki; Tadashi Suzuki; Yuichiro J Suzuki; Michele S Swanson; Charles Swanton; Karl Swärd; Ghanshyam Swarup; Sean T Sweeney; Paul W Sylvester; Zsuzsanna Szatmari; Eva Szegezdi; Peter W Szlosarek; Heinrich Taegtmeyer; Marco Tafani; Emmanuel Taillebourg; Stephen Wg Tait; Krisztina Takacs-Vellai; Yoshinori Takahashi; Szabolcs Takáts; Genzou Takemura; Nagio Takigawa; Nicholas J Talbot; Elena Tamagno; Jerome Tamburini; Cai-Ping Tan; Lan Tan; Mei Lan Tan; Ming Tan; Yee-Joo Tan; Keiji Tanaka; Masaki Tanaka; Daolin Tang; Dingzhong Tang; Guomei Tang; Isei Tanida; Kunikazu Tanji; Bakhos A Tannous; Jose A Tapia; Inmaculada Tasset-Cuevas; Marc Tatar; Iman Tavassoly; Nektarios Tavernarakis; Allen Taylor; Graham S Taylor; Gregory A Taylor; J Paul Taylor; Mark J Taylor; Elena V Tchetina; Andrew R Tee; Fatima Teixeira-Clerc; Sucheta Telang; Tewin Tencomnao; Ba-Bie Teng; Ru-Jeng Teng; Faraj Terro; Gianluca Tettamanti; Arianne L Theiss; Anne E Theron; Kelly Jean Thomas; Marcos P Thomé; Paul G Thomes; Andrew Thorburn; Jeremy Thorner; Thomas Thum; Michael Thumm; Teresa Lm Thurston; Ling Tian; Andreas Till; Jenny Pan-Yun Ting; Vladimir I Titorenko; Lilach Toker; Stefano Toldo; Sharon A Tooze; Ivan Topisirovic; Maria Lyngaas Torgersen; Liliana Torosantucci; Alicia Torriglia; Maria Rosaria Torrisi; Cathy Tournier; Roberto Towns; Vladimir Trajkovic; Leonardo H Travassos; Gemma Triola; Durga Nand Tripathi; Daniela Trisciuoglio; Rodrigo Troncoso; Ioannis P Trougakos; Anita C Truttmann; Kuen-Jer Tsai; Mario P Tschan; Yi-Hsin Tseng; Takayuki Tsukuba; Allan Tsung; Andrey S Tsvetkov; Shuiping Tu; Hsing-Yu Tuan; Marco Tucci; David A Tumbarello; Boris Turk; Vito Turk; Robin Fb Turner; Anders A Tveita; Suresh C Tyagi; Makoto Ubukata; Yasuo Uchiyama; Andrej Udelnow; Takashi Ueno; Midori Umekawa; Rika Umemiya-Shirafuji; Benjamin R Underwood; Christian Ungermann; Rodrigo P Ureshino; Ryo Ushioda; Vladimir N Uversky; Néstor L Uzcátegui; Thomas Vaccari; Maria I Vaccaro; Libuše Váchová; Helin Vakifahmetoglu-Norberg; Rut Valdor; Enza Maria Valente; Francois Vallette; Angela M Valverde; Greet Van den Berghe; Ludo Van Den Bosch; Gijs R van den Brink; F Gisou van der Goot; Ida J van der Klei; Luc Jw van der Laan; Wouter G van Doorn; Marjolein van Egmond; Kenneth L van Golen; Luc Van Kaer; Menno van Lookeren Campagne; Peter Vandenabeele; Wim Vandenberghe; Ilse Vanhorebeek; Isabel Varela-Nieto; M Helena Vasconcelos; Radovan Vasko; Demetrios G Vavvas; Ignacio Vega-Naredo; Guillermo Velasco; Athanassios D Velentzas; Panagiotis D Velentzas; Tibor Vellai; Edo Vellenga; Mikkel Holm Vendelbo; Kartik Venkatachalam; Natascia Ventura; Salvador Ventura; Patrícia St Veras; Mireille Verdier; Beata G Vertessy; Andrea Viale; Michel Vidal; Helena L A Vieira; Richard D Vierstra; Nadarajah Vigneswaran; Neeraj Vij; Miquel Vila; Margarita Villar; Victor H Villar; Joan Villarroya; Cécile Vindis; Giampietro Viola; Maria Teresa Viscomi; Giovanni Vitale; Dan T Vogl; Olga V Voitsekhovskaja; Clarissa von Haefen; Karin von Schwarzenberg; Daniel E Voth; Valérie Vouret-Craviari; Kristina Vuori; Jatin M Vyas; Christian Waeber; Cheryl Lyn Walker; Mark J Walker; Jochen Walter; Lei Wan; Xiangbo Wan; Bo Wang; Caihong Wang; Chao-Yung Wang; Chengshu Wang; Chenran Wang; Chuangui Wang; Dong Wang; Fen Wang; Fuxin Wang; Guanghui Wang; Hai-Jie Wang; Haichao Wang; Hong-Gang Wang; Hongmin Wang; Horng-Dar Wang; Jing Wang; Junjun Wang; Mei Wang; Mei-Qing Wang; Pei-Yu Wang; Peng Wang; Richard C Wang; Shuo Wang; Ting-Fang Wang; Xian Wang; Xiao-Jia Wang; Xiao-Wei Wang; Xin Wang; Xuejun Wang; Yan Wang; Yanming Wang; Ying Wang; Ying-Jan Wang; Yipeng Wang; Yu Wang; Yu Tian Wang; Yuqing Wang; Zhi-Nong Wang; Pablo Wappner; Carl Ward; Diane McVey Ward; Gary Warnes; Hirotaka Watada; Yoshihisa Watanabe; Kei Watase; Timothy E Weaver; Colin D Weekes; Jiwu Wei; Thomas Weide; Conrad C Weihl; Günther Weindl; Simone Nardin Weis; Longping Wen; Xin Wen; Yunfei Wen; Benedikt Westermann; Cornelia M Weyand; Anthony R White; Eileen White; J Lindsay Whitton; Alexander J Whitworth; Joëlle Wiels; Franziska Wild; Manon E Wildenberg; Tom Wileman; Deepti Srinivas Wilkinson; Simon Wilkinson; Dieter Willbold; Chris Williams; Katherine Williams; Peter R Williamson; Konstanze F Winklhofer; Steven S Witkin; Stephanie E Wohlgemuth; Thomas Wollert; Ernst J Wolvetang; Esther Wong; G William Wong; Richard W Wong; Vincent Kam Wai Wong; Elizabeth A Woodcock; Karen L Wright; Chunlai Wu; Defeng Wu; Gen Sheng Wu; Jian Wu; Junfang Wu; Mian Wu; Min Wu; Shengzhou Wu; William Kk Wu; Yaohua Wu; Zhenlong Wu; Cristina Pr Xavier; Ramnik J Xavier; Gui-Xian Xia; Tian Xia; Weiliang Xia; Yong Xia; Hengyi Xiao; Jian Xiao; Shi Xiao; Wuhan Xiao; Chuan-Ming Xie; Zhiping Xie; Zhonglin Xie; Maria Xilouri; Yuyan Xiong; Chuanshan Xu; Congfeng Xu; Feng Xu; Haoxing Xu; Hongwei Xu; Jian Xu; Jianzhen Xu; Jinxian Xu; Liang Xu; Xiaolei Xu; Yangqing Xu; Ye Xu; Zhi-Xiang Xu; Ziheng Xu; Yu Xue; Takahiro Yamada; Ai Yamamoto; Koji Yamanaka; Shunhei Yamashina; Shigeko Yamashiro; Bing Yan; Bo Yan; Xianghua Yan; Zhen Yan; Yasuo Yanagi; Dun-Sheng Yang; Jin-Ming Yang; Liu Yang; Minghua Yang; Pei-Ming Yang; Peixin Yang; Qian Yang; Wannian Yang; Wei Yuan Yang; Xuesong Yang; Yi Yang; Ying Yang; Zhifen Yang; Zhihong Yang; Meng-Chao Yao; Pamela J Yao; Xiaofeng Yao; Zhenyu Yao; Zhiyuan Yao; Linda S Yasui; Mingxiang Ye; Barry Yedvobnick; Behzad Yeganeh; Elizabeth S Yeh; Patricia L Yeyati; Fan Yi; Long Yi; Xiao-Ming Yin; Calvin K Yip; Yeong-Min Yoo; Young Hyun Yoo; Seung-Yong Yoon; Ken-Ichi Yoshida; Tamotsu Yoshimori; Ken H Young; Huixin Yu; Jane J Yu; Jin-Tai Yu; Jun Yu; Li Yu; W Haung Yu; Xiao-Fang Yu; Zhengping Yu; Junying Yuan; Zhi-Min Yuan; Beatrice Yjt Yue; Jianbo Yue; Zhenyu Yue; David N Zacks; Eldad Zacksenhaus; Nadia Zaffaroni; Tania Zaglia; Zahra Zakeri; Vincent Zecchini; Jinsheng Zeng; Min Zeng; Qi Zeng; Antonis S Zervos; Donna D Zhang; Fan Zhang; Guo Zhang; Guo-Chang Zhang; Hao Zhang; Hong Zhang; Hong Zhang; Hongbing Zhang; Jian Zhang; Jian Zhang; Jiangwei Zhang; Jianhua Zhang; Jing-Pu Zhang; Li Zhang; Lin Zhang; Lin Zhang; Long Zhang; Ming-Yong Zhang; Xiangnan Zhang; Xu Dong Zhang; Yan Zhang; Yang Zhang; Yanjin Zhang; Yingmei Zhang; Yunjiao Zhang; Mei Zhao; Wei-Li Zhao; Xiaonan Zhao; Yan G Zhao; Ying Zhao; Yongchao Zhao; Yu-Xia Zhao; Zhendong Zhao; Zhizhuang J Zhao; Dexian Zheng; Xi-Long Zheng; Xiaoxiang Zheng; Boris Zhivotovsky; Qing Zhong; Guang-Zhou Zhou; Guofei Zhou; Huiping Zhou; Shu-Feng Zhou; Xu-Jie Zhou; Hongxin Zhu; Hua Zhu; Wei-Guo Zhu; Wenhua Zhu; Xiao-Feng Zhu; Yuhua Zhu; Shi-Mei Zhuang; Xiaohong Zhuang; Elio Ziparo; Christos E Zois; Teresa Zoladek; Wei-Xing Zong; Antonio Zorzano; Susu M Zughaier Journal: Autophagy Date: 2016 Impact factor: 16.016